|
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2016/10/27 ¤U¤È 11:34:53
|
¥_·¥¬PªÍ¶¡¥ÖÀù¤T´Á¸ÕÅçOS»PPFS¤§CPȧ¡¤w¶W¹L80%¡ADSMB«Øij´£¦µ²§ô¤T´ÁÁ{§É¸ÕÅç 1.¨Æ¹êµo¥Í¤é:110/04/27 2.¤½¥q¦WºÙ:¥_·¥¬PÃÄ·~¶°¹Î 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î 5.µo¥Í½t¥Ñ: ¤@¡B¥»¤½¥q©ó¤µ¤é¦¬¨ìFDA»{¥i¤§¿W¥ß¾÷ºc¡u¼Æ¾Ú©M¦w¥þºÊµø©eû·|¡]DSMB¡^¡v¥D°Ê¨Ó¤å¡ADSMB¹ï¥¿¶i¦æ¤§ªÍ¶¡¥ÖÀù¤T´ÁÁ{§É¸ÕÅç§@¥X¶i¤@¨B¤§«Øij¦p¤U¡G ¥Ñ©ó¾ãÅé¦s¬¡²v¡]OS)»PµL´c¤Æ¥Í¦s´Á¡]PFS)¨âªÌ¤§CPȧ¡¤w¶W¹L80%¡A¦Ò¶q¬D¾ÔÄvª§©ÊªvÀø»P·s«aªÍª¢¤§½ÄÀ»¡ADSMB«Øij¥»¤½¥q»PºÊºÞ¾÷ºc¡]FDA¡^Ápô¡A¦Ò¼{©ó¤TӤ뤺°±¤îÄ~Äò¦¬¿ý¯f¤H´£¦µ²§ô¥¿¶i¦æ¤§Á{§É¸ÕÅç¡A¨Ã¹ï¨ü¸ÕªÌ«ùÄò°lÂܤ@¦~¡C ¤G¡B¨C¦ìDSMB¦¨û³£©Ó»{¡A¦³Ãö«Øijªº¨Mµ¦¹Lµ{¬O°ò©ó¹ï©Ò´£¨Ñ¼Æ¾Úªº¥þ±µû¦ô¡CDSMB¦¨û®Ú¾Ú¹ï©Ò´£¨Ñ¼Æ¾Úªº¼f¬d¡B¥L̪ºÂå¾Ç±M·~ª¾ÃÑ¡A¥H¤Î¥LÌ°Ñ¥[DSMB·|ij´£¥X¤F¤Wz«Øij¡CDSMB¦¨û²z¸Ñ¡A³o¨Ç«Øij¬O°ò©ó¦@Ãѧ벼±o¥Xªº¡C ¤T¡B¥»¤½¥qªñ´Á±N»PFDA¶i¦æ·|ij¡A¦Ò¼{¨Ì´`DSMB¤§«Øij»PFDA¨ó°Ó´£¦µ²§ôªÍ¶¡¥ÖÀù¤T´ÁÁ{§É¸ÕÅ窽±µ¥Ó½ÐÃÄÃÒ¡C 6.¦]À³±¹¬I:µL 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ: ¤@¡B¬ãµo·sÃĦWºÙ©Î¥N¸¹¡G¥HADI-PEG 20Áp¦X¤ÆÀøÃÄ Pemetrexed¤Î Cisplatin ªvÀø¥½´ÁªÍ¶¡¥ÖÀùªº¦h°ê¦h¤¤¤ß¤G/¤T´ÁÂùª¼Á{§É¸ÕÅç ¤G¡B¥Î³~¡G¥HÁp¦X¥ÎÃĪvÀø¥½´ÁªÍ¶¡¥ÖÀù ¤T¡B¹wp¶i¦æ¤§©Ò¦³¬ãµo¶¥¬q¡G²Ä¤T´Á¹wp©ó¬ü°ê¡B^°ê¡B¿D¬w¡B¥xÆW¤Î¸q¤j§Qµ¥5Ó°ê®a¦h¤¤¤ßÁ{§É¸ÕÅç¡A¤Î«áÄò¥xÆW¡B¬ü°ê¡B¼Ú·ùµ¥¦U¦a°Ï·sÃĬdÅçµn°O¼f¬d¡C ¥|¡B¥Ø«e¶i¦æ¤¤¤§¬ãµo¶¥¬q¡G (1)´£¥X¥Ó½Ð¡þ³q¹L®Öã¡þ¤£³q¹L®Öã/¦U´Á¤HÅéÁ{§É¸ÕÅç(§t´Á¤¤¤ÀªR)µ²ªG¡G²Ä¤T´ÁÁ{§É¸ÕÅç (2)¥¼³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥iªÌ¡A¤½¥q©Ò±Á{¤§·ÀI¤Î¦]À³±¹¬I¡G¤£¾A¥Î¡C (3)¤w³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥iªÌ¡A¥¼¨Ó¸gÀç¤è¦V¡G¤£¾A¥Î¡C (4)¤w§ë¤J¤§²Ö¿n¬ãµo¶O¥Î¡GÄݾ÷±K¸ê°T¡A¬G¤£¤©¤½¶}´¦ÅS¡C ¤¡B±N¦A¶i¦æ¤§¤U¤@¬ãµo¶¥¬q¡G (1)¹wp§¹¦¨®É¶¡¡G²Ä¤T´Á¸ÕÅç¹wp¦¬®×210¤H¡AºI¦Ü¥Ø«e¤w¦¬®×65¤H¡A¹ê»Ú¦¬®×®Éµ{±N¨Ì°õ¦æ¶i«×½Õ¾ã¡C (2)¹wpÀ³t¾á¤§¸q°È¡GµL¡C ¤»¡B¥«³õ²{ªp¡G ¥þ²yÀù¯gµo¥Í²v³v¦~´£°ª¡AÀHµÛ¤H¤f«ùÄò¦¨ªø¡AÀù¯g¯f¤H¼Æ¦¨ªøÁͶÕÅãµÛ¡AÀù¯gªvÀø¥«³õ±N¦]Àù¯g¯f±w¤H¼Æ¼W¥[¦Ó³v¦~´£°ª¡CADI-PEG 20 ¬O°w¹ï¸~½F²ÓM¦b·s³¯¥NÁ¤Wªº«¤j¬ðÅܦӶq¨q°µªº³Ð·s¥Íª«ÃÄ¡A¾AÀ³¯g¥]¬A¦hºØ¤£¦PÀù¯g¡C¥»¤½¥q¥Ø«e¿n·¥¶i¦æªÍ¶¡¥ÖÀù©M³n²Õ´¦×½FªºÁ{§É¸ÕÅç¡A¨Ã«ùÄò¶i¦æ¨ä¥LÀù¯gÁ{§É¸ÕÅç³W¹º¡A«Ý¥¼¨ÓÁ{§É¸ÕÅç³°Äò§¹¦¨¨Ã¨ú±oÃÄÃÒ«á¯à³v¨BÂX¤jADI-PEG 20ªºÀ³¥Î¥«³õ¡C ¤C¡B·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¤@©w¯à¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê±Á{·ÀI¡A§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C |
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2017/11/1 ¤U¤È 11:24:01²Ä 1765 ½g¦^À³
|
»«¹£¤j¡A©e©}±z°µªÑ¸t¡AªÑ¯«´N§O¸ò¦Ñ´·m°Õ¡I±ß¦wÅo |
|
|
·|û¡G»«¹£ô10144807 µoªí®É¶¡:2017/11/1 ¤U¤È 11:19:51²Ä 1764 ½g¦^À³
|
¦Ñ´¤j¥¦w 쥻·Ç³ÆÃö¿OºÎı¤F¡A¦ý¬O¬Ý¨ì¤F¦Ñ´¤jµo¨¥¡A¤p§Ì¤£§K¦³ÂI¤ßÁn¤£º¡¡A¨ä¹ê¬O¦Y¦Ñ¤jôªº¾L ½T¹ê4/26¤½§G18¶ô¼W¸ê®É¸s²Õ¬P¤ÍÌ«sÂE¹M³¥¡A¦ý¬O¦Ñ´¤j§O§Ñ¤F¡AÁÙ¦³¦ì¥s¤p¶Pªº»«¹£¤p§Ì¸õ¥X¨Ó»¡¡A§ÚXXXªºXXXX±b¤á¡A¤@±i¤£½æ¡A20´X¶ôªº®ÉÔ»QµÛ¤â«ü±a»âµÛ»«¹£¿ËªB¦n¤Í¤p¤ßÁlÁlªº±µµÛ¤j©M¤Î´°«nªº³æ¤l ª½¨ì¤µ¤Ñ¡Aªì°J¥¼ÅÜ¡A½a±o¥u³Ñ¤Uº¡¤âªº¬P¬P¡A©ú¦~ªº¬P¬PÄ£¤W°ê»Ú»R¥x®É¡A¥Í§ÞªÑ¯«®Ç³Â·Ðµù°O¤@¦ì¨S¦³¼z®Ú¥u·|¸òªº»«¹£§Ú§a¡A«¢«¢¡A§O¤H¯º§Ú¤ÓºÆÅö¡A§Ú¯º¥L¤H¬Ý¤£¬ï°Ú ©ú¦~¤j®a¤@©w·|¦³²´ºÖ¥i¥H¬Ý¨ìÄ«ªG¤é³ø ¯Q¾|¤ì»ôªº¹Dºp¤åªº¡A¦pªG¨ºÓ¤pÑeÑe¤£´±µn¡A§ÚÀ°¥Lµn¡A¤º®e§ÚÀ°¥L¼g¡A¿ú§ÚÀ°¥L¥X¡A»«¹£¦b¥²´I¸Ì¯d¤Uªº¨C¤@Ó¦r¡A±N¨Ó³£¥i¥H±o¨ì¦LÃÒªº ¤°»ò³£¨S¦³ÅÜ¡A·|Åܪº¥u¦³§Aªº¤ß¡A¦@«j |
|
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2017/11/1 ¤U¤È 10:57:12²Ä 1763 ½g¦^À³
|
¤j®a¯uªº³£«ÜÁo©ú,¥xÆWªº¥Í§Þ§ë¸ê¤H¤§¥Î¥\,§ó¬OÅý¤H·q¨Ø! ®t¤£¦h´N¬O³o¼Ë,¦Ñ´ª¾¹Dªº¤]¦³,¨Ã¤£¬O¤°»ò¤º¹õ,¥u¬O¦Ñ´»{ÃѪº¤H¦h¤@ÂI,¾Çªø§Ì¶¡ªº·P±¡¤]ÁÙ¤£ ¿ù,³£¦³¦bÁp¨t,¤¬¬ÛÃö¤ß,è¦n¦b¦UÓ¨¤¸¨³£¦³¤@¨Ç¾Çªø§Ì¦b¥ô¾,¶iתº!¦³¬ÛÃö¾÷ºc©Î¾÷Ãö¹ÎÅé¾Ç·| ´N·|¸ò¥L̵y·L²á¤@¤U,¥Ø«eªº¥Í§ÞÁͶÕ,«Ü¦h¨Æ±¡¤]¤£¯à°Ýªº¤Ó©úÅã,¤£µM·|Åý¤Hı±o§A«Ü°Q¹½! ¦ý¬O,¹ï¥Î¥\ªº¦Ñ´¨Ó»¡,¤£¥ÎÁ¿ªº¤Ó²M·¡,¦Ñ´·|¦Û¤v¨DÃÒ!³o¼Ë¹ï¤è¤]¤ñ¸û¤£·|¬°Ãø,§ó¦óªp¥L̪¾¹D ªº¤]¤£¬O¥þ³¡! ®É¶¡ÂIÁö¤£¤¤¥ç¤£»·¨o! impressive data¬O¤°»ò,¦Ñ´¤£·|¨º»ò¥Õ¥Ø¥h°Ý³o»ò®Ö¤ßªº°ÝÃD,¥LÌ·íµM¤]¤£¤@©wª¾¹D,¥u¬O²á¤Ñ¤¤ »¡,«D±`impressive!!!³o¼Ë¤£´N°÷¤F¶Ü¡H¬°¤°»ò¡H ¦]¬°¦Ñ´¥i¥H±q¤wª¾¼Æ¾Ú¨Ó§PÂ_: ¡´Tecentriq³æÃÄNSCLC phase 3 OAK study-----2016/10/19FDA approved Tecentriq pk Docetaxel ORR= 58/425 (14%) pk 57/425 (13%) CR= 6/425 (1%) pk 1/425 (<1%) PR= 52/425 (12%) pk 56/425 (13%) SD= 150/425 (35%) pk 177/425 (42%) ¦pªG§âOAK studyªºsubgroup-PD-L1 expression¤¤§C,¤¤,±j¶§©Ê©Ô¥X¨Ó¬Ý(TC1/2/3 or IC1/2/3) ORR=43/241 (18%) pk 36/222 (16%) CR=5/241 (2%) pk 1/222 (<1%) PR=38/241 (16%) pk 35/222 (16%) SD=79/241 (33%) pk 85/222 (38%) ¡´TecentriqÁpÃĪº°Æ§@¥Î Tecentriq (¤]¥sMPDL3280A)¦bASCOªºµoªí Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Tecentriq + carboplatin + paclitaxel= (Arm C, n=8) Tecentriq + carboplatin + pemetrexed= (Arm D, n=14) Tecentriq + carboplatin + nab-paclitaxel= (Arm E, n=15) G3-4 ¯Åªº°Æ§@¥Î anemia (Arms D & E, 7%), neutropenia (Arm C, 13%; Arm D, 7%) thrombocytopenia (Arms D & E, 7%) No pneumonitis was seen. ¡´Keytruda+car+pem¤@½u¥ÎÃĪvÀønon-squamous NSCLCªºkeynote-021----FDA ¥Hphase 2ªº¼Æ¾Ú©ó 2017/05/10 approved; ¦ý¬Ophase 3ªºkeynote 189¦b2017/10/27ºM¾P¼Ú·ùÃÄÃÒ¥Ó½Ð,¦]¬°ÁÙ»Ýn ¥]¬AOS¬°co-primary endpointªº¼Ï¯Ã¹êÅç!!! Keytruda+car+pem pk car+pem ORR= 33/60 (55%; 95%CI 42¡V68) pk 18/63 (29%; 95%CI 18¡V41)------p=0.0016 mPFS= 13¡P0 months (95% CI 8¡P3~not reached) pk 8¡P9 months (95% CI 4¡P4¡V10¡P3)--p=0.010 6-months OS= 92% pk 92%-----------¨â²Õ¨S¦³®t²§!!!----©Ò¥H¼Ú·ùÁÙ¬O¤ñ¸û«O¦u,´N¬On¬ÝmOS!! >=G3ªº°Æ§@¥Î¨â²Õ¨S¦³®t²§!!! anaemia= (seven [12%] of 59) pk (nine [15%] of 62 decreased neutrophil count= (three [5%]) pk two [3%] ¡´IDO+Keytruda Phase 1/2 (2017 ASCOªº¼Æ¾Ú)-----ADIªº«l¼Ä!!!·|¤£·|³QADI¥´Ãz?´Á«Ý¤¤.... NSCLC, phase 1/2 ORR¡÷35%(14/40) CR¡÷5%(2/40) PR¡÷30%(12/40) DCR¡÷63%(25/40) ì¹êÅçECHO-202, Keynote-037, NCT 02178722 for all solid tumor n=463¡÷primary completion: 2018/11 (ÁÙ¦³¤@¦~§¹¦¨) Polarisªºdatan¦h¦n?¨ä¹ê¬OÁp¤°»òÃĦѴ³£¤£½T©w!!!TecentriqÁÙ¨S¶}©l, KeytrudaÀ³¸Ó¤]¨S¨º»ò§Ö¡I ¦ý¬O¬JµM»¡very impressive,¦Ñ´¤µ¤Ñ´N¬O«D±`´Á«Ýªº±µ¤F91±i,³o´X¤Ñ±µªº¥[¤@¥[¦³400±i,èè¬Ý Äw½X¤~ª¾¹D¥É¤s«°¤¤®Ú¥»¤w¸g°±¤F, ¿ù©Ç¥L,ì¨Ó¤µ¤Ñ¬O¤p¶§¤j³oºØ´²¤áªº¦Û±þ³æ,¥i±¤!¦Ñ´¤@ª½³£¬O®_¤j¤áªº,¤µ¤Ñ±þ¨ì´²¤á,ºâ§Ą«¹B! ¦º¦b¦Ñ´¤M¤U,¶À¬u¸ô¤W¤]¸Ó·P¨ì¥úºa§r!!! ¦Ñ´»¡¤F«Ü¦h¦¸,¶^¤U¨Óªº¥s¾÷·|,º¦¤W¥hªº¬O·ÀI!°ß¦³°ò¥»±¤~¬O¤ý¹D!¦pªG¦A¶^¤U¥h«ç»ò¿ì? ·íªì¤½§G18¶ô¼W¸ê®É,¬P¸s¸Ì«sÂE¹M³¥,·í¤Ñ¤]¬O§«ô¤T,¦Ñ´©]¶Eµ²§ô«á¬Ý¨ì°T®§,¯º¶}Ãh! ¦¹¤D¤Ñ½ç¨}¾÷!¯u¬O¤Ñ§U§Ú¤]!!! ¥i¥H°Ý¬P¤Í¨DÃÒ!!!¥u¦³¦Ñ´¤@Ó¤H¬O¼ÖÆ[ªº! ¦p¤µ¥É¤s«°¤¤¥á¨ì¯}70,ÁÙ¬O¥u¦³¦Ñ´¤@Ó¤H¼Ö¶}Ãhªº§C±µ,½Ð§A̧i¶D¦Ñ´: 1. ªÑ¥«¸Ì°µªº¨ì³o¼Ëªº¤H¬O¦h¼ÆÁÙ¬O¤Ö¼Æ? 2. ªÑ¥«¸ÌÁȨ쪺¬O¦h¼ÆÁÙ¬O¤Ö¼Æ? «Ý¬P¬P¨Æ¥ó¸¨¹õ,·à¤l¹F¨ì¥Øªº¦a«á,½Ð°O±o¥xÆWªº¥Í§Þ·sÃĪѯ«¬O½Ö!!!¡÷³oÂIµê¦W,¦Ñ´ÁÙ¬O®¼·Rªº!!! ¦pªG¥¢±Ñ¤F,¦Ñ´¦Û·|«õ¬}¸ú°_¨Ó,±q¦¹¤£¸I¥Í§ÞªÑ!!! |
|
|
·|û¡G±j¥§25810144809 µoªí®É¶¡:2017/11/1 ¤U¤È 10:56:11²Ä 1762 ½g¦^À³
|
¦Ñ´¤j¡B»«¹£ô¤Î¦U¦ì°í¼Ý¤£©Þªº¬P¤Í̱ߦw ¶ý¶ý¦³¥æ¥N¡A¦n¦n°Ú°µ¤H¡A¤£³q°µspy ©Ò¥H§Ú¹ê¦b¤£¤Ó·Q¦^À³SPYªº¯d¨¥ ¦ý¬Ý¨ì¤µ¤Ñ¥É¤s«°¤¤¤£½æ¤F ÁÙ¯u·QµoÓ·P©À¤å.... ¦^·Q¨º¬q³Q¤j©M¤ÎÃÛ¨kâhªº¤é¤l ¥»¨Ó¬O«ë¥LÌ«ë±o¤úÄoÄoªº ¦ý·í¥L̽槹¤F ¦^ÀY¬ÝµÛ¦Û¤vº¡º¡ªº®w¦sªí ¤£ª¾±µ¤F¦h¤Ö¥L̩ߥXªºÄ_ª« ¯uªº¤ß¦s·P¿E¡A¯uªº·Q©À¥LÌ ³Ìªñ¥É¤s«°¤¤¤]¨Ó¤@¦¸ ¤S¶X¶Ã±µ¤F¤@¨ÇÄ_ª« µM«á¥L¤S¤£½æ¤F §Ú·Q¹L¤£¤[ «ä©Àªº¹ï¶H¤S¦h¤F¤@¦ì ³oºâ¬O´µ¼wôº¸¼¯¯gÔ¸s¶Ü? §Ú¤]¤£ª¾¹D ¥uª¾¹D¥_·¥¬PÁ`ºâ¤Sn¦A¦^¨ì¥LÀ³¦³ªº»ùÈ ¤ß¤¤ªº¼Æ¦r©l²×¤£ÅÜ ¦aªO»ù¡A¤W¿³Âdªº105¤¸ ¥[ªo§a¥_·¥¬P |
|
|
·|û¡GLKK10141678 µoªí®É¶¡:2017/11/1 ¤U¤È 10:50:41²Ä 1761 ½g¦^À³
|
§Ú¥i¬O³£没ÅÜ®@,¤@©w¨ì³Ì«á¤@ù,¥B¤@©w¨ì²×ÂI¯¸,ÁÙn½Ð³f¨®À°¦£¸üªF¦è,¦]¬°¤Ó¦h¤Ó«,没¿ìªk. |
|
|
·|û¡G¸Û«H¦ó®¬10139574 µoªí®É¶¡:2017/11/1 ¤U¤È 10:40:02²Ä 1760 ½g¦^À³
|
68¤Ñ¡A¨º»òªøªº®É¶¡¡A ·d¤£¦n²Ä¤@½ü¸Õ¤ô·Åªº¡]¨ÖÁʩαÂÅv¡^¥X»ù³£°e¨ì¤F¡A·íµMÁÙn½Í¦n¦h½ü¡C ³o¬q´Á¶¡³Ì«áªº¨p¶Ò¤]·|§¹¦¨¤F§a¡A©Î³\Ápkªì¦^¼Æ¾Ú¤]¤½§G¤F ©Î³\ÁpT¤w¶}©l¡C ¦åÀù°eµoªí¤]¦b³o¬q´Á¶¡§a¡C¡]³o¬O¶W«½Sªº®ø®§¡^ÀH«K1Ó¥«³õ³£¤ñ355¤j °ò¥»±¶V¨Ó¶V¦n¡A«ç»ò¤H¤ßÅܤF¡H ®©°Ú¡I«ç»ò¤~Å¥§¹¤@¦±¤TÅ|¡A¦è¥X¶§Ãö¤wµL¬G¤H°Õ |
|
|
·|û¡G»«¹£ô10144807 µoªí®É¶¡:2017/11/1 ¤U¤È 09:59:50²Ä 1759 ½g¦^À³
|
¦U¦ì¬P¤Í±ß¤W¦n°Ú ¤µ¤Ñ¤S¬O±þ¼®ªº¤@¤Ñ¡A«Ü¦h¬P¤Í¦b¤µ¤Ñ²¦·~¤F¡A¯¬ºÖ§AÌ¡A¦³®ÉÔ§Ô¤£¦í¤ß¸Ìªº·Î¼õ¥X³õ³Ý¤f®ð¤]¤£¬O¥óÃa¨Æ ¨CÓ¤H¦³¦Û¤vªº¦Ò¶q¡A¦Û¤vª¾¹D¦Û¤v¦b°µ¤°»ò´N¦æ¤F¡A¬P¬Pªº°ò¥»±¤@ÂI³£¨S§ïÅܳo«Ü¤j¬P¤Í̳£¦³´£¥X¡A¤p§Ì¤£¦b¦¹¦h¥[ÂضD¡A§ïÅܪºÀ³¸Ó¬O§ë¸êªºª^³ò¡A¤jªÑªF¥X²æªº½T·|Åý¤Hı±o®£·W¡A®£·W´N·|«æļ¡A«æļ´N·|§â¤½¥qªº¥»½èµ¹§Ñ¤F¤@°®¤G²b ¤µ¤Ñªº½L»¡¬ï¤F´N¬O¦h±þ¦h¡A´²¤á½ò´²¤á¡A¥É¤s«°¤¤¤@±i³£¨S½æ¡A¤H¤£¬O¥L±þªº¡A¦ý¬O®£·Wªº®ðª^¬O¥L±a°_ªº¡A¤µ¤Ñ±þ¥Xªº¬P¤Í»{¯u·Q·Q¡A°²¦p¥É¤s«°¤¤¤w¸g¤£¦A½æ¤F¡A¨º¬P¬Pªº°ò¥»±ÁÙ¬O¤@¼Ë¶Ü¡HªÍ¶¡¥ÖÀù2/3´ÁÁ{§É¶i¦æ¤¤¡A¨xÀù³æÁuÁ{§É¹êÅç¶i¦æ¤¤¡A¦åÀù¡A¯ØŦÀù¾Ü¤@©Î¬O¤@°_¦b³W¹º·sªºÁ{§É¡AAKÁpÃĪº¼Æ¾Ú¦~©³¦³¨S¦³¦³¾÷·|¬Ý¨ìªì¨Bªºµ²ªG¡HADI¥[ù¤ó·sªºÁ{§É¹êÅçµ¥µ¥¡A¦b¹ï·Ó¤µ¤Ñªº»ù®æ64¡A9¤ë¥÷¤~§¹¦¨ªº¨p¶Ò63¡]¨p¶ÒnÂê¤T¦~³á¡A¤µ¤Ñ¶R¨ì64¶ôªº¬P¤Í«D¦ý¦¨¥»¸ò¨p¶Ò¥u®t¤@¶ô¿úÁÙ¤£¥Î³QÂê¤T¦~¡A¦Ó¥B¤]¤£¥Î³QÂê¤W¦Ê±i¥H¤WªºªÑ²¼¡Aµ¥©ó¸ê²£¦b3¦~¤º³£¤£¯à°Êªº¡^ Á¿¨ì³oÃä¡A»«¹£ôªº¤â«üÀY¤SÄo°_¨Ó¤F¡A·Ç³Æ¤Sn¦Y¤â¹L¤é¤l¤F ¤§«e¦³¬P¤Í«Øij»¡»«¹£ôn¦¬¶°¨ì1000ªÑ¤~¯à½æ¤@±i¡A»«¹£ôÅ¥¶i¥h¤F¡A¸ò¦U¦ì¬P¤Í³ø§i¤@¤U¡A¥Ø«e»«¹£ôªº¿ËªB¦n¤Í«ùªÑ¤w¸g¼W¥[¨ì1000ªÑ¡]±i¡^¤F¡Aþ¤Ñ·|¤£·|¤ß±¡¤£¦n¡A»«¹£ô¤]Åܦ¨¤j©M¤û¸òÃÛ¨k¤F¡A«¢«¢ ÁÙ¬O»«¹£ô¸ò¿ËªB¦n¤Í·|¤@°_©êµÛ³o¨Ç1000ªÑ¡]±i¡^¸ò¤½¥q¤@°_¨«§¹¦¨¥\ªº³Ì«á¤@ù¸ô©O¡H ¸Ü»¡¦h¤F¡AÁÙ¬O»°§Ö¨ÓªM58±ß¤W°µÓ¦n¹Ú¥h |
|
|
·|û¡GºÃ´bªÌ10140504 µoªí®É¶¡:2017/11/1 ¤U¤È 08:48:49²Ä 1758 ½g¦^À³
|
impressive data from BCI? |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/11/1 ¤U¤È 08:39:17²Ä 1757 ½g¦^À³
|
ºÃ´bªÌ¤j ±zÁo©ú ÁpK¬O¦b¦¨¤j°µªº ¬O¥Ñ³¯±m¶³±Ð±Â¥D«ùªº BCI°µªº¬OªÍ¶¡¥ÖÀù ¥ÑPeter Szlosarek³Õ¤h ¥D«ù Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (TRAP) https://clinicaltrials.gov/ct2/show/NCT02029690?term=ADI-PEG+20&draw=1&rank=4 Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ATOMIC) https://clinicaltrials.gov/ct2/show/NCT02709512?term=ADI-PEG+20&draw=1&rank=18 ¦Ü©ó·|¦³¬Æ»ò¦n®ø®§ ¥u±o½Ð¦Ñ´¤j±Ð±Â¨Ó´¦¶}Á¼©³¤F ÁÂÁ¤j®a! |
|
|
·|û¡GºÃ´bªÌ10140504 µoªí®É¶¡:2017/11/1 ¤U¤È 08:25:21²Ä 1756 ½g¦^À³
|
Ãø¹D¬O68¤Ñ¤§«á ´Nn¦VFDA´£¥X©Mù¤ótecentriqÁp¦X¥ÎÃĪºÁ{§É¥Ó½Ð¡H |
|
|
·|û¡GºÃ´bªÌ10140504 µoªí®É¶¡:2017/11/1 ¤U¤È 08:09:05²Ä 1755 ½g¦^À³
|
Barts Cancer Institute, Queen Mary University of London. ¥Dn¬O°µªÍ¶¡¥ÖÀùªº¤¤¤ß ¦ý¬Oªk»¡·|®É §d³Õ¦³»¡ ªÍ¶¡¥ÖÀù¦¬®×ªº³t«×¤ñ¸ûºC ©Ò¥HÀ³¸Ó¤£·|¬O¸òªÍ¶¡¥ÖÀù¬ÛÃöªº®ø®§ ¶Ë¸£µ¬ ·Q¤£¥X¨Ó ¥u¦n½Ð³ÌÁ¿¸q®ðªº¦Ñ·¨¤j¦ÂI¤½§Gµª®×¤F |
|
|
·|û¡G¥Í§Þ°g10141555 µoªí®É¶¡:2017/11/1 ¤U¤È 07:59:26²Ä 1754 ½g¦^À³
|
¦Ñ´¤j±z¦n¡A¦U¦ì¬P¤Í¤j®a¦n! ¤j®a§O§Ñ¤FÁÙ¦³«æ©Ê°©Åè©Ê¥Õ¦å¯f¡]AML)©M»H¯ÖÀùªº¨Æ¡C |
|
|
·|û¡G¥Í§Þ00710142005 µoªí®É¶¡:2017/11/1 ¤U¤È 07:46:13²Ä 1753 ½g¦^À³
|
¦Ñ´¤j10/31¹w§i+¤µ¤Ñpoªº¼Æ¾Ú-----¸Ñ°g¤¤ ----------------------------------------------------------------------------------------------- ¦Ñ´10141055 µoªí®É¶¡:2017/10/31 ¤U¤È 11:15:05 Á`¤§,¦nÀ¸¦b«áÀY,©ú¤Ñ¦A¨Ó¬Ý¬Ý,¦h¤Ö¤H·|«á®¬¤µ¤Ñªº¨M©w!!!©ú¦~¦A¨Ó¬Ý¬Ý,¦h¤Ö¤H·|«á®¬¤µ¦~ªº¨M©w!!! ----------------------------------------------------------------------------------------------- ¦Ñ´10141055 µoªí®É¶¡:2017/11/1 ¤W¤È 11:27:17²Ä 1740 ½g¦^À³ from 11,1 after 68 (unit) 1,08 (T) impressive d from BCI ----------------------------------------------------------------------------------------------- ¦Ñ´10141055 µoªí®É¶¡:2017/11/1 ¤U¤È 04:28:17²Ä 1762 ½g¦^À³ ¦Ñ´¤£·|PO¤@¨Ç¨S¥ÎªºªF¦è,¤¤¤ÈPOªº¼Æ¦r¤Ñ¾÷n¦n¦n¬Ý,¤£¯à¹y®©¤]·|º¥®©ªº! ¯¬¤j®a¦n¹B~~ |
|
|
·|û¡GºÃ´bªÌ10140504 µoªí®É¶¡:2017/11/1 ¤U¤È 07:37:39²Ä 1752 ½g¦^À³
|
BCIÀ³¸Ó´N¬O Barts Cancer Institute ¦ý¬O¦L¶H¤¤ Ápkeytruda¬O¦b¦¨¤j°µªº ²q·Q¤j ±z¤ñ¸ûÁo©ú ³Â·Ð±z¦A²q²q68¤Ñ¤§«á·|¦³¤°»ò¨Ænµo¥Í¡H |
|
|
·|û¡G¥Í§Þ°g10141555 µoªí®É¶¡:2017/11/1 ¤U¤È 07:35:26²Ä 1751 ½g¦^À³
|
ºÃ´b¤j±z¦n! ©êºp! ¸ò²q·Q¤j¤@¼Ë¡A¥u¹ï¤é´Á²q´ú¡A¹ïBCI¨ÌµM¤£ª¾¡A¦]¬°BCIªºÁY¼g¦³¤Ó¦h¥i¯à©Ê¤F¡C §ë¸ê·sÃĤ@©wn§ì¦í«ÂI¡A°ò¥»± & ·sÃļç¦b»ùÈ¡C2~3Ó¤HÁpKÃĪº¼Æ¾ÚÀ³¸Ó§Y±N¦³ÃФF¡A¦ý¬O6Ó¤HÁpKÃĪºÁ`Åé¼Æ¾Ú¹w¦ôÀ³¸Ón¨ì¦~©³¡C°£¤F쥻ªº°ò¥»±¤§¥~¡AÃB¥~ªºÃzµo©Ê¼ç¦b»ùÈ´N¦bÁpKÃĪº¼Æ¾Ú! ¥H¤W¸ê°T¶È¨Ñ°Ñ¦Ò¡A¤Á¤Å°µ¬°§ë¸ê¨Ì¾Ú! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/11/1 ¤U¤È 07:17:41²Ä 1750 ½g¦^À³
|
BCI Barts Cancer Institute, Queen Mary University of London. Polaris Group to Highlight Clinical Development Plans for Phase 3-Ready Candidate, ADI-PEG 20, During Symposium in Taiwan http://polarispharma.com/news/polaris-group-to-highlight-clinical-development-plans-for-phase-3-ready-candidate-adi-peg-20-during-symposium-in-taiwan/ ·|¤£·|±i«a§õÀ¹§r? ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡GºÃ´bªÌ10140504 µoªí®É¶¡:2017/11/1 ¤U¤È 07:06:08²Ä 1749 ½g¦^À³
|
¥Í§Þ°g¤j ½Ð±Ð¤@¤U BCI¬O«ü¤°»ò¡H |
|
|
·|û¡G417488810141226 µoªí®É¶¡:2017/11/1 ¤U¤È 07:03:38²Ä 1748 ½g¦^À³
|
¥Í§Þ°g¤j+1 ¤p§Ì¶Ã¼g¡Asorry! |
|
|
·|û¡G417488810141226 µoªí®É¶¡:2017/11/1 ¤U¤È 06:58:10²Ä 1747 ½g¦^À³
|
impressive data from BCI ©M»H¯ÖÀù¦³Ãö¶Ü? |
|
|
·|û¡G¥Í§Þ°g10141555 µoªí®É¶¡:2017/11/1 ¤U¤È 06:57:57²Ä 1746 ½g¦^À³
|
¦Ñ´¤j±z¦n¡A¦U¦ì¬P¤Í¤j®a¦n! ¸ò²q·Q¤j¤@¼Ë: from 2017/11/1 after 68 (days) 2018/1/08 (T) impressive d from BCI ©¡®É¡A¤»Ó¤HÁpkÃļƾڸӥX¨Ó¤F(2017¦~©³)¡C©¡®É¥_·¥¬Pªº¬G¨Æ¶}©l¤Wºt¤F¡A«ø¥Ø¥H«Ý¡C ¥H¤W¶È¨Ñ°Ñ¦Ò¡A¤Á¤Å°µ¬°§ë¸ê¨Ì¾Ú! |
|
|
·|û¡GºÃ´bªÌ10140504 µoªí®É¶¡:2017/11/1 ¤U¤È 06:50:26²Ä 1745 ½g¦^À³
|
§Úı±o²q·Q¤j¤é´Áªº²q´ú¥i¯à¬O¹ïªº ³oÓimpressive day from BCI BCI¬O¤°»ò©O¡H ¼Ú¬¥©_¤j §A¬JµM¹ï¥_·¥¬P³o»ò¦³¿³½ì §A²qBCI¬O¤°»ò¡H |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/11/1 ¤U¤È 06:42:53²Ä 1744 ½g¦^À³
|
"¤p§Ì¥u·Q¨ì¤é´Á ÁÙ¦³¨ä¥L²[¸q¶Ü? ²q´úÁöµM¦³½ì ¦ý¥i¯à¤]¥NªíµÛJ§è ¶È¨Ñ°Ñ¦Ò " °Ú«¢ ³o¼Ë¼g®e©ö»~·|°Õ §ï¬°³o¼Ë¤ñ¸û¦n ""¤p§Ì¥u·Q¨ì¤é´Á ÁÙ¦³¨ä¥L²[¸q¶Ü? ¤p§Ìªº²q´úÁöµM¦³½ì ¦ý¤p§ÌY²q¤£¤¤ ´N¬OJ§è°Õ ©Ò¥H¶È¨Ñ°Ñ¦Ò " ÁÂÁ¤j®a! |
|
|
·|û¡GºÃ´bªÌ10140504 µoªí®É¶¡:2017/11/1 ¤U¤È 06:41:13²Ä 1743 ½g¦^À³
|
¥Í§Þ°g¤j ¥i§_¤À¨É±zªº²q´ú¡H from 11,1 after 68 (unit) 1,08 (T) impressive d from BCI |
|
|
·|û¡G¤ý£«¬Â10136621 µoªí®É¶¡:2017/11/1 ¤U¤È 06:38:35²Ä 1742 ½g¦^À³
|
68·|¤£·|¬O³o´Á¶¡ªº§¡»ù¡A¨p¶Ò»ùq¦b55¥ª¥k¡C¹ï¤£°_¶Ã²qªº |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2017/11/1 ¤U¤È 06:31:42²Ä 1741 ½g¦^À³
|
¦Ñ´¤j±Ð±ÂÁ¤Ѿ÷ªº¤j¤å " from 11,1 after 68 (unit) 1,08 (T) impressive d from BCI " 20171101 ~ 20180108 68Ó¤é¤l ¥O¤H¦L¶H²`¨è ¦³Án¦³¦âªº¤é¤l from BCI µM¦ÓBCI¥NªíµÛ¬Æ»ò©O??? ¤p§Ì¥u·Q¨ì¤é´Á ÁÙ¦³¨ä¥L²[¸q¶Ü? ²q´úÁöµM¦³½ì ¦ý¥i¯à¤]¥NªíµÛJ§è ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G¥Í§Þ°g10141555 µoªí®É¶¡:2017/11/1 ¤U¤È 06:23:54²Ä 1740 ½g¦^À³
|
¦Ñ´¤j±z¦n¡A¦U¦ì¬P¤Í¤j®a¦n! from 11,1 after 68 (unit) 1,08 (T) impressive d from BCI ¦n´Á«Ý¦Ñ´¤jªº¹w´ú!!! |
|
|
·|û¡GºÃ´bªÌ10140504 µoªí®É¶¡:2017/11/1 ¤U¤È 04:46:55²Ä 1739 ½g¦^À³
|
¨âӼϯøÕÅç¡G¨xÀù©MªÍ¶¡¥ÖÀù ¦A¥[¤W©Mù¤óªºÁp¦X¥ÎÃÄ¡G«D¤p²ÓMªÍÀù©MªÍ¶¡¥ÖÀù¡]¨Ì·Ó¥Ø«e«G²´ªº¼Æ¾Ú¬Ý¨Ó,À³¸Ó¤]·|¬OӼϯøÕÅç¡^ ¯ØŦÀùªº¼Æ¾Ú¤]¤£¿é´¼Àº ³o¼Ëªº°ò¥»±¨S¦³64¤¸ªº»ùÈ¡H ¦pªGªÑ»ù¬O640,¤]³\¥i¥H½æ¥X,¦]¬°¤w¸g¤ÏÀ³¤F°ò¥»±ªº»ùÈ,¦ý¬O64ªºªÑ»ù,§Ú¹ê¦b§ä¤£¨ì½æ¥Xªº²z¥Ñ |
|
|
·|û¡G¸Û«H¦ó®¬10139574 µoªí®É¶¡:2017/11/1 ¤U¤È 04:35:54²Ä 1738 ½g¦^À³
|
ªÑ²¼¤U¶^¤j®a¤ß±¡³£¤£¦n¡C ¦ý°ò¥»±¨S¦³ÅÜ¡I §ë¸êªÑ²¼¥»¨Ó´N¬O©ñªø´Áªº¡A¤£¦h»¡³o¨Ç¤j¥ë³£ª¾±¡ªº ·d¤£¦n¬P´Á¤»¤é´N¦³¦n®ø®§¡A©Î³\§a ³o¤@Ó¤ë¨Ó¡A±b±¤Ö¤F¥xÄ_°¨i8¡A¦ª¾±¡´N¾Þµu½u¡A ¬Ý¬Ý¼Ú¼ÚÅܤƦۦp¡A°¸±æ¹Ð²ö¤Î |
|
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2017/11/1 ¤U¤È 04:28:17²Ä 1737 ½g¦^À³
|
°ò¥»±¨SÅܪº±¡ªp¤U,ªÑ»ù¤U¶^¤£¦n¶Ü? ¤Ñ¦aµL¥Î¤j,§A¬O¦b½|¦Ñ´¶Ü? «H©À¤j,¤£¥Î¤Ó¦b·N¾´¾´©M©_©_°Õ!¤£¥Î¤Ó¬Ý±o°_³o¨â°¦,¥L̨S³o»ò¤j¯à@! ªÑ»ù¤£¬O¥Ļp¤@§p´N·|¶^ªº!¬Ý¥Ļp¤@§p,¦Ñ´ªº¤ß±¡Ë¬O®¼¦nªº! ¨ä¹êÁÙ¬On·PÁ¥ɤs«°¤¤°Õ!¦Ñ´±µªº«Ü¶}¤ß! ¨CÓ¤H¤ß¸Ì³£¦³¤@©wªº»ùÈ,ı±o«K©yªº¦Û·|¦³¤H¶i¨Ó±µ,¦ó¥²¤jÅå¤p©Ç? ¥±`¤ß§a! ¦Ñ´¤£·|PO¤@¨Ç¨S¥ÎªºªF¦è,¤¤¤ÈPOªº¼Æ¦r¤Ñ¾÷n¦n¦n¬Ý,¤£¯à¹y®©¤]·|º¥®©ªº! ¯¬¤j®a¦n¹B~~ |
|
|
·|û¡G¤p¶§10139627 µoªí®É¶¡:2017/11/1 ¤U¤È 04:18:23²Ä 1736 ½g¦^À³
|
¤Ñ¤j§A¦n ª±¤F´X¦~ªº¥Í§ÞªÑ¤µ¤Ñ²×©ó¤U©w¨M¤ß¥X²M ¥xÆW¥Í§Þ²£·~¯uªº¤£¬O¤@¯ë´²¤á¥i¥H§ë¸êªº ¥u¦³¥ô¤H®_³Îªº¥÷¡B³Ìªñ§Ú¥u¦³¬Ý¨ì¦³¤H˪Ѳ¼ ¦ý±µªÑ²¼ªº¤H¥u¦³§C±µ¨S¦³¨g±µ°Ú¡I ÁÙ¦³Ó¤H·Pı¦¹ª©¶V¨Ó¶V±µªñ¯E¹©ª©¤F~Ãö±¼¦¹ª© »¡¤£©w¤]¬O¤@¼Î¦n¨Æ¡C |
|
|
·|û¡G¤Ñ¦aµL¥Î10142903 µoªí®É¶¡:2017/11/1 ¤U¤È 03:55:55²Ä 1735 ½g¦^À³
|
ªÑ»ù¶^Âk¶^ ¦³¤H¦b˪Ѳ¼ ¦ý¦³¤H¨g±µ ¶R½L³£¦b60~70%¥ª¥k ±µªº¤H¤@©w¬O¥Õè¤j²Â³J |
|
|
·|û¡G@¦ÌµX10144792 µoªí®É¶¡:2017/11/1 ¤U¤È 03:46:43²Ä 1734 ½g¦^À³
|
¼Ú¤j¦n! º¥ý·PÁ±z¤é¥HÄ~©]¡AµI»I²½°ªº¤@ª½°¥´Àð¸õ°w¦¡¥X²{! nÅý§A¤F¸Ñªº¬O¡A¤j³¡¤Àªº¬P¤Í¤w¸g¬O¦º½Þ¤£©Èºu¤ô¿S¤F! ©Ò¥H§A¶V¬OÃöÃh§ÚÌ¡A§ÚÌ«D¥¹¤£·|·PÁ¡A¦Ó¬O¤ß¤¤¥X²{¡u·Ð°Ú¡v¡u·Ð°Ú¡v¡u¯u·Ð°Ú¡v ¯ëªº§o³Û~ ªÑ»ù¶^¨CÓ¤H¤ß¸Ì³£¤£¦n¨ü¡A§An¬O¤H¦n¤j¥i¤£¥Î¤@ª½¨Ó³Û¸Ü¡AÀ´ªº¤H´NÀ´¤F¡A «Øij§A¤]¶}Ó¼Ú¤j¶}Á¿°ó¡A³Ì¦n¨C¤Ñ¸ò¦Ñ·¨¹ï·F! ¤ñ¤ñ½Öªº¸£¯»¤ñ¸û¦h! ¤pªº¤]´¿«ä¦Ò¹L¤@Ó°ÝÃD¡A¸U¤@¯uªº¸¨¨ì18¡A¨º§Ú±b±¤]´N°Ï°Ï¥b¦ÊªºÁ«·l°Ú~¤£¥i©È! ¸U¤@ÁpÃĦ¨¥\¨º¥i¤£·|¬O¥b¦Ê¥H¤Wªº¼Æ¦r¦Ó¤w~¦n²¢°Ú! 18¬O³Ì»ôÀYªº¥µ¥¡A§Ú¯u¤ß¬è먺¤Ñ ªº¨ì¨Ó! 18¶ôªº¤p¬P¬P~¤Ñ°Ú°Ú°Ú!!!©¡®É§A´N¶}©l³Û¦h¤F§a¡G) |
|
|
·|û¡GDavid Xu10143450 µoªí®É¶¡:2017/11/1 ¤U¤È 03:46:14²Ä 1733 ½g¦^À³
|
®£©È¤£¥u¥¢·~¡B¦³¥i¯àµL®a¥iÂk |
|
|
·|û¡G¬P²y±U°_10145048 µoªí®É¶¡:2017/11/1 ¤U¤È 03:40:12²Ä 1732 ½g¦^À³
|
§Ú¤]¾á¤ßÃöª©¦³¤H·|¥¢·~¡A·|¨S¦³»R¥x¡ã ²¦³º¡A¥L¥u´±¦b³o¸Ì¼L¡ã |
|
|
·|û¡GºÃ´bªÌ10140504 µoªí®É¶¡:2017/11/1 ¤U¤È 03:29:18²Ä 1731 ½g¦^À³
|
ÁÙ¬O«Ü·PÁ¤@¸ô¨«¨Ó³¦ñµÛªºªB¤Í §ë¸ê¬ÕÁ«ì¥»´N¬O¦Û¤vn¬°¦Û¤vt³d §Ú¤]¤£ÃÙ¦¨Ãöª© ª©¤WÁÙ¬O¦³«Ü¦hªB¤Í¤À¨É°ò¥»±ªº°T®§ ³o¬O¤@ӫܴΪº¥æ¬y¶é¦a |
|
|
·|û¡G¼Ú¬¥©_10144203 µoªí®É¶¡:2017/11/1 ¤U¤È 03:16:20²Ä 1730 ½g¦^À³
|
¦U¦ì§O³o¼Ë ¤@Àɨg¶^ªºªÑ²¼ ¤@¤U¤ln¸ò¥É´¹¥ú¤ñ ¤@¤U¤ln¸ò¤j¥ß¥ú¤ñ ¤£¤Ó¹ï§a ¦Ó¥B¤§«e¤£¬O¤@°ï¤H¤@ª½¦bµo·P´n¤å ¤@ª½¦b·P®¦¥X³fªº¤j¤á ²{¦b³oӼˤl... ¦³ÂI§Ñ®¦t¸q¤F³á... |
|
|
·|û¡Gªü¼w10145406 µoªí®É¶¡:2017/11/1 ¤U¤È 02:43:39²Ä 1729 ½g¦^À³
|
§ë¸êªÑ²¼,©¹©¹§Q¥Î¤H¤ß®zÂI¤H¤H·QÁÈ¿ú©È½ß¿ú¦í®M©Ð,§Q¥Î®£·WÅý´²¤áÁ¿ªÑ²¼½æ¥X,¥_·¥¬P°ò¥»±¨SÅÜ,¥u¬O¤H¤ß¦bÅÜ,¦pªG·Qµu½u¤£©y§ë¸ê¥Í§Þ,¦]¥Í§Þ¨SÀ禬,¦pªG¬Ý¦n¥_·¥¬P§âªÑ»ù©ñ¤@®Ç,ªÑ»ù¦b«ç»ò¶^,¤ßºAÀ³¸Ó¤£·|¨ü¼vÅT |
|
|
·|û¡G¶§©úÂæ®Æ--ªl¨§10145262 µoªí®É¶¡:2017/11/1 ¤U¤È 02:16:19²Ä 1728 ½g¦^À³
|
·Pı³oºØ¸êª÷©PÂण¹L¨Óªºª¬ªp ¤£·|µo¥Í¦bÓ¤H¨¤W¡AÀ³¸Ó¬O¬YÓ³æ¦ì¡H ¤£¦h»¡ |
|
|
·|û¡G¤jGE10145523 µoªí®É¶¡:2017/11/1 ¤U¤È 02:12:02²Ä 1727 ½g¦^À³
|
®³©Ð¤l¥hɤ]n¤@Ó§«ô µ¥§Úµ¥§Ú |
|
|
·|û¡G«Cµì10141603 µoªí®É¶¡:2017/11/1 ¤U¤È 02:04:56²Ä 1726 ½g¦^À³
|
¤j®a¦n ¼Ú®zÂûªº¤ÏÀ³¦³ÂI¤j®@¡I«¢¡I ¤£¹L¡I§Ú¤]ÃÙ¦¨¤£nÀH«K»¡Ãöª©ªº¸Ü°Õ¡I ²¦³º§ÚÌÁÙ»Ýn¦Ñ´¤j¦b±M·~ª¾ÃѤWªº±a»â¡C ¦Ó¥B¦³ÂûÂû¾´¾´ªº¦s¦b¡A ³oÓª©¤£¬OÅ㪺§ó¼ö¾x¶Ü¡H«¢¡I Ä~Äò¼W¥[«ùªÑ¤¤¡A¼ç¤ô¥h¡C |
|
|
·|û¡G¼Ú¬¥©_10144203 µoªí®É¶¡:2017/11/1 ¤U¤È 01:48:11²Ä 1725 ½g¦^À³
|
Ãöª©..? ¤£¤Ö¬P¤Í̪º¤ßºA²ª½Åý¤H¤£´±®¥ºû ¤£¯à½èºÃ ¤£¯à»¡¹ê¸Ü ¤£µM´N¤U¨®ºu³J ¤£µM´N³¬¼L ²{¦b¤S¦³·s·Qªk °®¯Ü§âª©Ãö±¼ ¤°»ò³£¤£ª¾¹D³Ì¦n Ãø©Ç¹ï©¤¬F©²Á`¬O¤£·QÅ¥¨ì¤°»ò ´N§ì¤H ´N«Êºô ´N«Ê±þ ¸Ñ¨M±¼´£¥X°ÝÃDªº¤H °ÝÃD´N¤£¦s¦b¤F¶Ü? °®¯Ü¤j®a¼g«H¥hµ¹¬F©² »¡6550¥_·¥¬P¥u㺦¤£ã¶^¦n¤F |
|
|
·|û¡G«H©À10145622 µoªí®É¶¡:2017/11/1 ¤U¤È 01:40:20²Ä 1724 ½g¦^À³
|
¦Ñ´¤j¡B¦U¦ì¬P¤Í¤j¤j¦n¡G ¤p§Ì¤]¬O¬P¬P§ë¸ê¤H¤§¤@,°ò¥»±¬Ý¦nªº±¡ªp¤U,ªÑ»ù¥¼º¦¤Ï¶^, ¤w³vº¥°Ê·n«ù¦³ªÌªº«H¤ß,¦A¥[¤W¸¨¤«¤U¥Û¬Ý°Iªº¤H¤@¤Ñ¨ì±ß ¯d¨¥,¤ß¤¤¯u¬O¤¨ýÂø³¯,¥¿©Ò¿×¹D¤£¦X¤£¬Û¬°¿Ñ,¦ó¥²·d±o¦¹ª©¯Q·Ï¿`®ð, ¸Û¤ß«Øij¦Ñ·¨¤j±N¦¹ª©Ãö³¬,Åý¬P¬P¦^Âk¥¿y,Y°ò¥»±ªø´Á¬Ý¦n,¥«³õ¦ÛµM·|ÁÙ¥¦¤½¹D, §Ú¤´´Á«Ý¬P¬Pµo¥úµo«Gªº¨º¤Ñ¨ì¨Ó,ªÑ»ùYÄò¶^,¦b¯à¤O½d³ò¤º¤´·|¦A¥[½X,·í¬Ý¦nªº±¡ªp¤U, ²ö§Ñªì°J¡C ¥[ªo¬P¬P!!! |
|
|
·|û¡GºÃ´bªÌ10140504 µoªí®É¶¡:2017/11/1 ¤U¤È 01:27:51²Ä 1723 ½g¦^À³
|
°ò¥»±³Ó©ó¤@¤Á+1 ³o¼Ëªº°ò¥»± ¦pªGÁÙ¯à¶^¨ì40 ¨º§Ú¤]¬O»{¤F |
|
|
·|û¡GDavid Xu10143450 µoªí®É¶¡:2017/11/1 ¤U¤È 01:16:32²Ä 1722 ½g¦^À³
|
¬P¤ÍÌ ¤È¦w ¥H¤U¨Ñ°Ñ¦Ò¡A¶R½æ¬ÒÓ¤H¦Û¥Ñ¡A¦h°Ñ¦Ò¦h¤ñ¸û ¬Ý¬Ý2015¬ù7¤ë¥ª¥k¤j¥ß¥ú¥Ñ3750¥ª¥k³s¶^¥b¦~¶^¦Ü1900 ¨º¥b¦~À³¸Ó¬O¯Q¾~³»§p®É´Á ¦ý¬O¥Ñ2016¦~ªì¤Sº¦¨ì6000¡A¦Ü¤µÁÙ5700¥ª¥k¡]°ò¥»±³Ó©ó¤@¤Á¡^ |
|
|
·|û¡GQQD10145401 µoªí®É¶¡:2017/11/1 ¤U¤È 12:12:16²Ä 1721 ½g¦^À³
|
65 ¨Ó¤FÅo! ª`·N³á! |
|
|
·|û¡G¤p¶§10139627 µoªí®É¶¡:2017/11/1 ¤U¤È 12:12:08²Ä 1720 ½g¦^À³
|
ª±¨Óª±¥hÁÙ¬O¹q¤lªÑ¦nª± ¥ý«e¬Ý¨ìX°ßªº©MXÂyªº¶i¨Ó ¯d¨¥§Ú´Nª¾¹D¨Æ±¡¤£§®ªG¯u¦p¦¹ ¦³¥LÌ¥X²{ªº¦a¤è³£¤£¬O¦n²{¶H |
|
|
·|û¡G³Á§JªL10142093 µoªí®É¶¡:2017/11/1 ¤W¤È 11:56:19²Ä 1719 ½g¦^À³
|
¬P¬Pªº¯ÊÂI´N¬O¤jªÑªF¹ê¤O¤Ó®t¡A¤£¬O«Ü¦³¿ú¡A¬°¤F¨p¶ÒÁÙ»Ýn½æ¦ÑªÑ¡C |
|
|
·|û¡G¤p¶§10139627 µoªí®É¶¡:2017/11/1 ¤W¤È 11:56:07²Ä 1718 ½g¦^À³
|
¼Ú¤jÁ¿ªº¦³²z §Ú¥ý¥X³õ¤F |
|
|
·|û¡G¼Ú¬¥©_10144203 µoªí®É¶¡:2017/11/1 ¤W¤È 11:47:25²Ä 1717 ½g¦^À³
|
¤£n·Q»¡¥É¤s«°¤¤ÁÙ¦³¦h¤Ö ¤]¤£¥Î¥hpºâ¥É¤s«°¤¤ªº®w¦s¶q §ó¤£n·Q»¡¥É¤s«°¤¤½æ§¹´N¨S¨Æ¤F ¥_·¥¬P¤@ª½´N¬O¤@Ó±µ¤O˳fªº±¡ªp ¥É¤s«°¤¤²{¦b¬O¾Ô¥Ç ¬O¦]¬°²{¦b´Î¤l¦b¥L¤â¤W µ¥¥L˧¹¤F ·|¦³¤U¤@Ó¨é°Ó±µ¤O˳fªº ¤@¼Ëªº¦æ¬° ¤£¤@¼Ëªº¦WºÙ½}¤F ¦^·Q¤@¤U¥_·¥¬P±q¤W¿³Âd¥H¨Ó ¤w¸g´XÓ¨é°Ó±µ¹L³oÓ˳fªº´Î¤l¤F ¨CÓ¤j®a³£¥H¬°¬O³Ì«á¤@´Î §O·Q¤Ó¦h ©ñ¼e¤ß±¡§a |
|
|
·|û¡G@¦ÌµX10144792 µoªí®É¶¡:2017/11/1 ¤W¤È 11:30:47²Ä 1716 ½g¦^À³
|
¹ï¥IÄê¤jªÑªF´N¬O§A¥á§Ú¤£¾ß! ¬Ý§An½æµ¹½Ö! µL¶q¤U¶^³Ì¦n~18¶ô§Ö¨Ó§r! |
|
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2017/11/1 ¤W¤È 11:27:17²Ä 1715 ½g¦^À³
|
from 11,1 after 68 (unit) 1,08 (T) impressive d from BCI |
|
|
·|û¡GªÅ¤]ªÅªÅ10145331 µoªí®É¶¡:2017/11/1 ¤W¤È 09:48:14²Ä 1714 ½g¦^À³
|
¥HFDA¨S¦³n¨D¼È°±Á{§É¸ÕÅç(clinical hold)¨Ó¬Ý¡A¦w¥þ©Ê¤£¬O°ÝÃD¡C ¥½´ÁÀù¯gÁ{§É¸ÕÅç¡A¦º¤`²v¤ñ¨ä¥LÃþ§Oªº¸ÕÅç°ª¡C ¸ÕÅç°õ¦æ´Á¶¡µo¥Í¦º¤`Ӯפ£¬O°ÝÃD¡A«nªº¬Oµû¦ô¦º¤`»P¥ÎÃĪºÃö«Y¡C ¦pªGªì¨Bµû¦ô¥i¯à»P¸ÕÅçÃĦ³Ãö¡AFDA·|¥ý¼È°±Á{§É¸ÕÅç(clinical hold)¡A¶i¦æ§ó¸Ô²Óµû¦ô¡C ¬ÝP¦ºªºì¦]¬O§_¯uªº»P¥ÎÃĦ³Ãö¡H¥i¤£¥i¥H±±¨î¡H·ÀI¦³µL°ª©ó§Q¯q¡H¦A¨M©wn¤£nÅý¼t°ÓÄ~Äò°õ¦æ¸ÕÅç¡C ²Ä¤@¦¸¥Ó½ÐÁ{§É¸ÕÅ窺·sÃÄ¡A¦³®Öã¸ò¤£®Ö㪺°ÝÃD¡C «áÄò¬ÛÃöªº¸ÕÅç¡A°ò¥»¤W¬O¤£»Ý¦A¸gFDA®Öã¡C ¥X¿úªº¬O¼t°Ó¡AÁ{§É¸ÕÅç¸ê®Æ¤£ºÞªø±o¤°»ò¼Ë¤l¡A¹ïÁ{§ÉÂå¾Ç©Î¦h©Î¤Ö³£¦³À°§U¡C ¸ÕÅç¹Lµ{¥X²{¦w¥þ©Ê°ÝÃD©Î¬O°µspecial protocol assessment¡A¥t·í§O½×¡C ADI-PEG 20 HCCªºpivotal trial²q´ú¬O°µ¹LSPA¡A¤~·|±o¨ì³æÁu¡BORR 95%¤U¤j©ó15%ªºµ²½×¡C ¦ý³oÓµ²½×¡A¨Ã¤£¥NªíFDA»{¦PADI¨ã³o¼ËªºÀø®Ä¡C FDA¥u¬O´£¥X¸ÕÅçµ²ªG¦Ü¤Ön¹F¨ì³o¼ËªºªùÂe¡A¤~¦³¥i¯à®Öã¡C ¹F¤£¹F¨ì³oÓªùÂe¡A¬O¼t°Óªº³d¥ô¡C ¹L¥h¨â¦~FDA®Ö㪺Àù¯g¥ÎÃÄ¡A¦³¤£¤Ö¬O¥ÎORR·í§@¥DnÀø®Ä«ü¼Ð¡C ORRªº¦n³B¬O¸`¬Ù¬ãµo¸ê·½¡A¦ý¶·¨ã³Æ¤@©w±ø¥ó¡C¸Ô±¡¥i°Ñ¾\ Guidance for Industry¡GClinical Trail Endpoints for the Approval of Cancer Drugs and Biologics page 7 and 8¡C ORR§@¬°¥DnÀø®Ä«ü¼ÐªºÁ{§É¸ÕÅç¡A±`¨£³æ¿W¥ÎÃÄ¡C Áö»¡¬O³æÁu¡A¦ý¨ä¹ê¬O¦³ÁôÂùï·Ó²Õ¡CÁôÂùï·Ó²ÕORRªº95%¤W±µªñ0¡A°ò¥»¤W¥iµø¬°0¡C ¦]¬°¥½´ÁÀù¯g¡A¸~½F·|¦ÛµMÁY¤pªºÓ®×«Ü¤Ö¡F¸~½F®ø¥¢ªº¡Aµ¥¦P¯«¡B¦ò¡B¤W«Ò³Ð³yªº©_ÂÝ¡C ¥»®×¬OÁp¦X¥ÎÃÄ¡A¬J¦³ªº¸ÕÅç¸ê®ÆÅã¥Ü¬YºØµ{«×¡Afolfox¥iÁY¤p¨xÀù¸~½F¡C 1+1¦Ü¤Ön¤j©ó1¡C¦]¦¹¡AFDAn¨D95%ªº¤Un¤j©ó15%¡C ±q14¦ì¨ü¸ÕªÌ4¦ì¦³¤ÏÀ³¨Ó±À¦ô95%ªº¤U·|¤j©ó15%¡C¦]¼Ë¥»¼Æ¤p¡B·ÀI¤j¡C ³Ì¦n¦b30¨ì60¦W¨ü¸ÕªÌ¦³4¨ì6Ó¤ëµû¦ô¸ê®Æ®É¡A¦A°µ¤@¦¸¤ÀªR¡C ¤ÀªRµ²ªG¦p¦P¹w´ú¡A«i©¹ª½«e¡C®t«Ü¦h¡A«O¯d¾Ô¤O¡C¤¶©ó¨âªÌ¤§¶¡¡AÀYµh¡C ±N¨Ó¤£ºÞ¦¨¥\©Î¥¢±Ñ¡A¾ãÓ¬ãµoªº¹Lµ{¤Îª©¤Wªº°Q½×¡A¬O·sÃĬãµo«Ü¦nªº°Ñ¦Ò¡C |
|
|
·|û¡G¥xÆW¤û´×10145517 µoªí®É¶¡:2017/11/1 ¤W¤È 04:03:17²Ä 1713 ½g¦^À³
|
¦Ñ´¤j¤j¨¯W±z¤F¡I´Á«Ý¬P¬P©ú¦~¦³«G²´ªºÁ{§É¼Æ¾Ú¥XÄl°Õ¡ã |
|
|
·|û¡G¬P¥úÀéÄê10145521 µoªí®É¶¡:2017/11/1 ¤W¤È 03:47:46²Ä 1712 ½g¦^À³
|
Á`¤§§A§â°ò¨È¡Ahtc,¸ò¬P¬P·í¦¨Ãix,¦ý§Ú§â¬P¬P·íÂû»L....so¦U¦ìÆ[²³§A̦ۤv§PÂ_Åo °v©t¤ä¡]³æÃÄ¡^¤ñ¸ûºCko§A¡AÃø¹D¤£¯à£y£¹£«£¿¤H¡]Áp¦X¥ÎÃÄ¡^¨Ó¤@°_¶}«ó¶Ü¡H |
|
|
·|û¡G¥m¾´10141821 µoªí®É¶¡:2017/11/1 ¤W¤È 01:55:52²Ä 1711 ½g¦^À³
|
ÄƦV¥_¤è10144825 Y§A·Qª¾¹D¦w¥þ©Êªº°ÝÃD¡A¥i¥H¬Ý¬Ý§Ú¹L¥hªº¶K¤å¡A§Úªº¶K¤å«Ü¤Ö¡A¦ý¤£®e©ö¬ÝªºÀ´¡A ²³µVµVÃ~¥Ò°í¦pÅK¾À¡A¤M¼CÃø«I¡A·QÂI¿ô¥LÌ¡AÃø¨o¡I |
|
|
·|û¡G¥m¾´10141821 µoªí®É¶¡:2017/11/1 ¤W¤È 01:19:35²Ä 1710 ½g¦^À³
|
«¢¡I «ç»ò¤£®³°ò¨È°µ¤ñ³ë¡A«ç»ò¤£®³§»¹F¹q°µ¤ñ³ë¡A·íªì§Ú¥´¤F¤@´X¦æ¦r¡A¦ý¬O¤Ó¨¯»¶¡A¨S¦³¶K¤W¨Ó¡C ## ±i¥@©¾©ç¤F¤@¤U¦Û¤vªºÃBÀY¡AÆg¹D¡GºÖ§B¯u¥L¶ýªº¤Ñ¤~¡A·íªì§Ú«ç»ò¨S·Q¦X¨ÖÀøªk¨ì³o©Û¡A§Úªº§¾Àù88¦^¤Ñ¦³±æ¤F¡C«H»}¥¹¥¹n®³§¾Àù88»P20ºØÀù¯gªº²Ä¤@½u¤jÃĨ֥ΡA¦ý¬O·Q¨ì¿W¤O§¹¦¨Á{§É¸ÕÅç©Ò»Ýt¾áªºÃe¤jÂåÀø¶O¥Î¡A¤£¸T¤S±¨±£¤F°_¨Ó¡C ³æÃĵL®Ä¡A¨Ö¥Î¥i±æ¥[¦¨¡H¤Ñ¤~¤~·|·Q±o¥X¨Ó¡AºÆ¤l¤~·|¬Û«H³o°¸Ü¡C ## |
|
|
·|û¡G¬P¥úÀéÄê10145521 µoªí®É¶¡:2017/11/1 ¤W¤È 12:50:18²Ä 1709 ½g¦^À³
|
°O±o¤¤¸Î¦b1¦Ê¦h®É®üôµ¥¤@°ï¤j¤á¤]¬O¤j¶q¥X³f¡A¦ý¤¤¸Î°ò¥»±¨ä¹ê³£¨SÅÜ¡A©Ò¥H²{¦bÁÙ¤£¬O¤S¨ì2¦Ê¤F¡C½Ð°Ý¼Ú¾´¤G¤H²Õ¡A´²¤á¦b100¤¸¶R®É¤@©w¬Oı±o«K©y¤~¶R§a¡A¦pªG¥L¹w´Á¯àº¦¨ì150¨º²{¦b¤£¬OÀ³¸Ó§ó°ª¿³¥i¥H¥[½X¶Ü¡H°£«D100¤¸®Éall in¤U¥h¦Ó¨S¦¥[½X¡A³o»ò®tªº¸êª÷±±ºÞ©Ç½Ö°Ú¡IÁÙ¬O§A̪ºªø´Á§ë¸ê¬O¤@Ó¤ë¡H |
|
|
·|û¡G¤@¤ô´H10144832 µoªí®É¶¡:2017/10/31 ¤U¤È 11:56:16²Ä 1708 ½g¦^À³
|
¦Ñ´¤j«e½ú±ß¦w¡B¦U¦ì¬P¤Í¤j¤j̱ߦw¡G ½Ð¬Y¦ì·¥«×Ãöª`¥B·R¤À¨Éªº¤j¤j¤£n¤@¬ñ¤l¥´Â½¤@²î¤H¡I ¤pªº¸g¹L¤ñ¹ï¤½¶}ªºÄw½X¸ê°T«á¡A µoıÁÙ¬O¦³¤£¿ù¡Bª¾¤À¤oªº¤jªÑªF«ùÄò°í©wªº¤ä«ù¤½¥q¡I ¡]¨Ã«D¬O«ü¥É¤s«°¤¤¡^ ¦pªG³oÓ¤jªÑªF¤£¬O¬Ý¦n¤½¥qªº¥¼¨Ó¼ç¤O¡A ¤j¥i°âªÑ«á¸¨³U¬°¦w¡A ¦ó¥²¦A§â¥Õªáªáªº»È¤l®³¥h»{Áʨp¶ÒÂê¦í¤T¦~©O¡H ·íµMÅo¡I «HªÌ´N«H¡I ¤£«HªÌ¤]µLªk«j±j¡I ºK¿ý¾ã²z¸ê®Æ¦p¤U¨Ñ°Ñ¡G ¡¶¤é´Á¡¹¦¨¥æªÑ¼Æ¡»¥þÅé¨é°Ó¨C¤é®w¦s¼W´îªÑ¼Æ¡´¥þÅé¨é°Ó¨C¤é®w¦sÁ`ªÑ¼Æ -------------------------------------------------------------------------------------------------------- ¡¶2017/10/31¡¹1,729,663¡»555,240¡´43,734,617 ¡]¬ÛÃö¼Æ¾Ú»¡©ú½Ð°Ñ¦Ò²Ä486½g¦^À³¡A ¥H¤W¤§¡u¥þÅé¨é°Ó¨C¤é®w¦sÁ`ªÑ¼Æ¡v¼Æ¾Ú¡A ¦]·½ÀY¸ê®ÆÅܼƲ³¦h¡A¶È«Y·§²¤¼ÆÈ¡A ¦p¦³¿ù»~¤§³B¡A½Ð¦U¦ì¬P¤Í¤j¤j¦h¦h¥]²[¨Ã¤£§[´f¤©½ç±Ð¡C¡^ |
|
|
·|û¡GºÃ´bªÌ10140504 µoªí®É¶¡:2017/10/31 ¤U¤È 11:26:56²Ä 1707 ½g¦^À³
|
l®Ú¾Ú³æÁu¬ã¨sªºÃĪ«ÀòãªùÂe°ª¡A¥²¶·¬O¯f¨Ò«D±`¤Ö¨£¥BÀø®Ä¬Û·íÅãµÛªºÃĪ« |
|
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2017/10/31 ¤U¤È 11:15:05²Ä 1706 ½g¦^À³
|
¤µ¤Ñ¶}¤F¤@¥xHNSCC T4BN2C«ÜÃø¶}ªº¤M,®tÂI¤U¤£¨Ó!ÁöµM¤S¦A¦¨¥\±Ï¦^¤@ÓT4BN2Cªº¯f¤H,¶}§¹¦³ÂI«á®¬·F¹À³o»ò²Ö,À³¸ÓÂ൹¤½¥q½Ð¯f¤H¥h¦¨¤j¥ÎADI+Keytrudaªº!!! ¦ý¬O¦bµ¥¤Mªº¹Lµ{¤¤,ªL¥_ÁÙ¬O¶i¤F20ªÑ!!! ¤µ¤Ñ«Ü²Ö¤F,¨S®É¶¡¸ò¾´¾´©M©_©_ª±! Á`¤§,¦nÀ¸¦b«áÀY,©ú¤Ñ¦A¨Ó¬Ý¬Ý,¦h¤Ö¤H·|«á®¬¤µ¤Ñªº¨M©w!!!©ú¦~¦A¨Ó¬Ý¬Ý,¦h¤Ö¤H·|«á®¬¤µ¦~ªº¨M©w!!! |
|
|
·|û¡G§ë¸ê¬ö«ß10145266 µoªí®É¶¡:2017/10/31 ¤U¤È 11:03:52²Ä 1705 ½g¦^À³
|
ADI¶i¦æªºÁ{§É¤w¶W¹L1,000¤H ¬O¤£¬O¹³¦³¤H»¡±o¡A¥´¤@°w¦º¤@¥b?? ¬O¤£¬O¹³¦³¤H»¡±o¡A§d³Õµo²{¥u¥ÎADI·|¦º¤H¡A©Ò¥HÅܦ¨Áp¦X¥ÎÃÄ¡A·QnÁô°Î³æÃĹ걡?? ¦pªG¬O... ¨º¨Ç¥@¬É³»¦yÀù¯g¤¤¤ßªº±Ð±ÂÁÙ¤@ª½°t¦X¥_·¥¬Pµoªí½×¤å§èÁÀ! FDA¤]¤£³Û°±¡AÁÙÅý¥_·¥¬P«ùÄòÁ{§É¡A¬Æ¦ÜÁÙµ¹³æÁu¼Ï¯Ã¸ÕÅç! ù¤óÁÙ§K¶Oµ¹ÃÄ¡A¨º¨ÇÅU°Ý¬O³£§j¹q·®°§ï¦Ò¨é³á ¦³¨S¦³¦w¥þ©Ê°ÝÃD¡A»¡¯uªº...À³¸Ó¤£»Ýn¦A°Q½×¤F |
|
|
·|û¡Gªü¾ç10145307 µoªí®É¶¡:2017/10/31 ¤U¤È 10:34:05²Ä 1704 ½g¦^À³
|
¬Ý¨ì¦p¦¹¼ö¾x¯u¬O¦³½ì ªÑ²¼¨C¤Ñªºº¦¶^¨S¦³¥ô¦óì¦] ¯Âºé´N¬O¦³¤H·Q½æ¡A¦³¤H·Q¶R¡A¥H·b¦Xªº»ù®æ¦¨¥æ ¦³¤HÄ@·N§C»ù¤j¶q½æ¥X¡A©Î³\¬OÀò§Q¤Fµ²¡AÄw±¹¸êª÷Âà¾Ô¤U¤@®aÄ~Äòª£ªÑ ¦³¤HÄ@·N¦b³oÓ»ù®æ¤j¶q±µ¦¬¡A©Î³\¬O¬Ý¦n¥¼¨Óµo®i¡A¥Î²{ª÷¤ä«ù ´Á¶¡¦³¤H³QªÑ»ùÀ~¨ì¦Y¤â¤â¡A»°§Ö°±·l ¤]¦³¤H¦V¤U«ùÄòÅu¥ µL½×¦p¦ó¡A¼@¥»ÀH¤H¼g¡An¤ñÅ宪¡A§Úµ´¹ï¤ñª©¤W¼g¤â§ó¼F®` ¤@¤éº¦¶^¡A¯Âºé¤ß²z§@¥Î¥[¤W¤H¬°¾Þ§@¦Ó¤w °Ý°Ý¤j®a FDA°h¥ó¥_·¥¬P¤F¶Ü¡H Á{§É¼Æ¾Ú¤j¥¢±Ñ¡A¯f±w¯gª¬§óÄY«¤F¶Ü¡H °ê»ÚÃļt«Å¥¬¦X§@¥¢±Ñ¡A¤£¦A»P¥_·¥¬P¶i¦æ¥ô¦ó¦X§@¤F¶Ü¡H ¤½¥q¤jªÑªF¦³¤º½u¥æ©ö¡A¸ò¬Y³»¤@¼Ë¡A³s¶ä¶ä¶ä³Ì¦ì°ªÅv«ªº¤H³£§â«ùªÑ½æ¥X¤F¶Ü¡H ¥_·¥¬P¦Û¤v«Å¥¬ª±¤£¤U¥h¤F¡A¤½¥q¹Î¶¤¸Ñ´²¡A§Þ³N«K©y½æ¥X¤F¶Ü¡H ÁÙ¬OÁ{§É¼Æ¾Ú³y°²³Q·b¯}¡A¨ºFDA³o¨Ç¤H¸ò¯Q¾~¤@¼Ë¦Y«Ëªø¤jªº¶Ü¡A©~µMÁÙ®Öã³æÁu¥[³t¼f®Ö¡H §A¶R¥_·¥¬Pªºªì°J¬O¡H ¬O°ò¥»±¡AÁÙ¬OÄw½X±¡AÁÙ¬O§Þ³N¤ÀªR¡H ¦pªG¬O°ò¥»±¡A¨º°ò¥»±¦³§ïÅÜ¡AÁÙ¬OÅܧó¦n¤F¡H ¦pªG¬OÄw½X±¡A¨º§A¬O°Ñ¦ÒþÓ¤jªÑªFªº¶i¥X¨Ó¨M©w¶i¥X³õ¡H¡H ¦pªG¬O§Þ³N¤ÀªR¡A§Aªº¼µÀ£§¡½u¯}¤F¡A¬On¶i³õÁÙ¬O¥X³õ¡H ¦pªG¬O°ò¥»±¡A¨º§A¨C¤Ñ³£¦bÃöª`Äw½X¨«¦V·F¹À¡H ©Ò¿×ªº¤ÀªR«Í¡A´N¬O¨£¶^»¡¶^¸Ü¡A¨£º¦»¡º¦¸Ü¡A¨£¤H´N»¡·F¸Ü ¯}¾Ç®Õªº§K¬~¤j¾ÇºÓ¤h¾Ç¾ú¡A·d¤£¦n³s¤j¾Ç³£¨SŪ§¹ªº¤Hªº¸Ü¯àÅ¥¡A¯Q¾~¤jªº«K´N¯à¦Y °£«D¥L¬O¤ý¥Ã¼y¡A³¢¥x»Ê ¤£µM§Ú¹çÄ@¬Û«H°ê»Ú¹ê¤Oªº¹Î¶¤¤ÎÃļtÁÙ¦³FDA |
|
|
·|û¡G¾Ç²ßªÌ10145489 µoªí®É¶¡:2017/10/31 ¤U¤È 10:27:54²Ä 1703 ½g¦^À³
|
¦U¦ì¬P¤Í¦n¹Ù¦ñ¦n 2016¤ÀªR®v¤@P¬Ý¦n´äªÑ¡A¦ý´N¬O¤£º¦¡A¨ì¦p¤µ2017¡A´äªÑ¤jº¦¬Ý¦^¤£¦^¡A¥þ²yªÑ¥«ÄË°Tº¦³Ì¦h¡C©ú¤Ñ¬O11¤ë·sªº¤@¤Ñ¡AÅwÅw³ß³ßªï±µ¡A¨Ƥw¹L¡A³£¦¨¬°·sªº¤F¡C ÁÂÁ¬P¤Í±`¤À¨É¿N¸£«áªººëµØ¡A·P®¦¡C¤S¹L¤F¥¦wªº¤@¤Ñ¡C |
|
|
·|û¡GÂÅ®æ210145614 µoªí®É¶¡:2017/10/31 ¤U¤È 10:23:37²Ä 1702 ½g¦^À³
|
¦n¹³¤Z¨Æ«D¶Â§Y¥Õ §Ú«ù¦³´N»Ý120%ªº«H¥õ ¤£µM´N¸Ó¤U¨®¡K¡K? §Ú¥i¤£¥i¥H¥u«H¥ô¤½¥q¹Î¶¤¡A«H¥ô§d§B¡A µM«á«ù°ª«×ÃhºÃºô¸ô¤Wªº¨¥½×? ³o¬O¨â¥ó¨Æ¡A¤£n±i¸¥´©¨¸ §Ë±o°ª«×«Ü°ª ¾ú¥v´N¬O¤£Â_¦b«ºt ¤£½×§A¬O¤£¬Oè±q¯E¹©ºM¥X©Î¤´²`³´ |
|
|
·|û¡GÄƦV¥_¤è10144825 µoªí®É¶¡:2017/10/31 ¤U¤È 10:08:09²Ä 1701 ½g¦^À³
|
¨Ï¥Î½Ķ¬Oµ¹¬Ý¤£À´ªº¤H¬Ýªº¡Aì¤å®Ñ¤£¬O»¡ªº°÷²M·¡¤F¶Ü¡H¦Ü©ó¦º¤`©M¥ð§Jªº®×¨Ò¦³¦bþ³õªk»¡·|¸ÑÄÀ¹L©O¡H¤£n¥H¬°°Ñ¥[©Î¦¬¬Ýªk»¡·|¬O¤Ö¼Æ¤Hªº±M§Q¡A¦pªG¯u¦³ªº¸ÜÄ@»D¨ä¸Ô°Ú¡A§ÚÁÙ¯uªº·Qťť¤½¥qªº»¡ªk¡C¤µ¤Ñ°ê²¼¤¤¥¿¨Ã¨S¦³§¹¥þ±µ¦¬ÁÉ´IªºÄw½X¡A³o¬O²Ä¤@¦¸µo¥Í»~®t¤ñ¸û¦h±i¡A¦Ó¥B©¹¤U±þ¥L¤]¨S¥[½X¡A©Ò¥H§Úªº²z¸Ñ¬O¥L¤w¸gÁY¤â¤F¡A·íµM³Ñ¤U300±i¤]¤£¦hÀ³¸Ó¥i¥H§Y®É¥X¥ú¡A¦ý«ç¯à½T©wÁÉ´I¥u½æ¤F³o¤@¦¸©O¡H¥L¤â¤WÁÙ¦³¤G¸U¦h±i°Ú¡I§ó¦óªp°ê²¼¤¤¥¿²Ä¤@¦¸±µ¤â¬O¹j¤Ñª½±µ»{½ß½æ¥X¡A¤S¦p¦ó¯à½T©w¥L¬Oªø´Á«ù¦³ªº¤ßºA©O¡HÃø¹D¨S¦³¥u¬OÅýÁÉ´I¦b´Á¤º¥X²M«á¦AÂà½æªº¥i¯à¶Ü¡HªÑ¥«´N¬O¦p¦¹¥Rº¡¤£½T©w©Ê¡A¥H¤W¶È¨Ñ°Ñ¦Ò¡A½Ð¤Å±¡ºü©Êµ§¾Ô¡AÁÂÁ¡I |
|
|
·|û¡GTsai10144789 µoªí®É¶¡:2017/10/31 ¤U¤È 09:46:34²Ä 1700 ½g¦^À³
|
¦U¦ì¬P¤Í̱ߦw ¤µ¤Ñ还¯u¼ö¾x¡A¥_·¥¬P¯uªº«Ü¨üÅwªï³á~ »«¹£ô¡I´Á«Ý³¯¦~58 ¥_·¥¬P¡I¥[ªo¡I |
|
|
·|û¡G¬P²y±U°_10145048 µoªí®É¶¡:2017/10/31 ¤U¤È 08:10:44²Ä 1699 ½g¦^À³
|
¦U¦ì±ß¦w~¥_·¥¬P¯uªº«Ü¨üÅwªïªº~ ·Q·Q~¦pªG¬P¤Í̤£¦b¨®¤W®É,¤£¨ì12¤p®Éªº®É¶¡,§A·|³o¼Ë»{¯u¶Ü¡H ¦pªGÁÙ¦³®a¤Hn³¦ñªº¸Ü,¥i¥H¤U¯Z¤F§a~¨¯W¤F¡C ·|û¡G¼Ú¬¥©_10144203 µoªí®É¶¡:2017/10/16 ¤U¤È 02:32:17²Ä 1453 ½g¦^À³ ¯«¯µ¤j¤á±µ¤â ¶R®ð±j¤j §¤Ã¤F nöt¤F «¢«¢ µ¥¼Æ¿ú°Õ¡I¡I ---------------------------------------------- ·|û¡G¼Ú¬¥©_10144203 µoªí®É¶¡:2017/10/31 ¤W¤È 09:08:53 ²Ä 1682 ½g¦^À³ ¬Ý¬Ý¼Ó¤U¨ºÓD¤°»òªº³oºØ´N¼Ð·Çªº°ê¤¤¥Íðã½|¸ò³oºØ¤H¬°¥î ·|û¡G¼Ú¬¥©_10144203 µoªí®É¶¡:2017/10/31 ¤U¤È 12:23:49²Ä 1697 ½g¦^À³ ¤µ¤Ñ³£³o¼Ë¨g¶^¤FÁÙ¦b¨ºÃ仡¤°»ò¤£¬O¹Ú§j¤f裏Áxªº¤HÁÙ¯u¤£¤Ö ·|û¡G¼Ú¬¥©_10144203 µoªí®É¶¡:2017/10/31 ¤U¤È 03:37:49²Ä 1704 ½g¦^À³ ¨º¨Ç³Q¬~¸£ªº¤H ·|§â²{¦b½æ±¼ªº¤H»¡¦¨¬O³Q¬~±¼¥i¬O§AÀR¤@¤U¤ß¤@·Q¤@¦Ê¦hªº®ÉÔ³o¨Ç¤H¤]¬O³o¼Ë»¡ªº ·|û¡G¼Ú¬¥©_10144203 µoªí®É¶¡:2017/10/31 ¤U¤È 04:13:45²Ä 1706 ½g¦^À³ §Ú¤£Ä±±oÀ£¤O¤j¤]µLªk¤U¨® ¦]¬°§Ú®Ú¥»¤£¦b¨®¤W ·|û¡G¼Ú¬¥©_10144203 µoªí®É¶¡:2017/10/31 ¤U¤È 06:33:51²Ä 1714 ½g¦^À³ §Ú»¡ªº³£¬O¨Æ¹ê¨Ã¥B³£»PªÑ»ù¨«¶Õ»P¤j¤á¦æ¬°¬Û¥h¤£»·§óµL¶Ã½s¬G¨ÆÄF¤H ·|û¡G¼Ú¬¥©_10144203 µoªí®É¶¡:2017/10/31 ¤U¤È 07:22:39²Ä 1719 ½g¦^À³ «¢«¢«¢¥_·¥¬P¹Î¶¤ ·íµM¤£¬O§Ú¯àµûÂ_ ·|û¡G¼Ú¬¥©_10144203 µoªí®É¶¡:2017/10/31 ¤U¤È 07:53:14²Ä 1721 ½g¦^À³ ¥i¼¦¬Y¨Ç¤H¥i¤£¥i¥H¾ÇµÛ´N¨Æ½×¨Æ§O¦AÀ°·N¨£¤£¦Pªº¤HÀ¹¦UºØ´U¤l ·|û¡G¼Ú¬¥©_10144203 µoªí®É¶¡:2017/10/31 ¤U¤È 08:01:14 ²Ä 1723 ½g¦^À³ ¶¶±a¤@´£¦³ªÅªº¤H¤]¥i¥H¥h¯E¹©ª©³}³} |
|
|
·|û¡G¼Ú¬¥©_10144203 µoªí®É¶¡:2017/10/31 ¤U¤È 08:01:14²Ä 1698 ½g¦^À³
|
¶¶±a¤@´£ ¦³ªÅªº¤H¤]¥i¥H¥h¯E¹©ª©³}³} ·íªì±q700¦h¤U¶^ 500¦h 400¦h 300¦h ³£¦³¤H»¡©³³¡¨ì¤F ½æ±¼ªº¤H¬O²Â³J ·|«á®¬ ¥L²{¦b¥u¦³¤@¦Ê¦h ¤@¨âÓ¤ë«e ¥_·¥¬P¸¹ºÙnºÙÅQ¥Í§Þ Åܦ¨¥Í§ÞªÑ¤ý µ²ªG²{¦b¸ò¬P¤Í²´¤¤«ÜÄꪺ¯E¹©±q2:1Åܦ¨ªñ3:1¤F |
|
|
·|û¡G¸Û«H¦ó®¬10139574 µoªí®É¶¡:2017/10/31 ¤U¤È 07:54:57²Ä 1697 ½g¦^À³
|
¬Ý¬Ý¼Ú¤j´X¤Ñ«e¤~³Û¦h¡An¼Æ¶r¡A¤W§«ô½ªÅ°ÛÁö¡A YµL§Q¥i¹Ï·|³o¼Ë¶Ü¡H ¼Ú¼Ú¡A§A¤£¬Ý¦n¸ò¾´¾´§ÖÂ÷¶}§a §ÚÁÙ¬Oºû«ù¤@±i¥i´««n³¡¤G©Ðªºµû»ù¡I §Ú³ßÅw¯d¨¥¦b¥ý¡A¥Nªí°¸¹w´ú«Ü²r¡I «r§Ú°Ú |
|
|
·|û¡G¼Ú¬¥©_10144203 µoªí®É¶¡:2017/10/31 ¤U¤È 07:53:14²Ä 1696 ½g¦^À³
|
¥i¼¦ ¬Y¨Ç¤H¥i¤£¥i¥H¾ÇµÛ´N¨Æ½×¨Æ §O¦AÀ°·N¨£¤£¦Pªº¤HÀ¹¦UºØ´U¤l ²{¦b¤S¬O¤°»ò¯}¾Ç©±ªº§K¬~ºÓ¤h ? §Ú¦bªÑ¥« ´NÁ¿ªÑ²¼ ¬Y¨Ç¤HªF§è¦è§è ªÑ²¼ÁÙ¬O¤@ª½¶^ µL¶d¤S°l°ªªº´²¤áÌ°Ú ¬Ý²M·¡¤F¶Ü ³o¨Ç´N¬O·íªì¹ª§j§AÌ°l¦b³Ì°ªÂIªº¨º¨Ç¤H°Ú ¬Û«Hªº¤H ¤£¬OÄY«Á«·l ´N¬O±qÁȤ@¿Åܦ¨ÁȤ@ÂI ¤õ½u±Ï´©¤¤ ¤¦¦õµØ²±¹y©Ò¹¢ºtªº«OÅߦ³¥y¦W¨¥ ¤l¼u¤£·|ÄF¤H ¦bªÑ¥«¤¤¤]«Ü²³æ ªÑ»ù»PÄw½X¤£·|ÄF¤H ¤£ºÞ§A¬Û«H¤½¥qÁÙ¬O¬Û«H«Ü¦£ªºÂå¾Ç±Ð±Â ÁÙ¬O¬Û«H¸s²Õ ÁÙ¬O¬Û«H§A¬YÓ¦³¶RªÑ²¼ªºªB¤Í ³£¨S¦³Ãö«Y §A¥un°O±o³o¥y ªÑ»ù»PÄw½X¤£·|ÄF¤H ´N¥i¥H¤F ¦Ü©ó¨º¨Ç§A©Ò«H¿àªº¤H ¦pªG§Aµo²{¥L¥¿¦b¥´À»²§¤w ¶Ã®âÅB¦UºØ¨¤Àµ¹»¡¹ê¸Üªº¤H §A©Î³\´Nn¦Ò¼{³oÓ¤H¬O¤£¬OÁÙȱo«H¿à ©ÎªÌ¬O¥L¬O¤£¬O¹³¤@ÀY®â¤U¥hªº¶Ç¾P¤U½u ¤w¸g¶}©l¨ê¥d¶R¦Û¤vªº²£«~ ÁÙÄF¦Û¤v¯àÁȤj¿ú ¥X²{¤F³o¼Ë¥¢¥h§PÂ_¤Oªºª¬ªp¤F |
|
|
·|û¡Gªü¾ç10145307 µoªí®É¶¡:2017/10/31 ¤U¤È 07:27:54²Ä 1695 ½g¦^À³
|
¦U¦ì¿Ë·RªºªB¤Í §A¿ï¾Ü¬Û«H¾Ö¦³¶W±j¥Í¤Æ³Õ¤hªº¹Î¶¤¡A²{¥N§K¬Ì¸~½F¾Ç¤§¤÷Lloyd J. Old©Ò°í«ùªºADI-PEG ÁÙ¬O§A¿ï¾Ü¬Û«H¤£ª¾¹D¬Oþ¶¡¥xÆWªº¯}¾Ç©±²¦·~ªº¤j¾Ç¥Í©ÎªÌ¬O§K¬~ºÓ¤h©O¡H §A¿ï¾Ü¬Û«H§d§Bªºªk»¡·|¼Æ¾Ú ÁÙ¬O§A¿ï¾Ü¬Û«H¤£ª¾¹D¬Oþ¶¡¥xÆWªº¯}¾Ç©±²¦·~ªº¤j¾Ç¥Í©ÎªÌ¬O§K¬~ºÓ¤h©Ò½sªº¼@¥»©O¡H |
|
|
·|û¡G¼Ú¬¥©_10144203 µoªí®É¶¡:2017/10/31 ¤U¤È 07:22:39²Ä 1694 ½g¦^À³
|
«¢«¢«¢ ¥_·¥¬P¹Î¶¤ ·íµM¤£¬O§Ú¯àµûÂ_ ¤£¹L¦³¥«È¯àµûÂ_ ªÑ»ù¤w¸gµûÂ_¥X¤F¤½¥qªº»ùȤF ªÑ»ù¤S¬O¥Ñ³o¨Ç¤jªÑªF¤j¤á±þ¥X¨Óªº ¤j·§¤½¥q¦b¤j¤áªº²´¤¤»·¤£¦p¦b´²¤á²´¤¤ªºÈ¿ú ¨ì¬O³oÓD¤°»ò³¾¤òªº §A°£¤F·|¤H¨§ðÀ» §A§i¶D§Ú§AÁÙ·|¤°»ò ? |
|
|
·|û¡G¬P²y±U°_10145048 µoªí®É¶¡:2017/10/31 ¤U¤È 07:14:34²Ä 1693 ½g¦^À³
|
»«¹£ôªº¨¤À¤£¬O¤pùù¥i¥HÂI¦Wªº¡ã¤pù¡A§A´N¤£¥Îµ¥¦^ÂФF¡ã ¦ýÁÙ¬OÁÂÁ±zªºÂI¾\¡C ¥_·¥¬P·PÁ±zªº¤ä«ù¡C |
|
|
·|û¡G¬P²y±U°_10145048 µoªí®É¶¡:2017/10/31 ¤U¤È 07:05:03²Ä 1692 ½g¦^À³
|
¼Ú¤j¡AÁÂÁ±z µ½¨}¦p±z¡A¤£¦p±z¤]¤À¨É¤@¤U¡A±z¤£¥uÃöª`¥_·¥¬P¡A ÁÙ¦³¨º¨Ç¬O±z»¡ªº°I¤Hªºì¦]¡A¦nÅý¤j®a¤]¥i¥HÁ×Á×ÀI¡C §Úª¾¹D¥xªÑ¤£·|¥u¦³¥_·¥¬P¶^ªº¡]°I¡^¡A¥ýÁÂÁ±z®@¡ã ³£Ãö¤ß¥_·¥¬P³o»ò¤[¤F¡ã³o´XÓ¤ë¤~¨Ó¯d¨¥¡ã ¥i¥H¤¶²Ð§Ú¥h±z¨ä¥Lªº¯d¨¥³B¬Ý¬Ý¶Ü¡H |
|
|
·|û¡GFred10145613 µoªí®É¶¡:2017/10/31 ¤U¤È 06:57:24²Ä 1691 ½g¦^À³
|
»«¹£ô±z¦n¡I¥i¯àn³Â·Ð±zªº¿ËªB¦n¤Í´êº¡1000ªÑ¡A³o¼Ë¤~¯à½æ£¸±i¡I |
|
|
·|û¡GDavid Xu10143450 µoªí®É¶¡:2017/10/31 ¤U¤È 06:43:35²Ä 1690 ½g¦^À³
|
¯Q¾~©_ ¥_·¥¬P§d³Õ¹Î¶¤¡G¤£¬O§A³oºØ©@¯à°÷µûÂ_ |
|
|
·|û¡G¼Ú¬¥©_10144203 µoªí®É¶¡:2017/10/31 ¤U¤È 06:33:51²Ä 1689 ½g¦^À³
|
§Ú»¡ªº³£¬O¨Æ¹ê ¨Ã¥B³£»PªÑ»ù¨«¶Õ»P¤j¤á¦æ¬°¬Û¥h¤£»· §óµL¶Ã½s¬G¨ÆÄF¤H «on¤@¤U¤l³Q»¡¦¨¬O¤°»ò³Q¦ÑÁó½|ªºÁ«·l¾Þ½L¤â ¤@¤U¤l¤S¬O¤°»ò®a®x¥¢¦X ½Ñ¨Æ¤£¶¶ªºÅ¼¦Ñ¹« °ª¤U¥ß§P°Ú ! ¤£¹L§Ú¨S®t ¦]¬°¬Y¨Ç¤HJ»¡¤K¹D+ðã½|»P¦Û¤v·N¨£¬Û¥ªªº¤H¤£¬O¤@¨â¤Ñ¤F §Ú¥u¬O·Q½Ð¥Ø«eÄY«Á«·lªº¬P¤ÍÌ ²{¦b³oÓÂI°±·l¥i¯à¤]¤w¸g·l¥¢ºG«¤F °®¯Ü´N¤£n°Ê§@ ´N·í¬O¥h©Ô´µºû¥[´µ¿é¤F¤@§â ¤U¦¸ª`·N´N¦n¤F ¤d¸U¤£n¦]¬°¬Y¦¸§ë¸ê¥¢§Q§@¥X¤£²z´¼©Î¬O¶Ë®`¦Û¤vªº¨Æ |
|
|
·|û¡G»«¹£ô10144807 µoªí®É¶¡:2017/10/31 ¤U¤È 06:04:06²Ä 1688 ½g¦^À³
|
¹ï¤F¡A§Ñ¤F§i¶D¦U¦ì ³o¦¸ÁÉ´IÂàÅýªº2500±iªÑ²¼¥Ø«eÀ³¸Ó¬O¥Ñ¦P¤@Ó±b¤á±µ¤âªº¡]°ê²¼¤¤¥¿¡^ ¥H¥Ø«eÁÉ´I¤w¸gÂà¤F2200±iªº§¡»ù¨Ó¬Ý¡A°ê²¼¤¤¥¿¤j·§±µ¤âªº¦¨¥»¬ù72-73¡A2000±i¡]¦]¬°¦³¤@¤Ñ°ê²¼¤¤¥¿±µ¤â300±i¤§«e¹j¤Ñ½æ¥X¡A¤§«á¤S¶R¦^100¦h±i¡^ °ê²¼¤¤¥¿¬°¤F±µ¤â³o2000¦h±iªºªÑ²¼¦Ü¤Öªá¤F1.4»õ §Ú¤]¤£¾å±o³o¦ì±µ¤âªº¤H¬O¦ò¤ß¨ÓªºÁÙ¬O¤w¸g½Ð±M·~¤H¤hµû¦ô§¹«á±þ§¹»ù«áªº»ù®æ¡A¥Í·N¤Hªººâ½L¥Ã»·¤ñ§ÚÌ´²¤áªº¤j¤Îºë©ú ¥Ø«eÀ°¥Lºâ¤@¤U¡A±bÁ«¬ù1¤d¦h¸U °ê²¼¤¤¥¿ªº¤U¤@¨B©O¡H§Ú̵¥µÛ¬Ý§a¡I |
|
|
·|û¡GDavid Xu10143450 µoªí®É¶¡:2017/10/31 ¤U¤È 05:51:32²Ä 1687 ½g¦^À³
|
¬P¤ÍÌ ±ß¦w ¶R½æªÑ²¼¬O§ë¸ê¤½¥q¥¼¨Ó»ùÈ¡A¤£¥i¯à¨C¤Ñ±i/¤]¤£¥i¯à¥uº¦¤£¶^/§ó¤£¯àµu´ÁÁȼɧQ ¡]Ó¤H»{¬°£¸¦~¥H¤U³£Äݵu´Á¡^¡]§Y«K¬O©w¦sªÑ¤]n£¸¦~¤~¯à¤À¬õ¡^ ³o¸Ì¬O¬P¤Í¤¬¬Û¹ªÀy¤¬¬Û¥´®ðªº¦a¤è¡A¤£¶R¤]¥Î¤£µÛ£¸¤Ñ¨ì±ß¨Ó³o¸Ì°Û°I¡]¤ß³N¤£¥¿¡^ §Ú¹ï³o°¦¯Q¾~©_¡]ż¦Ñ¹«¡^ªº¬Ýªk¡G§Úªº·Qªk¤jP¤W»P»«¹£ô¹p¦P ²{¹ê¥Í¬¡¤¤ªº¯Q¾~©_¦³¥i¯à¬O®a®x¤£©M¥B½Ñ¨Æ¤£¶¶¡A©Ò¥H¸ú¦bºô¸ô¤W¨ì³B°Û°I¡C ¬Ý¬Ý³o¼Ë¥i¯à¼W¥[¤@¨Ç¸¨Ãøªº¡B¬Û¦P³B¹Òªº¤H¡]¦Û¤v·Pı¤£¨º»ò©t³æ¡^¡A |
|
|
·|û¡G³ß³ß¿}10144054 µoªí®É¶¡:2017/10/31 ¤U¤È 05:40:29²Ä 1686 ½g¦^À³
|
¬P¤ÍÌ ªÑ»ù©l²×¬O¯µ±Kªº¥ý¦æ«ü¼Ð......... ¤H¤£·|¸ò¿ú¹L·N¤£¥h³o¬O¤£Åܪº¹D²z |
|
|
·|û¡G»«¹£ô10144807 µoªí®É¶¡:2017/10/31 ¤U¤È 05:33:22²Ä 1685 ½g¦^À³
|
¬P¤ÍÌ¥¦w°Ú ¬Û«H¤j®a¤µ¤Ñªº¤ß±¡³£¤£¤Ó¦n¡A¬Æ¦Ü¦³¤H¤U¨®¤F¡A³£¨SÃö«Y¡A¦Û¤vªºªÑ²¼¦Û¤vt³d´N¦n¡A¤£¥Î¥h©Ç§O¤H ªÑ²¼¶^¤j®a´N·|¶}©l¦³«Ü¦ht±ªº·Qªk¡A¤H¤§±`±¡¡A»«¹£¤p§Ì¥u·Q¸òÁÙÄ@·N°í«ùªº¬P¤Í»¡¡A²ö§Ñªì°J 20¶ôªº®ÉÔ§Ú̼µ±o¹L¡A²{¦b68-70·|¼µ¤£¹L¶Ü¡H»«¹£¤]¬O«Ü¦hªB¤Í¶R¦b90-100¡A¥]§t¤p§Ì¦Û¤v¥h°Ñ¥[ªk»¡·|·|«á¤]¬O¥[½X µu´Á«á±¥[½Xªº±b¤W¬OÁ«·lªº¡A¦ý¬O§Ú¨S·Q¹L¨C¤Ñ¦b¨ºÃä¤@ª½¬ÝµÛ±b¤Wªº¼Æ¦r¡A¨º¨ÇªF¦è¦b©ú¦~³£·|¦³Óµª®× §Ú¦Û¤vªºª¬ªp¦Û¤v²M·¡¡A©Ò¥H¤µ¤Ñ¯Q¾|¤ì»ôÁ¿¤F¤°»ò¤]¬O¬Ý¬Ý¯º¯º´N¦n ¤Ï¦Ó§Ú¶}©l²q¯Q¾|¤ì»ô¨ì©³¬O¤°»ò¨¤¦â¡HÁô¨¦b500¤Hªº¸s²Õ¡A¤£´±¦b¸s²Õ¸Ìµoªí¦Û¤vªº¬Ýªk¡HµM«á»¡¦Û¤v¨S¶R¬P¬P«o¤@ª½Ãö¬P¬P¡HÃø¨ì§A¬O·tÅÊ»«¹£¤p§Ì§Ú¶Ü¡H·Qµo¨¥¤Þ°_§Úªºª`·N¡H«¢«¢ ¨ä¹ê§Ú¤j·§²qªº¥X§A¬O½Ö¡HÀ³¸Ó¤£¬O¤j©M°ê®õ´N¬O¤¸¤j´°«nªº¾Þ½L¤â§a¡C ¤@ª½¨«¤£¥X¥h¬°¤°»ò¦Û¤v¨º»òÄø¦b50-20ªº®ÉÔµû¦ôn§â¬P¬P½æ¥X¡A²{¦b³Q¦ÑÁóqªº«ÜºG¨S¦a¤èµo¬ª§a¡A©Ò¥H§A¦ÑÁ󵹧A¤@Ó¥ô°È¡A·íªì¦h¤Ö¿ú½æªºµ¹§Ú¥Î¨ºÓ»ù®æ¶R¦^¡A©Ò¥H§A¤~·|³o»òÃöª`¬P¬P§a¡AµM«á¬Ý¨ì¬P¬P¶^ªº®ÉÔ»°§Öµo¤å¬ÝªÅ¡AÀ~À~´²¤á»s³y®£·W®ðª^ ¦ý¬O»«¹£¸ò§AÁ¿¡A»«¹£ªº¿ËªB¦n¤Í¤@¦@¦n´X¦ÊªÑ¤@±i³£¤£·|½æ¡AÁÙ·|Ä~Äò¶R¡A©Ò¥H§AÁÙ¬O¬Ù¬Ù§a Ä~Äò¥h¤Ï¬Ù¦Û¤v¬°¤°»ò20´X¶ôn½æ¥X⋯⋯ ¤°»ò³£¤£ÅÜ¡A·|Åܪº¥u¦³§Aªº¤ß¡A¦@«j §Ú·R58¡A§Ú·R58 Go go Polaris! |
|
|
·|û¡GJimimycin10138346 µoªí®É¶¡:2017/10/31 ¤U¤È 04:55:03²Ä 1684 ½g¦^À³
|
ÁöµM¤j®a½|¼Ú¤j¤j¡A¥i¬O¥L¬O¹ïªº¡C¦pªG¸ÕÅç¯u¦³¦n¼Æ¾Ú¡A¤½¥qªÑ»ù¦´N¤jº¦¤F¡Aªk»¡·|«á¤j¶^¡AªÍÀù¤j·|«á¤j¶^¡A®£©È¦³¤°»ò¥¼Ãzµoªº®ø®§¡AÅý¤jªÑªF§V¤Oªº½æ¡CµL·¤£°_®ö¡A«K©y½æªÑ²¼·F¹À¡AÂÔ·VÂI |
|
|
·|û¡G¤jGE10145523 µoªí®É¶¡:2017/10/31 ¤U¤È 04:53:50²Ä 1683 ½g¦^À³
|
ÁÂÁ¼ڥý¥Íªº¼ö¤ß ¨CÓ¤H³£¦³¦Û¤vªº°±·lÂI Âå®v¦b¶}¤MnÁx¤j¤ß²Ó ¤£À´ªº¤H ¥u·|¦b®ÇÃä¤@ª½³Û ¡e¦n¦MÀI¦n¦MÀI ¤£n¶}¤F¡f |
|
|
·|û¡GºØºÖ¥Ð10144845 µoªí®É¶¡:2017/10/31 ¤U¤È 04:46:51²Ä 1682 ½g¦^À³
|
¦U¦ì¬P¤Í ¥¦w~ ¤jªÑªF³o¼Ë½æ,¬Û«H¦U¦ì¤]³£¦bÆ[¹î ¦Ñ¤Ò¤]«Ü¯Ç´e,©ú©ú°ò¥»±¶V¨Ó¶V¦n,¬°¦ó¤jªÑªFn³o¼Ë½æ¥X! ¬°¤FÁקK¤ß±¡¨ü¨ì¼vÅT,¦Ñ¤Ò¨M©w»·¹C¥L¶m. §Æ±æ¦^¨Ó®É,¦U¦ìªº¤ß±¡¤w¸g¦³©Ò¤£¦P! Go Go Polaris. |
|
|
·|û¡G¼Ú¬¥©_10144203 µoªí®É¶¡:2017/10/31 ¤U¤È 04:13:45²Ä 1681 ½g¦^À³
|
§Ú¤£Ä±±oÀ£¤O¤j ¤]µLªk¤U¨® ¦]¬°§Ú®Ú¥»¤£¦b¨®¤W ¦Ü©ó§Ú¤£¦b¨®¤W¸ÜÁÙ³o»ò¦hªºì¦]¬O¿³½ì §Ú¤]¤£¬O¥u¦³Ãöª`³oªÑ¦Ó¤w |
|
|
·|û¡G¤jGE10145523 µoªí®É¶¡:2017/10/31 ¤U¤È 03:55:21²Ä 1680 ½g¦^À³
|
»¡¯uªº ¤jªÑªF³o¼Ë½æ §Ú¤]¤£¯à»{¦P ¦ý¬O¦Ñ¸Ü¤@¥y ı±oÀ£¤O¤Ó¤j ½Ð¤U¨®´N¦n |
|
|
·|û¡G¼Ú¬¥©_10144203 µoªí®É¶¡:2017/10/31 ¤U¤È 03:37:49²Ä 1679 ½g¦^À³
|
¨º¨Ç³Q¬~¸£ªº¤H ·|§â²{¦b½æ±¼ªº¤H»¡¦¨¬O³Q¬~±¼ ¥i¬O§AÀR¤@¤U¤ß¤@·Q ¤@¦Ê¦hªº®ÉÔ³o¨Ç¤H¤]¬O³o¼Ë»¡ªº 100ÁÙ¦b¦a©³¤U ³s¤s¸}¤U³£¤£¬O ¤@Ó¦h¤ë¦Ó¤w ²{¦b¥u³Ñ¤U60´X ·Q¤@¤U§a »¡¤£©w¨ì¤Fn¸ó2018¦~ ©Î¬O¹A¾ä·s¦~³oÓ¥¿»Ýn¿úªº®ÉÔ ¬Ý¨ì¨º®ÉªºªÑ»ù §A·|¼y©¯§A§â¿ú¯d¤F¤U¨Ó ¦Ó¤£¬O¬Æ»ò³Q¬~±¼ §Ú¬Ý¬O³Q¬~¸£§a ¤@ª½»¡¬°¤F¨p¶Ò©Ò¥HÀ£»ù µ²ªG»{ªÑªº³£¬O²{¦³ªº¤jªÑªF ÁÙ¬O½æ¦ÑªÑ´«·sªÑ ¤£¥u¹Ï§Q¤j¤á ¦û´²¤á«K©y §óÄY«ªº¬O §C»ù¨p¶Òªº¸êª÷ °÷¥Î¶Ü ³o¦¸¤S¼W¸ê ¤S³o»ò¦hªº¨p¶ÒªÑ µ²ªGª±³oºØ¤âªk§C»ù»{ÁÊ ·|¤£·|©ú¦~¤S»¡¿ú¤£°÷¤F ¤Sn²{¼W ¤Sn¨p¶Ò¤F? ªÑ¥»¤£Â_¿±µÈ ½Ön¨ÖÁʳo¼Ëªº¤½¥q? ·í¥~°êÃļt³£¶Ì³J¶Ü? ³£¤w¸g³Q¦C¤T½u¥ÎÃĤF ÁÙ¥H¬°¦h¦³»ùÈ? ¦³»ùȨì¦A¦p¦ó¶Ã·d ¶R¤è³£n·Ó³æ¥þ¦¬? (¦pªG¯u¦³¶R¤èªº¸Ü) §Ú¤]¬Ý¹Lªk»¡·|ªº¼v¤ù §d¸³¦b³Ì«á¦³»¡§Æ±æ¤U¤@¦¸ªº¨p¶Ò»ù¯à¤ñ¤W¦¸°ª¤@¨Ç §A¦U¦ì¬Ý²{¦bªº§Î¶Õ ı±o¤U¤@¦¸ªº¨p¶Ò»ù³Ñ¤U¦h¤Ö? |
|
|
·|û¡G¤p¶§10139627 µoªí®É¶¡:2017/10/31 ¤U¤È 03:06:08²Ä 1678 ½g¦^À³
|
ÁÙ¨S¶}½L§Ú´N¹w´ú¤µ¤ÑªÑ»ù·|¦¬¦b68¤¸¥ª¥k «Ü¦n¹w´úªº¨C¤Ñ¶^2¤¸¡B·Ó³o¶^ªk¦A¶^1Ó¤ë«Ü§Ö ´N¨£¨ì20¤¸¤F |
|
|
·|û¡G¶§©úÂæ®Æ--ªl¨§10145262 µoªí®É¶¡:2017/10/31 ¤U¤È 02:52:34²Ä 1677 ½g¦^À³
|
µ²§ô¤F ¤£¦h»¡ |
|
|
·|û¡G¤p¶§10139627 µoªí®É¶¡:2017/10/31 ¤U¤È 01:44:47²Ä 1676 ½g¦^À³
|
´X¤Ñ§Ú¤Ï¦Óı±o¥m¾´¤j©M¼Ú¤jÁ¿ªºÆZ¦³²zªº ¥i±¤¥»¤H¸êª÷¨S¦³«Ü¶¯«p¥u¬O¤@Ó°Ï°Ï¥ô¤H ®_³Îªº´²¤á¨S¦³¿ìªk¨Ï¥Î¥m¾´¤jªº²Ä¤TºØµ¦²¤ |
|
|
·|û¡G³Á§JªL10142093 µoªí®É¶¡:2017/10/31 ¤U¤È 01:32:43²Ä 1675 ½g¦^À³
|
³Ñ¤Uªº¨p¶Ò¡A®É¶¡q¤F¶Ü¡H |
|
|
·|û¡G¬P²y±U°_10145048 µoªí®É¶¡:2017/10/31 ¤U¤È 01:04:46²Ä 1674 ½g¦^À³
|
¦Ñ´¤j¤È¦w¡A¦U¦ì¬P¤Í¤È¦w¡A ¦Ñª¯¥S¡A§A«Ü´Î¡A§A¦³¥O¤H¸r¼}ªº¯u·R¡A¤]ÁÂÁ§Aªº¤À¨É¡C ¨S¦³·Rªº¤H¥u¯à»Ä»Ä¤F¡ã¨S¦³¤H·|«ü±æ»Ä»Ä¨Ó¬@±Ï¤°»ò¡ã»Ä»Ä¤]¥u¯à¬O»Ä»Ä¡ã |
|
|
·|û¡G¥m¾´10141821 µoªí®É¶¡:2017/10/31 ¤U¤È 12:51:32²Ä 1673 ½g¦^À³
|
¤jªÑªF¬°¤F°Ñ»P¨p¶Ò¡A¥¿¦bÀ£§CªÑ»ù¡A À³¹ïµ¦²¤¡G 1.¸òµÛ¤@°_½æ¡AÀ°³h½aªº¤jªÑªF¡AÀ£§C¨p¶Ò»ù¡C¸q¤§©Ò¦Ü¡A¬°©Ò·í¬°¡AÄ묹¦Û¤v¡A·Ó«G§O¤H¡A¤é¦æ¤@µ½¡A§ï¤Ñ¦A§C±µ¦^¨Ó´N¦n¤F¡C 2.¤£¬°©Ò°Ê¡A¤Ñ¶ò¤£Åå¡C¤ßŦn°÷¤j¡A³Ì«á¥i¯àÁÙ¬O·|³Q¬~¥X¥h¡A¤@¥h¤£¦^¡C 3.¥Î¤O¶R¤W¥h¡A»P¤jªÑªF¨ÓÓ¨â±ÑѶˡAÅý¤½¥q©w§ó«Nªº»ù®æ¡A±o¨ì§ó¦hªº¨p¶Ò²{ª÷¡Cµ²ªG¤jªÑªF¸Þ²§ªº¯º¤F¡C |
|
|
·|û¡G¼Ú¬¥©_10144203 µoªí®É¶¡:2017/10/31 ¤U¤È 12:23:49²Ä 1672 ½g¦^À³
|
¤µ¤Ñ³£³o¼Ë¨g¶^¤FÁÙ¦b¨ºÃ仡¤°»ò¤£¬O¹Ú §j¤f裏Áxªº¤HÁÙ¯u¤£¤Ö ¦pªG¬O¯uªº¦³«H¤ß¤]´N½}¤F ¥u©È¬O¥s§O¤Hnæín¼µ¦í ¦Û¤v«÷©R½æ ¦Ñª¯¤j ¬Ý¤F§Aªº¤º®e §Ú¯u¤ßÃø¹L |
|
|
·|û¡G«Cµì10141603 µoªí®É¶¡:2017/10/31 ¤U¤È 12:13:28²Ä 1671 ½g¦^À³
|
¦Ñª¯¤j §Æ±æ§Aªº¹Ú·Q«Ü§Ö·|¹ê²{¡C |
|
|
·|û¡G¸Û«H¦ó®¬10139574 µoªí®É¶¡:2017/10/31 ¤U¤È 12:09:05²Ä 1670 ½g¦^À³
|
¦Ñª¯¤j§Ú»{¬°¤£¬O¹Ú¡C Å¥§¹¤TÅ|«á¡A¦è¥X¶§ÃöµL¬G¤Hªü |
|
|
·|û¡G¤p¶§10139627 µoªí®É¶¡:2017/10/31 ¤U¤È 12:07:16²Ä 1669 ½g¦^À³
|
·Ó³oÓ¶^ªk«Ü§Ö´N·|©¹¨p¶Ò»ù¾aÃl¤F¡B§Ú±`±`¦b·Q ªÑ»ù¥Ã»·º¦¦b¥¼ª¾¼Æ¡B¦Ó¥_·¥¬Pªº§Q¦h¤@°ïªº¤H³£ª¾¹D ¤FÁÙ·|¦³½Ö¶i¨Ó©ïÃâ¡B©Ò¥H§Ú¤~¤£´±©¹¤UÅu¥~¤Ï¥¿ §Úªº«ùªÑ±i¼Æ¤]¤£¦h¤ß¤]³Â·ô¤F¡B¯E¹©³£½ß¤F¨º»ò¦h¤F ¶R¥_·¥¬P¤]ºG®M~¥i¯à¬O§Ú±aÁɧa¡H ´N·í¬O¤W¤F¤@ªù½Òú¾Ç¶O§a¡I |
|
|
·|û¡G¦Ñª¯10145373 µoªí®É¶¡:2017/10/31 ¤W¤È 11:58:07²Ä 1668 ½g¦^À³
|
»¡»¡§Ú¦Û¤v¦n¤F ·Q·íªì·|¶}ÃÒ¨÷¤á,¬O¦]¬°§Ú¤½¥q¦ÑÁó, ¥L¸ò§ÚÌ»¡¥i¥H¶iþ¤äªÑ®É,§Ú¶}¤F¤áÀY ¦ý¥L¥u¹ï§ÚÌ»¡,¤Ñ¤Ñª±ªÑ²¼¬OÁȤ£¤F¿úªº ·Q¾Ç,¤]¤Ó½ÆÂø,§Ú̳o¨Ç²Â³J¤]§O·Q¶}©l¾Ç,¦]¬°¤@©w¬Ý¤£À´ ´N¦Û¤v§ä¤@¶¡§Aıªº¥L¤£·|˪º,éwªº¤½¥q§ë¸ê,©ñÓ¤G¦~¦A½æ ³Ìªñ·Q·Q,¬°¦ó¤j®a³£¦º©Rªºn§ë¸êÂE®ü,¥x¿n¹q,¤¤¿û,¤¤µØ¹qµ¥µ¥ ¯uªº«ÜÀ´³o¶¡¤½¥q¦b·F¤°»ò¶Ü? §Ú´N¤£À´ ¦³¤°»ò¤j¨Æ¥ó?¤ñ¦p:±i©¾¿Ñ©ú¦~n°h¥ð¤F,§Ú¥uıªºªÑ»ù·|¶^,¦ý¨S¦³,¥¦¤@ª½º¦ ¬°¦ó§ÚÁÙ¦b¬P¬P 1. §Ú®M¨c¤F.§Ú®M¨c¤F.§Ú®M¨c¤F («Ü«n,©Ò¥H»¡¤T¹M) ¦Û¤v¨S³]°±·lÂI¶Ü?¦³¥´ºân³],¦ý 2. §d§B©Mù¤óÃļt¦X§@,§Ú¤S¿ðºÃ¤F 3. §Ú¯uªº¤]¥u³Ñ¤U¹Ú¤F.§Ú¯uªº¤]¥u³Ñ¤U¹Ú¤F.§Ú¯uªº¤]¥u³Ñ¤U¹Ú¤F («Ü«n,©Ò¥H»¡¤T¹M) ¥ý«eªº¿n»W³QªB¤ÍÄF¥ú(¶]¤F),¤Ó¤ÓÁÙ¬O¿ï¾Ü¶ù§Ú,¥Ø«eµLªkµ¹¦o¤@ÓÄÝ©ó¦Û¤v¦íªº¦a¤è,§ó§O»¡¥Í¤p«Ä Âù¤è®a¤H¤]³£·|ü®¤ß,¤×¨ä¬O¥t¤@¥bªº®a¤H,¹ï,§Ú«Ü¥i´c,¦ý§Ú·Q¤£¨ì¦p¦ó¥i¥H§Ö³t¦³¿úÁÙt¶Å¹ê²{¹Ú·Qªº¤èªk »¡¤F¤@°ï¼o¸Ü,¨ä¹ê«ÂI¥u¦³>>§Ú·Q¤ä«ù§d§B§a |
|
|
·|û¡G¤p°¨10135228 µoªí®É¶¡:2017/10/31 ¤W¤È 11:56:31²Ä 1667 ½g¦^À³
|
«ç»ò¶^±o¤ñéw·àÁÙºG |
|
|
·|û¡G³ß³ß¿}10144054 µoªí®É¶¡:2017/10/31 ¤W¤È 11:38:24²Ä 1666 ½g¦^À³
|
@¦Ì¤j 18¤¸¤@©w¶i³õ´Á«Ý¨ì¨Ó |
|
|
·|û¡Ggary10141706 µoªí®É¶¡:2017/10/31 ¤W¤È 11:37:24²Ä 1665 ½g¦^À³
|
¸¨«Ë°Õ¡I |
|
|
·|û¡G@¦ÌµX10144792 µoªí®É¶¡:2017/10/31 ¤W¤È 11:34:26²Ä 1664 ½g¦^À³
|
³ß¿}¤j!¤£¥Î¾á¤ß°Õ! ³»¦h¶^¨ì18¶ô¡A¤j®a»ôÀY¦¡ªº¥µ¥°Õ~ ©¡®É¤]Åwªï±z¶i³õ®@¡G) |
|
|
·|û¡G³ß³ß¿}10144054 µoªí®É¶¡:2017/10/31 ¤W¤È 11:27:36²Ä 1663 ½g¦^À³
|
¬P¤ÍÌ ¦³Ó²{¹ê°ÝÃD ¤d¸U¤£nµ¥¨ì¸ê²£³Ñ¤U1/10¤~¿ô®©¨ì§K¶Oªº³Ì¶Qªº¹D²z |
|
|
·|û¡Gkenken10138351 µoªí®É¶¡:2017/10/31 ¤W¤È 10:54:57²Ä 1662 ½g¦^À³
|
«ç»òÁÙ¦b°Q½×¦º¤`©M¥ð§Jªº°ÝÃD, ªk»¡·|¤W¤]¦^µª¹L¤F,¬JµM¨º»ò·|google ¤£¦p´N¦hÅ¥¤@¤Uªk»¡·|¤º®e ¤£n®ö¶Oª©± |
|
|
·|û¡Gsomeday10144962 µoªí®É¶¡:2017/10/31 ¤W¤È 10:47:14²Ä 1661 ½g¦^À³
|
²³¤j¤j¦n §Ú¬O¥Í§Þªù¥~º~ §Y«K¬O¦Ñ´¤jªº¤ÀªR§Ú¤]¥u¬O¥bª¾¥b¸Ñ ¤£¹L§ë¸êÁÙ¬O¦³¨ä¥Lªº¥~³¡²{¶H¥i¥H¨ó§U§PÂ_ ¤§«e¥_·¥¬P¨ú±o³æÁu¹êÅ窺Á{§É³]p¬O¤@Ó«ÂI ¥Ø«e¹ï§Ú¨Ó»¡³Ì¦³¤Oªº²{¶H´N¬O¥@¬É«e¤Q¤jÃļt¤¤¦³4®a¥¿¦b¤F¸Ñ¥_·¥¬PªºÃÄ §Ú¤£À´³o¨Ç±M·~ ¦ý¬O§Ú¬Û«HFDAÀ´ ¤]¬Û«H³o¨Ç¤jÃļtÀ´ ¤£¹L ³o¨Ã¤£·N¨ýµÛ¤@©w·|Áʨ֦¨¥\(·ÀI·NÃÑÁÙ¬On¦³ªº) ©Ò¥H §Úªº§ë¸êºA«×¬O·í¨Æ±¡ÅçÃÒ¨ìþ¸Ì §ÚÄ@·N§ë¸ê¨ìþ¸Ì ©Ò¥H§Úªº«ùªÑ¦¨¥»10´X 20´X 30´X.....¨ì80´X³£¦³ ºI¦Ü¥Ø«e¥u¶i¤£¥X ¤£ºÞÁʨ֩αÂÅv ¦Ü¤Ö²{¦bÃĪºÁ{§É¦b¶i¦æµÛ ¥ú¬O¨âÓ¶i¤J¼Ï¯Ã¸ÕÅ窺Á{§É´N¦³¥¦ªº»ùȤ£¬O¶Ü ÀH®É¨nµÛ¥Lªº¶i«×»P¼Æ¾Ú¥i¯à¬O§ó«nªº ¨º¬O°ò¦ ¤£¬O¶Ü? ¦b§ë¸ê¥_·¥¬P³o®a¤½¥qªº¹Lµ{¤¤ §ÚÓ¤H¬Oı±o³o¬O¤@¶¡¤£Â_¸¨¹êµÛ¹w´Áªº¤½¥q ©Ò¥H ¦hťť¤½¥q¤§¨¥ ¦Aºò¨nµÛ¤½¥q¤§¦æ À³¸Ó·|ÁקK«Ü¦h¯ÉÂZ ¯u¤ß«Øij¤@©wn¬Ý¬Ý¤½¥qªºªk»¡ ¥H¤W¬OÓ¤H¯u¹êªº§ë¸ê¤ß±o¤À¨É |
|
|
·|û¡G@¦ÌµX10144792 µoªí®É¶¡:2017/10/31 ¤W¤È 10:01:07²Ä 1660 ½g¦^À³
|
¦Ñª¯¤j! ¤£¦n·N«ä¤S´£¨ì±z¤F¡G) ¨ä¹ê¥H§Ú̳oºØ¶W¯Å¤p¤á¯à¬°¦Û¤v°µ¨ìªº ´N¬O¸ò¨ì¤@Ó§V¤O¤£¾Óªº¬ì¾Ç®a¦Ó¤w!§Ú¬Û«H§d³Õ ¬JµM³o±ø¸ô¯à°÷¨«¤F20¦~¡A§Ú̬°¦ón¨º»ò¥Ø¥ú µu²L¦b³o1¡B2¦~©O? ¥H±¬Û¾Ç¨Ó¬Ý¡A§d³Õ¤@¬Ý´N¬O©¾«p¦Ñ¹êÁy!§Ú¥s§Ú¥ý¥Í ¬Ý¡A¥L¤]³o»ò»{¬°! ¥Ø«eªÑ»ù¬Û¹ï§C°gÀ³¸Ó´N¬O¤Ó¥X¦W§a!? µu½u®e©ö³Q¤W¤U¨ä¤â¡A¤£¹L§Ú̳£¬On¨«§¹¥þµ{ªº¤H¡A´N ¤¹³\¦Û¤v°¸º¸¬Ý¤@¤UªÑ»ù´N¦n¡A§K±o¼vÅT¤ß±¡©O! ÁÙ¦³¤@¨Ç³ßÅw¥Î½Ķ³nÅé¬Ý¤å³¹ªº¤H¡A§A̤£ª¾¹D¸òì¤å·| ®t«Ü¤j¶Ü! ¤×¨ä¬OÂå¾ÇÃþ¨º»òÁ}ÀߪºªF¦è~«ÂI¬O¬ÝªºÀ´¤£·|¤À ªR¤]¬Oµ¥©ó¨S¥Î~~ ¬P¬P§AÄ~Äò¤º§t¥ú¡A©j©j¨CÓ¤ë»â¿ú¤~¦³¿ìªk¦A¾Ö©ê§A¤F! |
|
|
·|û¡G¤Ñ¦aµL¥Î10142903 µoªí®É¶¡:2017/10/31 ¤W¤È 09:56:40²Ä 1659 ½g¦^À³
|
¤j²Â³J¤S¦b¹ïºV¤F |
|
|
·|û¡G¤jGE10145523 µoªí®É¶¡:2017/10/31 ¤W¤È 09:13:34²Ä 1658 ½g¦^À³
|
AML¤@¯ë¨Ó»¡5¦~¦s¬¡²v¥u¦³20% ³o½g¤å³¹ªº¯f¤H¬OªvÀø«á´_µo©Î¬O¤ÀÃþ¤£¨ÎM7ªº¯f¤H ¬O¾D¤¤¤§¾D ADIªºªvÀø¤w¸gºâ¼F®`¤F |
|
|
·|û¡G¼Ú¬¥©_10144203 µoªí®É¶¡:2017/10/31 ¤W¤È 09:08:53²Ä 1657 ½g¦^À³
|
¬Ý¬Ý¼Ó¤U¨ºÓD¤°»òªº ³oºØ´N¼Ð·Çªº°ê¤¤¥Íðã½| ¸ò³oºØ¤H¬°¥î ¥_·¥¬P¤£¥u¤º¼~(¤j¤á¥X³f) ¦Ó¥B¥~±w(¦nÄFµLª¾¥B¼É¸õ¦p¹pªº´²¤á) ªÑ»ùÃø¥H¦³¦nªí²{ ³o´N¬O¤è®i³Õ¬°¦ónÅý°I¤H¸ò¦Û¤v¯¸¹ï¥ß±ªºì¦]¤F |
|
|
·|û¡GÄƦV¥_¤è10144825 µoªí®É¶¡:2017/10/31 ¤W¤È 08:49:30²Ä 1656 ½g¦^À³
|
¨º½g¤å³¹¬O¥ÎGOOGLE½ªº¡A»y·NÁöµM¤£¶K¤Á¡A¦ýì¤åªº·N«ä¬OADI-PEG 20¤´¦³P©Rªº¥i¯à©Ê¤£¬O¶Ü¡H§ó¦óªpÁÙ¦³¤@Ó¥ð§Jªº®×¨Ò¡A³o¬O³æ¤@¥ÎÃĪº¹êÅç¡A©Ò¥H¤£±Æ°£ÃÄ¥»¨¤´¦³¦w¥þ¤WªºÅU¼{§a¡H³o³¡¤À¤´¦³«Ý«áÄòªºÁ{§É¹êÅç¨ÓÂç²M¤F¡I ¥t¥~¡A³o´X¤Ñ¥J²Ó®Ö¹ïÄw½Xªº³¡¤À¡A»®µMµo²{¦Ü¤Ö¦³¤G¸U¦h±i¥¼¥[¤J¶°«O®w¦s¡A·N«ä¬O¥L̪º«ùªÑ±¾¦b¤@¤d±i¥H¤Wªº¯Å¶Z¡A¦ý¥¼Åã¥Ü¦bªÑªF¤H¼Æ¤W¡AÃø©ÇªÑÅv¤À´²ªí®É±`¦³¼Æ¾Ú¥¢¯uªº°ÝÃD¡A³o¬O§_¬°¤jªÑªF³°Äò¥X²æ«ùªÑ®³¦^¦¨¥»ªºÁôÂö¬}©O¡H³o³¡¤À¦³«ÝÆ[¹î¡A¦ýÆ[¹î³o¤TÓ¦h¤ë¨Óªº½æÀ£¨Ó·½¡A¹ê¦b¬O¤£¯à±Æ°£³o¤è±ªººÃ¼{¡A¦Ó¥B©Ò³Ñ±i¼Æ¤´µM¤£¤Ö¡A¥H¤W¬°µ½·N´£¿ô©M°Q½×¡A½Ð¤Å¶D½Ñ¤£²z©Êµ§¾Ô¡AÁÂÁ¡I |
|
|
·|û¡GDavid Xu10143450 µoªí®É¶¡:2017/10/31 ¤W¤È 07:56:28²Ä 1655 ½g¦^À³
|
¯Q¾~©_ §A¬O¤£¬O¥Ç½â¨Ö¥BÁÙ½â¨ì°©¤l¸ÌÀY ¬O¤£¬O§A¨C¤Ñ¥h§äÂå¥Í³£ÁÙ¤£¯à·k¨ì§AªºÄo³B £¸©wn¨Ó³o¸Ì°Û°IµM«á´«±o³Q²³¬P¤ÍÎx§A¡A§A¤~¯à¤îÄo£¸ÂI ¦pªG¬O³o¼Ë¡A§Ų́C¤Ñ«Ü¼Ö·N§K¶OÀ°§A |
|
|
·|û¡Gªü¾ç10145307 µoªí®É¶¡:2017/10/31 ¤W¤È 01:58:03²Ä 1654 ½g¦^À³
|
©_©Ç¤F º¦¨ì100~112¨º´X¤Ñ¡A«ç»ò¤£¨£¯Q¾~ô¸ò¥m¾´¿ß¥X¨Ó´£¿ô¤j®an¦³¦M¾÷·NÃÑ¡H º¦ªº®ÉÔ®ø¥¢°Î¸ñ¡A¶^ªº®ÉÔ´N¶}©l¤Ñªá¶Ã¼Y ¦Ñ¥j¸³§ó¦nª±¡AÁ|ªº¨º´XÓ¨Ò¤l§Ú³s¬Ý³£Ãi±o¬Ý¡A·í°ê»ÚÃļt¦Y¯Àªº¡A¦³«Ü¦h®É¶¡¸ò¿ú¥i¥H®ö¶O¦bADI-PEG¤W¡H ®³³Õ¹F©Îð¾W¨Ó·í¨Ò¤lÀ~À~ªü§b¤£¬O§ó¦n¡H¡H n¤ñÁn±æ¡AADI-PEGªºI´º¤ñ¿}¤À¤l§óÀ~¤H¡A¤@¥N§K¬Ì¾Ç¤§¤÷¤£©¯Ãã¥@¡A©¯Á««áÄ~¦³¤H ·í°ê»ÚÃļt¸Ìªº±M®a¬O¥Ø¤£ÃѤBªº¥Õ観¿úªº¼ï¥J¡A·í¥L̸£³U¸Ë«Ë¡H¡H ¸ÌÀY¿Õ¨©º¸¾ÇªÌ¡A¬ì¾Ç®a¡A°]°Èªk«ßÅU°Ý¡A¨º¤@Ó¸ê¾úºÝ¥X¨Ó¤£¬OÀ~¦º¤Hªº¡H ·í¥L̮ɶ¡«Ü¦h«Ü¶¢¦b³¥_·¥¬Pª±®a®a°s¬O¶Ü¡H¡H ¥xÆWÁÙ¦³þÓÃĸò¥_·¥¬P¤@¼ËÅQ®ð+¥¿®ð¡H ¤p§Ì¯uªº«Ü¦n©_§A̪º¸ê¾ú¡A¦³Âå¾ÇI´º¶ÜÁÙ¬O¦³µoªí¹L¬Æ»ò´Á¥Z¤§Ãþªº¡H¡HÁÙ¬O¥Îgoole¬d¤@¬d¡A¬Ý¤£À´ªºÁ٥νĶ¾÷¡A³Ì«á¥[ÂI¦Û¤vªº«Ë§¿´N¶K¤W¨Ó¡H ¤j³æ¹ïºV¦³«Ü¦h·N«ä¡A¦³¿³½ìªºªB¤Í¥i¥Hª½±µ¥´³o¥|¦r¥h¤F¸Ñ ¦ýµ´¹ï¤£¬O¬Æ»ò³o¨â¦æ«Ë§¿¥y ¬°¦ó¦³¿úªº¤j¤á³£¬O²Â³J ´N³o¨Ç¨S¿úªº´²¤á¬O¦³¼z²´ªºÁo©ú¤H? ¥á³æªº¬OÁo©ú¤j¤á¤£¬Ý¦n¡AÃø¹D±µ³æªº¤j¤á´N¬O¥Õè¡H ¬Æ»ò¥s¹ïºV¡H¤@Ó¥á¤@Ó±µ¡A¨S¥ýÁ¿¦n»ù®æ¸ò®É¶¡¡A¥á¥X¨Ó±µªº¨ì¡H¡H ¥á¥X¨Óªº¦³ÁÈ¿ú¤~¥á¥X¨Ó¡A½Ö·|°µÁ«¥»¥Í·N¡H ±µªº¤Hº¡·N¥Ø«e¶}»ù¤~Ä@·N±µ¡A½Ö·|¶RÆp¥Û»ù®æªº¥ÛÀY¡H ¸£³U¬O«Ü¦nªºªF¦è¡A¤£n¦Ñ¬O¥ÎGOOGLE¡An¥Î¤]¥i¥H¡A¦ý¤£n§â¦Û¤vªº«Ë§¿¥[¤W¥h¡A«Ü¯ä |
|
|
·|û¡G¬P¥úÀéÄê10145521 µoªí®É¶¡:2017/10/31 ¤W¤È 01:10:13²Ä 1653 ½g¦^À³
|
¤p¾´¾´¡A¤j¥ß¥ú±q3¡A4¦Ê¤¸º¦¨ì1000¤¸¶R¶iºâ¤£ºâ°l°ª¡H²{¦b5¤d¤F¾k¡AªÑ²¼¹ï§Ú¨Ó»¡¬O¬Ý¥¼¨Óªº»ùÈ¡A¦pªG§A»{¬°¥¼¨Ó¬P¬P¤£¥u100¡A¨º¶R100´N©ñµÛµ¥¥¼¨Ó°Ú¡A¤~¹L2¡A3Ó¤ë¬O¦b«æ¤°»ò¡H¬O¸ò¿ú²øÉ¿ú¨Ó¶R¬O¤£¬O¡H¦³¤H¦n¤ß¤À¨É³o¨Ç±M·~ª¾ÃѨS·P®¦´Nºâ¤F¡AÁÙÃhºÃªFÃhºÃ¦è¡A§A¥i¥H¤£n¶R°Ú¡C°ù¦Ñ±C¦³¥]¥Íªº¶Ü¡H |
|
|
·|û¡G¤@¤ô´H10144832 µoªí®É¶¡:2017/10/30 ¤U¤È 11:49:49²Ä 1652 ½g¦^À³
|
¦Ñ´¤j«e½ú±ß¦w¡B¦U¦ì¬P¤Í¤j¤j̱ߦw¡G ºK¿ý¾ã²z¸ê®Æ¦p¤U¨Ñ°Ñ¡G ¡¶¤é´Á¡¹¦¨¥æªÑ¼Æ¡»¥þÅé¨é°Ó¨C¤é®w¦s¼W´îªÑ¼Æ¡´¥þÅé¨é°Ó¨C¤é®w¦sÁ`ªÑ¼Æ-------------------------------------------------------------------------------------------------------- ¡¶2017/10/30¡¹2,640,625¡»1,110,874¡´43,179,377 ¡]¬ÛÃö¼Æ¾Ú»¡©ú½Ð°Ñ¦Ò²Ä486½g¦^À³¡A ¥H¤W¤§¡u¥þÅé¨é°Ó¨C¤é®w¦sÁ`ªÑ¼Æ¡v¼Æ¾Ú¡A ¦]·½ÀY¸ê®ÆÅܼƲ³¦h¡A¶È«Y·§²¤¼ÆÈ¡A ¦p¦³¿ù»~¤§³B¡A½Ð¦U¦ì¬P¤Í¤j¤j¦h¦h¥]²[¨Ã¤£§[´f¤©½ç±Ð¡C¡^ Go Go Polaris¡I¡I¡I |
|
|
·|û¡G¥m¾´10141821 µoªí®É¶¡:2017/10/30 ¤U¤È 11:08:41²Ä 1651 ½g¦^À³
|
¹ïºV·Q·F¤°»ò¡H¨ä¹ê§Ú¤j·§¥i¥H²q±o¨ì¡A¥u¬O·Q¬Ý§A»¡¯u¸ÜÁÙ»¡°²¸Ü¡AÄw½Xªº«ÂI¤£Á¿¡A¥u·|Á¿¤@¨Ç543ªº¡A«¢«¢¡C ±`¨Ó¬Ý¥_·¥¬P¡A¬O¦]¬°è¦n¤ñ¸û¦³¤ß±o¡A¬Ý¤£ºD¦³¤H¥MµÛ¥»¨ªº±M·~ª¾ÃÑ¡A¹ï¥_·¥¬P¤W¤U¨ä¤â¡A¹ªÀy¬P¤Í°l°ª¡A¸m¥L¤H·ÀI©ó¨{¥~¡A¦Ñ¶ÂD¥i¤£·|³o»ò®t«l¡C |
|
|
·|û¡GºØºÖ¥Ð10144845 µoªí®É¶¡:2017/10/30 ¤U¤È 11:08:08²Ä 1650 ½g¦^À³
|
¦Ñ´¤j ¥¦w, ±z¼gRAPªº¥\¤O¶V¨Ó¶V°ª¤F¡I¸Ó¤£·|ÁÙ·í¹L¼Ö¹Î¥D°Û§a¡H§ÚÃä¬ÝÃ䯺¡A³oºâ¬O§ë¸ê¬P¬P±a¨Óªº®T¼Ö¶Ü¡H «¢ ^^ |
|
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2017/10/30 ¤U¤È 10:35:29²Ä 1649 ½g¦^À³
|
ÄƦV¥_¤è¤j, the death was attributed to both grade 4 events, consistent with AML and possibly ADI-PEG20. §AªºÂ½Ä¶= ¦º¤`Âk¦]©ó¥|¯Å¨Æ¥ó¡A»PAML©M¥i¯àªºADI-PEG20¤@P ¦Ñ´ªºÂ½Ä¶= ¦º¤`Âk¦]©ó¥|¯Å¨Æ¥ó¡A»PAML(ªº¯gª¬)¤@P¡A©M¥i¯à¬OADI-PEG20§a¡I(¤£±Æ°£) ¥Í§Þ±M®a¤j, ADI+Keytruda and ADI+Tecentriq²z½×¤WÀ³¸Ó®t¤£¦h,¦ý¬O²{¦bn¶i¦æªº¬OADI+Tecentriq+Pem+Cis, ©Ò¥HÀø®Ä¤W¥i¯à¬O¥|ÃÄÁp¦X§ó³Ó¤@Äw,¦ý¬On¬Ý°Æ§@¥Îªº@¨ü«×! ADI+Keytrudaªº¼Æ¾Ú·|¤ñ¸û§Ö,¦ý¬OADI+Tecentriq+Pem+Cis,¤]³\Roche¥u¬Ý´XÓcaseªº°Æ§@¥Î©Mªì¨B ªºÀø®Ä´N°µ¨M©w¤F,³oÓ¥u¦³¤W«Òª¾¹D¤F!!! ¤j¨Æ¥ó¤°»ò®ÉÔ¨ÓÁ{,¨S¦³¤Hª¾¹D!!!¦Ñ´Ä@·Nµ¥9Ó¤ë¨ì2¦~!!!2¦~¤º¤£¬O¤j¨Æ¥ó¤]¬O¤¤¨Æ¥ó,´Nºâ¬O¤p¨Æ¥ó ¤]±o½3¿¥H¤W§r!!!Ū®Ñ¤H¨S¦b©Èªº!!! ¾´¾´,©_©_¡÷¨S¦³¬P¬P¬°¤°»ò³o»òÃö¤ß¬P¬P©O,°Ê¾÷¤£³æ¯Â! ·Qª¾¹D¹ïºVªº·N¸q¶Ü? ¯uªº·Qª¾¹D¶Ü? ¤£ §i ¶D §A ¼H¼H.......«¢«¢.......... yo yo yo ¥m¥m,¾´¾´,¥m¾´---¤£ª¾¸£³¡¨º¸Ì---³Q ¦º ·í! alpha, beta, gamma---¶Ì¶Ì¤À¤£²M·¡ªº¯ó ªd °¨! yo yo yo, everybody¤@°_¨Ó alpha, beta, gamma---¶Ì¶Ì¤À¤£²M·¡ªº¯ó ªd °¨! ¸£³U,¤f³U,¥¬³U---¥m¾´³q³q³£¨S±a ª¾ÃÑ,¨£ÃÑ,±`ÃÑ---¥m¾´³q³q³£¤£»{ÃÑ ¦Û´Ý,¹p´Ý,¤Ñ´Ý---¥m¾´¨C¤Ñ³£¦b´Ý yo yo yo, everybody¤@°_¨Ó..... ¼Ú,¸¨Âû!¶R¨ì¿}G,³Q®M¨ìÅÜÂû »¡¦Û¤v¬O°¸©_,¨C¤Ñ¨Ó¬Ý¬P¬P yo yo yo,¸¨Âû!¶R¨ì¿}G,³Q®M¨ìÅÜÂû ·Q¶R¬P¬P,¤ß¸Ì«ë¿}G,¼L¤W½|¬P¬P,¨C¤Ñ¤ß¥Í¶ú ¬Ý¨ì¥ÇÀY¯e,§á¦±¨ìÅܧΠ¼Ú,¸¨Âû! yo yo yo.......... |
|
|
·|û¡GºÃ´bªÌ10140504 µoªí®É¶¡:2017/10/30 ¤U¤È 10:17:40²Ä 1648 ½g¦^À³
|
¥Ø«e¦ü¥G¥u¯à¬è뤽¥q¤@¤ÁÁ{§É¸ÕÅ綶§Q ÀR«Ý¨Îµ go!go!polaris! |
|
|
·|û¡G12310000032 µoªí®É¶¡:2017/10/30 ¤U¤È 09:57:31²Ä 1647 ½g¦^À³
|
¦Ñ´¤j«e½ú±z¦n±ß¦w¡A¦U¦ì¬P¤Í̤j®a±ß¦w¡A ·P¿E«e½ú±M·~¿W¨ìªººëÅP¸ÑªR¡AÅýµª®×©I¤§±ý¥X¡A·P¿E¤£ºÉ!!!!! §ë¸ê¥»¬O¦Û¤vªº¨Æ¡A¤j®a³£¦¨¦~¤H¤F¡AÀ³¸Ón¹ï¦Û¤vªº¨M©wt³d¡A§Y¨Ï¬O¸ê°Tªº§PÂ_¡A¬O§_n¨ú¥Î·í°µ¦Û¤vªº§ë¸ê°Ñ¦Ò¤]³£¬O¦Û¤vªº¨Æ¡A¤S¨S¤H¹G§A¤@©wn¥h°Ñ¦Ò¡A¦pªG³s³o³£¤£À´¡A¯u¤£ª¾¹D¬O¤£¬O¥H¤p¾Ç¥Íªº´¼°Ó¨Ó§ë¸êªÑ²¼¡A¥O¤H¶Ì²´¡C¤@¤Ñ¨ì±ß¦b¨º»¡¬Ý¤°»ò¡A¯}¤°»ò¡A´£¿ô¤°»ò¡A¤°»ò°ä¤H«ç¼Ë¡A¤°»ò³Q°ä¤S«ç¼Ëªº¡A³o»ò¦n¤ß«ç¤£¦h¥hÂå°|°µ¦Û¤u¡A¦h¥hªÀ°ÏÀ°À°¿W©~¦Ñ¤H¡A¦h¥h°¾¶mÀ°§U¨º¨ÇµL®Ñ¥iŪªº«Ä¤l¡A³o»ò¦h®É¶¡¦b³o»¡¤T¹D¥|¡Aªí±¸Ë¦n¤ß¡A¤º¤ß½Lºâ¤°»òÃø¹D¥H¬°¤j®a³£¬Ý¤£¥X¨Ó¶Ü?¥_·¥¬PªÑ»ù20´Xªº®ÉÔ«ç»ò¤£¨£§AÌ¥X¨Ó³Û¡A¥s¤j®an¤p¤ß¡A«ç¼Ë«ç¼Ëªº¡A¨º®É¶Rªº¤H¥i¤]¬O¤£¤Ö©O?§A̳o»ò·|´£¿ô§ë¸ê¤Hn¤p¤ß¡A¨º¡A½Ð°Ý¡A¨º¬q®É¶¡§A̫礣¥X¨Ó§r¡AÁÙ¬Oè¦n¦b¤j«K¡A³s¤j20¤Ñ¤£°±°Ú¡A¤~¨Sªk¥´¦r°Ú¡A¬O¶Ü?¬O¶Ü?¬O¶Ü? ¤H¦b°µ¡A¤Ñ¦b¬Ý¡C¤Á°O¤Á°O~ |
|
|
·|û¡G¬K¬î10139014 µoªí®É¶¡:2017/10/30 ¤U¤È 08:01:37²Ä 1646 ½g¦^À³
|
½Ð°Ý¼Ú¤j 1.¨º¥i¥Hª¾¹D¥Ó³øÂàÅý¹ïºVªº¹ï¶H¬O½Ö¶Ü¡H 2.¬°¦ó¦³¿úªº¤j¤á³£¬O²Â³J ´N³o¨Ç¨S¿úªº´²¤á¬O¦³¼z²´ªºÁo©ú¤H? => Y¬O¥t¤@Ó¦³¹ê¤Oªº¤H±µ¤â¤F³o1800±i¡A¨º³oÓ±µ¤âªº¤H±z¤S«ç»ò¬Ý©O¡H |
|
|
·|û¡G¤é²±¦Ñ¥j¸³10142376 µoªí®É¶¡:2017/10/30 ¤U¤È 07:47:35²Ä 1645 ½g¦^À³
|
¦³¿³½ìªº¤H¥i¥H¥Î¡yº~±d ´¹¦t ¤¤¤é·s ¥¿®p·s¡z³o¥|°¦ªÑ²¼¤@°_·j´M¡A ª¦¤@¤U¤å¡A±z¥i¥Hµo²{¡A§K¶Oªº¸ê°T¥i¯à¦ñÀHµÛ·ÀI¡C |
|
|
·|û¡G¥Í§Þ00710142005 µoªí®É¶¡:2017/10/30 ¤U¤È 07:07:19²Ä 1644 ½g¦^À³
|
¦Ñ·¨¤j ¦U¦ì¬P¤Í ¤j®a¦n ¤§«eªº°ò¥»±¦Ñ·¨¤j¬O»¡Åý¤l¼u¸¡A®É¦Ü¤µ¤éªº°ò¥»±À³¸Ó¬OÅý¤õ½b¸¡A«Ý¶ñ¥R¼uÃÄ«á¡A§d§B¥u»Ý«ö¤@Áä´N¥iµn¤ë±æ¬P¤F¡C §Ö«ö§a¡@µ¥¶}¼ú§r¡ã¡ã¡ãBingo Bingo ¡I¡IGo go polaris~~~~~~ |
|
|
·|û¡G¥m¾´10141821 µoªí®É¶¡:2017/10/30 ¤U¤È 05:47:31²Ä 1643 ½g¦^À³
|
Á¼ڤj¸Ñ´b |
|
|
·|û¡G¤jGE10145523 µoªí®É¶¡:2017/10/30 ¤U¤È 05:03:49²Ä 1642 ½g¦^À³
|
·s¨Óªº¤S«ç¼Ë 30.50.100§Ú³£¦³¶R ¤µ¤Ñ70ÁÙ¬O¶R ¤£¯à±µ¨üªº´N¬O»°§Ö½æ§a |
|
|
·|û¡G¼Ú¬¥©_10144203 µoªí®É¶¡:2017/10/30 ¤U¤È 04:50:17²Ä 1641 ½g¦^À³
|
¤jGE §A¤S¬Oþ¨Óªº·s±b¸¹ ¤£¹L§AÁÙ¥i¥H ©Ó»{³o¬OÓ¹Ú·Q ¨ü¤£¤FÀ£¤O¥X³õ? ¨þ¨þ §A·s¨Óªº¡H ¼Ó¤U¥m¾´¤j ³o¹ïºV¤£´N¬O¤§«eªº¥Ó³øÂàÅý¶Ü ¤Ï¥¿²{¦bªÑ»ù´N¬O³o¼Ë ´N¬O·|¤@ª½§i¶D§A °Ú¡ãµ¥¨p¶Ò§¹´N¤£¥ÎÀ£ªÑ»ù¤F¡ã´Nnöt¤F¡ã§¤Ã¤F °Ú¡ãµ¥ÂàÅý§¹´N¨S½æÀ£¤F¡ãn¤@¸¨R¤Ñ¤F ÁÙn¤Hn·P®¦¥X³fªº¤j¤á ¬°¦ó¦³¿úªº¤j¤á³£¬O²Â³J ´N³o¨Ç¨S¿úªº´²¤á¬O¦³¼z²´ªºÁo©ú¤H? |
|
|
·|û¡G¥m¾´10141821 µoªí®É¶¡:2017/10/30 ¤U¤È 04:42:10²Ä 1640 ½g¦^À³
|
½Ð±Ðþ¦ìÄw½X¤j®v¯à¸Ñ´b¡A 10¡þ20ªº900±i¹ïºV¡A»P¤µ¤Ñªº1800±i¹ïºV¡A¥Nªí¦ó·N¸q¡H |
|
|
·|û¡G¤jGE10145523 µoªí®É¶¡:2017/10/30 ¤U¤È 04:29:37²Ä 1639 ½g¦^À³
|
¼Úxx ¨S¤H³QÄF ³£¥u¬O¹Ú·Q §A±µ¨ü³oÓ¹Ú´N¤J³õ ¤£±µ¨ü´N¥X³õ ¦³³o»òÃøÀ´¶Ü ¤§«e¶^¨ì20½Öª¾¹D¥i¥Hª¦¦^100 ²{¦b¶^¨ì70 §Ú¤]¤£ª¾¹D©ú¤Ñ·|¶]¨ìþ ¤@Ó¤ë«á©O ¨âÓ¤ë«á©O ı±o¨ü¤£¤FÀ£¤Oªº´N½Ð¥X³õ§a |
|
|
·|û¡G¼Ú¬¥©_10144203 µoªí®É¶¡:2017/10/30 ¤U¤È 04:14:20²Ä 1638 ½g¦^À³
|
¯uªº¬O¤@°ïµæ³¾ ¤£§Ôª½µø ªÑ²¼¥«³õ¤£¬O¤@Ó½µP¤ñ¤j¤pªº¹CÀ¸ ©Ò¥H¦³¨Ç¨Æ±¡¤£¬O½µP¤F¤~¯àµo²{ ¤@¯ë¦pªG¦³¤°»ò¨ÖÁʩάO»{¦C·~¥~°ªÃB·l¯q ¤£·|µ¥¨ì¤½¥qµo«°T¤~¶}©l¤Ï¬MªÑ»ù ·|¦bµo«°T¤§«eªÑ»ù´N©Ô«Ü¤j¤@¬q ¬Æ¦Ü¬O±µªñ½Í¦nªº»ù®æ¤F ©Ò¥H¦pªGªÑ»ù¨S°Ê§@©Î¬O½L¶^ ¤j·§´N¥i¥H²q¨ì¤£·|¦³¤°»ò¦n¨Æµo¥Í µ´¤£¥i¯à·d¤°»òªÑ»ù¤@ª½´X¤Q¤¸ ¬ðµM«Å¥¬¨CªÑ500¤¸³Q¨ÖÁÊ ¤£n³o»ò¤Ñ¯u¡ÏÄø¥i¤£¥i¥H ¦³®ÉÔ¯uªº¬Ý¤F«Ü¥Í®ð °ä¤Hªº«Ü¹L¥÷ ³Q°äªº§ó¥i´c |
|
|
·|û¡G¥Í§Þ±M®a10140885 µoªí®É¶¡:2017/10/30 ¤U¤È 03:12:47²Ä 1637 ½g¦^À³
|
½Ð±Ð¦Ñ´¤j¡G¤£¤~¤ÏÂЬݤF¦Ñ´¤j¤Î¦U¦ì¥ý¶iªº¤å³¹«á¡A©¿µM·Q¨ì¤U¦C´XÓ°ÝÃD¡G ¤@¡B´NÃĪ«ªº¯S©Ê¡AADIÁpK¸òÁpù¦¡ªºTecentriq¡A¹w´Á¤W¨º¤@ÓªºÃĮķ|¤ñ¸û¦n¡H ¦]¬°²{¦b§K¬ÌÀøªkÃĪ«¡A°ê»Ú¤W¦ü¥G¬OK¤ñT·¥ú¤@ÂI¡A¥i¬O¬Ý¦Ñ´¤j¡B»aÃǤj¹ïT¤¶²Ð©Òµoªº¤å³¹ ¤S¦n¹³T»PADIÁp¦X«á¡A®ÄªG·|Å̦ܳn¡A¤Ñ¤UµLÂù¡H¦¹¤]Ãö«Y¨ìù¤ó¶°¹Î¨ÖÁÊ¥_·¥¬P¤§¥ß³õ ¤G¡BÁpK©ÎÁpTªº¼Æ¾Ú¡A¦bÁ{§É¤W»Ýn¦h¤[ªº®É¶¡¤~·|¥X¨Ó¡H¥b¦~¡H¤@¦~¡H ¥H¤W¡A¦A½Ð½Ñ¦ì¥ý¶i«ü±Ð¡B«üÂI ¥t¡AÓ¤H·PÁ¨̷ӥ_·¥¬Pªº°ò¥»±¤Îªñ´Á¥i¯à³Q¦¬Áʪº¥i¯à©Ê¡A ªÑ»ù¯uªº§C¨ì¸Ø±i¡A¨ì®É¤j¨Æ¥ó¤@¥¹µo¥Í ¤@©w¬O¶W¤j¾_¾Ù |
|
|
·|û¡G¦Ñª¯10145373 µoªí®É¶¡:2017/10/30 ¤U¤È 02:51:53²Ä 1636 ½g¦^À³
|
@¤j §Úè¤j¯º¤F,§ÚÁÙ¦b®@ §Ú¬O¨S¦³¥»¿ú¦b¶i¤F ¦ý¥t¤@¥b¸ò§Ú¬P´Á¤ÁÙ¦bºë¯«³Û¸Ü ¥L»¡,n¥¿±ªº¬èë§ÖÂI¦³¤°»ò¤j¼t§â¬P¬P¶R¨« ÁöµM§Ú¨S¸ê®æ»¡¤°»ò¤£n½ä¨®a ¦ý¤]¬O¸ò§A»¡,¤£n½ä¨®a |
|
|
·|û¡G@¦ÌµX10144792 µoªí®É¶¡:2017/10/30 ¤U¤È 02:23:31²Ä 1635 ½g¦^À³
|
cue¤@¤U¦Ñª¯¤j! ½Ð°Ý±zÁÙ¦b¶Ü? §Ú¦¤W¤S§i¶D¦Û¤v¤j³g¤£³g¡A ½Ä¶i¥h¶R¤F¤@ÂI! ²{¦b¦³ÂI¤T±ø½u¤F lll |
|
|
·|û¡G±MÄݤѨÏ10145605 µoªí®É¶¡:2017/10/30 ¤U¤È 12:16:26²Ä 1634 ½g¦^À³
|
°Î¦WªºÄ_¨©¡A·R«Ü²³æ¥Ã¤£¥¢Áp¡A½Ð¸ò§ÚÁpô¡A¥_·¥¤§¥ú¡I |
|
|
·|û¡G¬}±x10144818 µoªí®É¶¡:2017/10/30 ¤W¤È 08:09:05²Ä 1633 ½g¦^À³
|
·|û¡G¬P¥úÀéÄê10145521 µoªí®É¶¡:2017/10/30 ¤W¤È 04:11:56²Ä 1657 ½g¦^À³ §O¤H¤¶²Ð¤kªB¤Íµ¹§A¡A¸ò§A´yz¤F¤k¥ÍªºÀuÂI¡A¦Û¤v¤]¬Û«H¤FµM«áªá¤F¿ú§â¡AµM«áÁÙ¤£¨ì¤@Ó¤ëÁÙ²o¤£¨ì¤â´N©Ç¤¶²Ð ¤HªêÄê¬O¦³¨º»òµU«æ¶Ü¡H³£´X·³¤H¤F¡A§âÓ©f³£¨S@©Ê³QÄF¤]è¦n¦Ó¤w ............................................................................................... µLªk¦P·N§ó¦h¤F~ ¥´µÛ¤é²±¦Ñ¥j¸³ªº¦W¸¹¡A¬Û«HÀ³¸Ó¤£¤p¤F~³o¬P´Á¨ì¦Uª©¥hÀH·N©ñ¸Ü(²´·ú·~»Ù«¡A¤@ª½¬Ý¨ì±z) ³£´X·³¤H¤F¡K§ë¸êµLªk¦Û§Ú§PÂ_¡H±zÁÙ½T©wn¨«§ë¸ê³o±ø¸ô¡H |
|
|
·|û¡G¬P¥úÀéÄê10145521 µoªí®É¶¡:2017/10/30 ¤W¤È 04:11:56²Ä 1632 ½g¦^À³
|
§O¤H¤¶²Ð¤kªB¤Íµ¹§A¡A¸ò§A´yz¤F¤k¥ÍªºÀuÂI¡A¦Û¤v¤]¬Û«H¤FµM«áªá¤F¿ú§â¡AµM«áÁÙ¤£¨ì¤@Ó¤ëÁÙ²o¤£¨ì¤â´N©Ç¤¶²Ð¤HªêÄê ¬O¦³¨º»òµU«æ¶Ü¡H³£´X·³¤H¤F¡A§âÓ©f³£¨S@©Ê³QÄF¤]è¦n¦Ó¤w |
|
|
·|û¡G¤é²±¦Ñ¥j¸³10142376 µoªí®É¶¡:2017/10/29 ¤U¤È 11:31:14²Ä 1631 ½g¦^À³
|
¥s¶i³o·à¡Aªø°²´Á¶¡¡A©I¤Ñ·m¦a¯ë¥s¶i·à¡C °²´Áµ²§ô10/11¡C12´N¬O³Ì°ªÂI¡I ¥u¬O¨Æ¹ê³¯z¡I |
|
|
·|û¡G¤@¤ô´H10144832 µoªí®É¶¡:2017/10/29 ¤U¤È 10:59:54²Ä 1630 ½g¦^À³
|
¦Ñ´¤j«e½ú±ß¦w¡B¦U¦ì¬P¤Í¤j¤j̱ߦw¡G ·PÁ«e½ú¦b°²¤é¦¡B±ß¨â¦¸¶O¤ß¸Ñ»¡»P¤jµL¨pªº¤À¨É¡I ¤]·PÁ»aÃǤj¡BºÃ´bªÌ¤j¡BÄƦV¥_¤è¤j´£¥X¬ÛÃö°ò¥»±ªº°ÝÃD»Pª¾ÃÑ¥HŹ¬P¤Í¡I ·PÁ»«¹£¤j¦³±ø¤£¯¿ªº§ë¸ê¹Lµ{¾ã²z¡Aȱo¬P¤Í̲`«ä¤ñ¹ï»P°Ñ¦Ò¡I ¹ï©ó±j¥§¤jªº²±±¡ÁܽСA¤d¸U¤£n¿ù¹L³oӤѽç¨}¾÷¡I @¦ÌµX¤j¡B123¤j¡A·PÁ¤§Ã㨥«¤F¡A¥u¬O·Q§V¤O°µ¦n¦Û¤v¸ÓºÉªº¥»¥÷¦Ó¤w¡I ¤é²±¦Ñ¥j¸³¤j¡A§ë¸ê¬O¦Û¤vªº¨M©w¡A¿éĹ³£ÁÙ¬On¦Û¤vt³d¡Aªp¥B¨Ó¤é¤èªø¡A¤£n¹L¦¤U©w½×³á¡I ³Ì«á¬ß±æ³Á§JªL¤j©Ò´£ªº¹Ú¹Ò¦¨¯u¡A§Y®ÉÂåªv±o¨ìÀù¯gªº¯f¤H¦Ó¯à¦¤é±d´_¡I ºK¿ý¾ã²z¸ê®Æ¦p¤U¨Ñ°Ñ¡G ¡¶¤é´Á¡¹¦¨¥æªÑ¼Æ¡»¥þÅé¨é°Ó¨C¤é®w¦s¼W´îªÑ¼Æ¡´¥þÅé¨é°Ó¨C¤é®w¦sÁ`ªÑ¼Æ --------------------------------------------------------------------------------------------------------- ¡¶2017/10/27¡¹1,066,024¡»328,231¡´42,068,503 ¡]¬ÛÃö¼Æ¾Ú»¡©ú½Ð°Ñ¦Ò²Ä486½g¦^À³¡A ¥H¤W¤§¡u¥þÅé¨é°Ó¨C¤é®w¦sÁ`ªÑ¼Æ¡v¼Æ¾Ú¡A ¦]·½ÀY¸ê®ÆÅܼƲ³¦h¡A¶È«Y·§²¤¼ÆÈ¡A ¦p¦³¿ù»~¤§³B¡A½Ð¦U¦ì¬P¤Í¤j¤j¦h¦h¥]²[¨Ã¤£§[´f¤©½ç±Ð¡C¡^ |
|
|
·|û¡G¤é²±¦Ñ¥j¸³10142376 µoªí®É¶¡:2017/10/29 ¤U¤È 10:48:36²Ä 1629 ½g¦^À³
|
³oӤ몺ªø°²´Á¶¡¡A¤£¬O¦³Ó¤@ª½¥s¶i·àªº¶Ü¡H µ²ªG©O¡H µ²ªG©O¡H µ²ªG©O¡H¡H¡H¡H¡H ·à·à·à |
|
|
·|û¡GÄƦV¥_¤è10144825 µoªí®É¶¡:2017/10/29 ¤U¤È 10:10:56²Ä 1628 ½g¦^À³
|
³o¬O¤WÓ¤ë¥Z¸ü¦b°ê»ÚÅv«Â´Á¥Z¡uNature¡v¨t¦Cªº¡uScientific Reports¡v¡AADI-PEG 20³æ¤@¥ÎÃĪvÀø«æ©Ê°©Åè©Ê¥Õ¦å¯f(Acute myeloid leukemia¡A²ºÙAML¡A¦åÀùªº¤@ºØ)¤G´ÁÁ{§É¸ÕÅçµ²ªG¡A³¡¤Àì¤å©M½Ķ¦p¤U All of the ITT patients were evaluated for toxicities as listed in Table 3. Overall, the toxicity was minimal and tolerated. The most common treatment-related adverse events were grade 1/2 skin rash (9.3%), grade 1/2 hyperuricemia (7%), and grade 3/4 leukopenia (7%). There were 2 patients who had grade 3/4 neutropenic fever (4.7%), and 2 patients had grade 3/4 anemia (4.7%). One patient had grade 4 tumor lysis syndrome and an infection and died; the death was attributed to both grade 4 events, consistent with AML and possibly ADI-PEG20. Due to the development of tumor lysis syndrome in this patient, prophylactic use of allopurinol was subsequently prescribed for all of the enrolled patients. Another patient had grade 4 anaphylactic shock and recovered without sequelae. ªþ¤W½Ķ¡G µû¦ô©Ò¦³ITT±wªÌªº¬r©Ê¡A¦pªí3©Ò¦C¡CÁ`Åé¤W¡A¬r©Ê·¥¤p¨Ã¥B@¨ü¡C³Ì±`¨£ªºªvÀø¬ÛÃö¤£¨}¨Æ¥ó¬°1/2¯Å¥Ö¯l¡]9.3¢H¡^¡A1/2¯Å°ª§¿»Ä¦å¯g¡]7¢H¡^©M3/4¯Å¥Õ²ÓM´î¤Ö¯g¡]7¢H¡^¡C¦³2¨Ò±w¦³3/4¯Å¤¤©Ê²É²ÓM´î¤Ö¯gµo¿N¡]4.7¢H¡^¡A2¨Ò±wªÌ¦³3/4¯Å³h¦å¡]4.7¢H¡^¡C¤@¨Ò±wªÌ¦³4¯Å¸~½F·»¸Ñºî¦X¼x¡A·P¬V¦º¤`;¦º¤`Âk¦]©ó¥|¯Å¨Æ¥ó¡A»PAML©M¥i¯àªºADI-PEG20¤@P¡C¥Ñ©ó¸Ó±wªÌ¸~½F·»¸Ñºî¦X¼xªºµo®i¡AÀH«á¹ï©Ò¦³¤J¿ï±wªÌ³W©w¤F§OáIËï¾Jªº¹w¨¾¥ÎÃÄ¡C¥t¦³±wªÌ¥X²{4¯Å¹L±Ó©Ê¥ð§J¡AµL«á¿ò¯g«ì´_¡C ÁöµM«e±´£¨ì¬r©Ê·¥¤p¡A¦ý¬O¨ä¤¤ÁÙ¬O¦³¤@¤H¦º¤`©M¥t¥~¤@¤H¥ð§J¡A³o¼Ëºâ¬O°Æ§@¥Î¤£¤j¶Ü¡H½Ð¦U¦ì¤j¤j¸Ñ´b¤@¤U¡AÁÂÁ¡I |
|
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2017/10/29 ¤U¤È 09:40:58²Ä 1627 ½g¦^À³
|
»aÃǤj,¤£n«È®ð,¦b³oª©¸Ì,§An½Í¤°»ò³£¥i¥H!!! ª¾¤vª¾©¼¦Ê¾Ô¤£¬p!!! ¬Ý¤@¤UKeytruda+car+pem¤@½u¥ÎÃĪvÀønon-squamous NSCLCªºkeynote-021 Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study The lancet oncology 2016 p-1497-1508 ³o½g¤ñ¸û¯S§Oªº¬O¦¬®×¦³26ÓÂå¾Ç¤¤¤ß,¥þ³¡³£¬O¦bUSA & Taiwan!!!¥i¨£¥xÆWªºÂåÀø¯u¤£¬O»\ªº!!! ³o¸Ì§ÚÌ¥u±j½Õ°Æ§@¥Î, ORR, mPFS, mOS¬°¦¸n Keytruda+car+pem pk car+pem ORR= 33/60 (55%; 95%CI 42¡V68) pk 18/63 (29%; 95%CI 18¡V41)------p=0.0016 mPFS= 13¡P0 months (95% CI 8¡P3~not reached) pk 8¡P9 months (95% CI 4¡P4¡V10¡P3)--p=0.010 6-months OS= 92% pk 92%-----------¨â²Õ¨S¦³®t²§!!! >=G3ªº°Æ§@¥Î¨â²Õ¨S¦³®t²§!!! anaemia= (seven [12%] of 59) pk (nine [15%] of 62 decreased neutrophil count= (three [5%]) pk two [3%] ¡´ª`·NKeytruda+car+pem¦bphase 2¥u¬D¾Ônon-squamous type!!!phase 3ªºkeynote 189¦b¨â¤Ñ«e 2017/10/27ºM¾P¼Ú·ùÃÄÃÒ¥Ó½Ð,¦]¬°ÁÙ»Ýn¥]¬AOS¬°co-primary endpointªº¼Ï¯Ã¹êÅç!!! À³¸Ó¤]¬O¦]¬°Phase 3ªºOS©MPhase 2ªºOS¤]³£®t¤£¦hªºì¦]!!! ¥Ø«e´±³æ¬Dsquamous type NSCLCªº -¦³³QLillyñ¨«ªº¤j³°«H¹F¥Íª«2017/05/18¶}©lPhase 3(¦ý¬O¬O¤G½u¥ÎÃÄ) -Keytruda+car+paclitaxel or nab-paclitaxel phase 3ªºKeynote 407 ¡´MerckºM¾Pkeynote 189ªº¼Ú·ùÃÄÃÒ¥Ó½Ð!!!------À³¸Ó¬O¦]¬°Phase 3ªºOS¤£ÅãµÛ!!! ¬Q¤Ñ¤]´£¹LTecentriq+cis+pem+adiªº°Æ§@¥Î¤]¤£¤j,«Ü¦w¥þ!!! Tecentriq (¤]¥sMPDL3280A)¦bASCOªºµoªí Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Tecentriq + carboplatin + paclitaxel= (Arm C, n=8) Tecentriq + carboplatin + pemetrexed= (Arm D, n=14) Tecentriq + carboplatin + nab-paclitaxel= (Arm E, n=15) G3-4 ¯Åªº°Æ§@¥Î anemia (Arms D & E, 7%), neutropenia (Arm C, 13%; Arm D, 7%) thrombocytopenia (Arms D & E, 7%) No pneumonitis was seen. ¡´¦ý¬ORoche³ºµM¤]§âTecentriqÁp¤ÆÀøÃĪºNCT01633970(Phase 3)¤¤¤î¤F!!!---FDA clinical trial ºô¯¸¤w¬d¤£¨ì³oÓÁ{§É¹êÅç!!¦b³oÓ®ÉÔRoche³ºµM§âTecentriq¥[¤J¤FADI+Pem+Cisªº¦æ¦C!!! µª®×¤£¬O¤w¸g«Ü©úÅã¤F¶Ü¡H ¡´Merck, BMS & Roche³£¹J¨ì¤F¤@Ó¹L¤£¥hªº²~ÀV¡A³o®ÉÁpADIÅS¥X¤F¤@¹DÀÆ¥ú¡I Go go polaris!!! |
|
|
·|û¡G¥m¾´10141821 µoªí®É¶¡:2017/10/29 ¤U¤È 08:55:43²Ä 1626 ½g¦^À³
|
¾´¾´¾´¾´¾´¾´¡A Only You ¤~ª¾¹D «¢«¢ |
|
|
·|û¡G±j¥§25810144809 µoªí®É¶¡:2017/10/29 ¤U¤È 08:47:49²Ä 1625 ½g¦^À³
|
¦Ñ´¤j±z¦n¡B¦U¦ì¬P¤Í¦n: ¨S¿ù¡A ³o´XÓ§«ôªº±¡ªp¸ò¥b¦~¦h¥H«e¦³ÂI¹³¡A¦³ÂIW... W¤é¤l¬OÃø§Ñªº¡A§óÃø§ÑªºW¤¤§@¼Öªº¹Lµ{¡A 쥻¥H¬°¨S¦³¾÷·|¦A¹J¨ì¡A¨S·Q¨ìÁÙ¦³©¯¦A«·Å¡A ¤W¦¸¨S¾÷·|¹J¨ìªº·s¬P¤ÍÌ¡A®¥³ß§AÌ¡A ¬°¤°»ò»¡®¥³ß©O? ¦]¬°¤p§Ì©l²×¬Û«H¦³W¹L¡A¤§«áÀò±oªº²¢¬üªG¹ê·|§ó¥[²¢¬ü¡A ÁÙ¦³¯à¤O¸É³fªº§â´¤¾÷·|§a¡A Åwªï¤@°_¥[¤Jµ¥«Ý¨É¨ü²¢¬üªG¹êªº¦æ¦C!! |
|
|
·|û¡G¶Â¿ÂÃÆ10145058 µoªí®É¶¡:2017/10/29 ¤U¤È 08:07:18²Ä 1624 ½g¦^À³
|
¥m¾´ ½Ð°Ý§Aª¾¹D¤°»ò¬O ¾´¾´¾´¾´¾´¾´? |
|
|
·|û¡GºØºÖ¥Ð10144845 µoªí®É¶¡:2017/10/29 ¤U¤È 07:30:22²Ä 1623 ½g¦^À³
|
»«¹£¤j¥¦w¡A¨ØªA§AªºÁxÃÑ&¨£ÃÑ¡AÅý½Ñ¦h¬P¤Í´ç¹L¨º¬q¬ÛÀá¥Hªj`¤â«ü»Q¨ì¨£°©ªº¤é¤l. ¾´¾´¡A§AÄ~Äò¥[ªo¡A¬¡¦b¦Û¤vªº¥@¬É§a¡I |
|
|
·|û¡G¤pªL10145248 µoªí®É¶¡:2017/10/29 ¤U¤È 06:13:36²Ä 1622 ½g¦^À³
|
¥m¥m¥S ¦pªG§A¤@ª½©ñªº¬O°²®ø®§ ¯uªº·|Åý¤H¬Ý¤£°_ |
|
|
·|û¡G¤jGE10145523 µoªí®É¶¡:2017/10/29 ¤U¤È 05:44:58²Ä 1621 ½g¦^À³
|
¤é¥»ªºE7080®ÄªG¥»¨Ó´N¤£¿ù ¨xÀù¤]«Ü¦n ¥¦¬OVEGFR ¤w¸g¦³ÃÄÃÒªº ¤£¯àºâ¬OÄvª§ÃĪ« ³oÓÃĪ«¤]¬O¦bÂX®iÃÄÃÒ³\¥i½d³ò |
|
|
·|û¡GºÃ´bªÌ10140504 µoªí®É¶¡:2017/10/29 ¤U¤È 05:25:19²Ä 1620 ½g¦^À³
|
¥H¤U¼Æ¾Ú¬Ý¨Ó,keytrudaÁp¦XE7080ªºÁ{§É¼Æ¾Ú«Ü¤£¿ù 1.PD-1+E7080 ¥Î©óµÇÀù¡G¦³®Ä²v83%¡A±±¨î²v100% ¦b¤µ¦~ªº¼Ú¬w¸~½F¾Ç¨ó·|¦~·|¡]ESMO¡^¤W¡AEisai¤½¥q¡]E7080ªº¥Í²£¼t®a¡^¤½¥¬¤FPD-1§ÜÅéKeytrudaÁp¦XE7080°w¹ïµÇÀùªºÁ{§É¼Æ¾Ú¡A¤@½u¨Ï¥Î¦³®Ä²v°ª¹F83%¡C Á{§Éµ²ªG¡G¦b©Ò¦³30¦ì±wªÌ¤¤¡A19¦ì¸~½F©úÅãÁY¤p¡A¦³®Ä²v63%¡F9¦ì±wªÌ¸~½Féw¤£ªø¤j¡A¯e¯f±±¨î²v96%¡C¦b12¦ì¥¼¸g¹L¨t²ÎªvÀøªº12¦ì±wªÌ¤¤¡A10¦ì±wªÌ¸~½F©úÅãÁY¤p¡A¦³®Ä²v83%¡F2¦ì±wªÌ¸~½Féw¤£ªø¤j¡A¯e¯f±±¨î²v100%¡C 2.Á{§É³]p¡G©Û¶Ò¤F23¦ì±ß´Á¤l®c¤º½¤Àù±wªÌ¡A¤j³¡¤À³£¦Ü¤Ö±µ¨ü¹L¤@¦¸¨t²ÎªvÀø¡CE7080ªº¾¯¶q¬O¨C¤Ñ20mg¡FPD-1§ÜÅéKeytrudaªº¾¯¶q¬O200mg¡A3©P¤@¦¸¡C Á{§Éµ²ªG¡G23¸Ì±11¦ì±wªÌ¸~½F©úÅãÁY¤p¡A¦³®Ä²v°ª¹F48%¡F¥t¥~¡AÁÙ¦³11¦ì±wªÌ¸~½Féw¤£¶i®i¡A¯e±±±±¨î²v96%¡C 3.2016¦~ªºESMO¦~·|¤½¥¬¤FPD-1§ÜÅéKeytrudaÁp¦X7080¥Î©ó¦hºØ¸~½Fªº¤p³W¼ÒÁ{§É¼Æ¾Ú¡A±±¨î²v°ª¹F100%¡C Á{§É³]p¡G©Û¶Ò13¦W±ß´Á¸~½F±wªÌ¡A¥]¬A2¦W«D¤pªÍÀù¡B8¦WµÇÀù¡B2¦W¤l®c¤º½¤Àù©M1¦W´c©Ê¶Â¦â¯À½F¡F¨ãÅ骺Áp¦X¤è®×¡GE7080ªº¾¯¶q¬O20mg©M24mg¨âºØ¡AKeytruda¬O200mg¤T©P¤@¦¸¡C Á{§Éµ²ªG¡G13¦W±wªÌ¤¤7¦ì¸~½FÁY¤p¡A¦³®Ä²v54%¡F6¦ì±wªÌ¸~½F¨S¦³ªø¤j¡A¯e¯f±±¨î²v100%¡C ¬èëADI-PEG20»PTecentriqªºÁp¦X¥ÎÃĦ³§ó«G²´ªºÁ{§Éµ²ªG |
|
|
·|û¡G¥m¾´10141821 µoªí®É¶¡:2017/10/29 ¤U¤È 03:42:42²Ä 1619 ½g¦^À³
|
»aÃÇ §A¶Kªº¤å³¹¸Ì¡A¦³½g¥i¥H¯}¦Ñªº²Ä¤G½b¡A¥u¤£¹L§A¤£ª¾¹D¡C |
|
|
·|û¡G»aÃÇ10141976 µoªí®É¶¡:2017/10/29 ¤U¤È 03:21:39²Ä 1618 ½g¦^À³
|
¥m¾´: §A³stimeline³£·d¿ù¤F¡A´N¤£n¦A¦ºÄñÄꥴ¡A·d±o®æ½Õ³£§Ö¨S¤F¡C ¦³ªÅ¾á¤ß§O¤Hªº§ë¸ê¼Ðªº¡A¤£¦p¦hÃö¤ß¦Û¤vªº§a¡C Å¥»¡§A¦Û»{¬°«Ü¥Î¥\¡A¨º´N´£¨Ñ§A¤@½g¤å³¹¦n¦n¬ã¨s¡A¸Ì±·d¤£¦nÂ泯EX¥h¦~2´Á¤£²z·QªºÃöÁäì¦]¡C Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus www.ncbi.nlm.nih.gov/pmc/articles/PMC4422597/ ÁÙ¦³¡A¤£¥Î°w¹ï§Ú°µ¥ô¦ó¦^ÂСA¦]¬°§A«e´X¦¸°w¹ï§Ú´£¥Xªº¦^°Ý¡AÅã¥Ü§A¯uªº¨S¦³¥Î¤ß¬Ý§Ú¶Kªº¤å³¹¡A§Ú¬O¤£·|¦^ÂШººØ¤£¥Î¤ßªº°ÝÃDªº¡C ¦Ñ´¤j¡A©êºp¡A¶K¤F¸ò¥»ª©¤£¬Û¤zªºªF¦è¡C§Ú¥u§Æ±æ¥m¾´¯uªº¤£n¦A®ö¶O¥Í©R¡A¬Ý¤F«Ü¤£§Ô¡C |
|
|
·|û¡G»«¹£ô10144807 µoªí®É¶¡:2017/10/29 ¤U¤È 02:12:45²Ä 1617 ½g¦^À³
|
¦U¦ì¬P¤Í¤È¦w°Ú ·PÁ¦Ѵ¤j¤S¤À¨É¦n¤åµ¹¤j®a¡A¦b¥Ø«eÁÙ¦³¤H¦b¨ÑÀ³Äw½Xªºª¬ªp¤U¡A¤H¤ßÃø§K¤ñ¸û´T°Ê¡Aµu½u§ë¸êªÌ¯S§O§ó¬Oºò±i¡A¦ý¬O¦pªG´«§@¬Oªø½uªº§ë¸ê¤H¡AÀ³¸ÓÁÙ¬O·|¥H¤½¥qªº°ò¥»±§@¬°«nªº°Ñ¦Ò¨Ì¾Ú ¦pªG§Ú̧â®É¶¡Ë¦^¥b¦~«e¡A¦U¦ì¥i¥H¬Ý¤@¤U¨º®ÉÔªºªÑ»ù¬O¦h¤Ö¡H°O±o¨S¿ùÀ³¸Ó¬O25¥ª¥k¡A·í®É¬P¬P¨S¦³©Ò¿×ªº°ò¥»± ²Ä¤@ ¨S¦³¸êª÷¡A·í®Ét¶Å¤ñ±µªñ99 ²Ä¤G »PKÃÄÁp¦X¥ÎÃĤ]¨S¦³¤U¤å ²Ä¤T ¨â¦ìì©lªÑªF´c·N˳f¡A¨â®a¥[°_¨Ó±µªñ1¸U±i ²Ä¥| ¤½¥q«Å§G18¶ô¼W¸ê¡A»P¥«³õªº»ù®æ¬Û®tªñ3¦¨ ²Ä¤ ¥xªÑ«ü¼Æ¤£Â_©¹¤W½Ä°ª¡A¬P¬P«o¨C¤Ñ¯}©³ ¬Ý¨ì¤W±ªº±ø¥ó¡A»«¹£·Q·Q¨º®ÉÔ¦Û¤v¯uªººÆ¤F¡AÁÙ¤@È¥[½X¡A¨º®ÉÔ§i¶D¦Û¤vªº¬O¡A´N·í§@¤H¥Í¤¤ªº¤@³õ½äª`§a¡A¦Ó¥B¤S¦³¤@¸s¬P¤Í¤j®a¤¬¬Û¥´®ð¡A¶Ì¶Ìªº¤@¸s¤H⋯»¡¬O¤¬¬Û¨ú·x¤]¦n¡A»¡¬OºÆ¤H°|¤]½}¡A¤j®a´N³o»ò¼µ¹L¨Ó¤F §Ų́Ӭݬݥb¦~«áªº²{¦b¡AªÑ»ù70¡A§Ú¬Û«H¤j¦h¼Æªº¦Ñ¬P¤Í±b¤W³£¬O¥¿ªº §Ú̦A¨Ó¬Ý¬Ý¥b¦~«á¬P¬Pªº°ò¥»± ²Ä¤@ 18¶ô¼W¸ê§¹¦¨¡A¤½¥q§K©ó¯}²£ªº§½± ²Ä¤G »PKÃÄÁp¦X¥ÎÃĤw¸g¶}©l®i¶}¡A¥i¥H´Á«Ý¤½¥q¼ÖÆ[ªº¼Æ¾Ú ²Ä¤T FDAã³\¬P¬P±Ò°Ê¨xÀù³æÁuÁ{§É¸ÕÅç¡A¹wp©ú¦~´N¦³µ²ªG ²Ä¥| ¤½¥q§¹¦¨¤F¨â¦¸ªº¨p¶Ò¡A¤À§O¶i±b¤F3»õ¦h¥H¤Î5»õ¦h¡AÅýÁ{§É¹êÅ礣©È¨S¦³¸êª÷ ²Ä¤ ªÍÀù¤j·|¤½§Gº}«Gªº¼Æ¾Ú¡Aù¤ó´£¨Ñ§K¬ÌÀøªk¥ÎÃÄTECENTRIQ§ë¤J«D¤p²ÓMªÍÀùªºÁ{§É¹êÅç 25¶ôªº®ÉÔ§ë¸ê¤ñªº¬OÁxÃÑ ²{¦b70¶ô§ë¸ê¤ñªº¬O¹ï°ò¥»±ªº»{ª¾¤Î@¤ß ¥Ø«e¬P¬Pªºª¬ªp¡A¥un¥É¤s«°¤¤°±¤î½æ¥X¡A±µ¤U¨Óªº´N¬O¥Î°ò¥»±¤ÏÀ³ªÑ»ù¤F ¤°»ò®ÉÔ¤jÃļt¶}©l«æ¤F¡A´N¬On¦bô¦n¦w¥þ±a·Ç³Æ¸ªº®ÉÔ¤F 20´X¶ôªº®ÉÔ»«¹£§Ú ·PÁ¤j©M°ê®õ¤Î¤¸¤j´°«n³o¨â®a¨é°ÓºB´n´£¨ÑÄw½X 70¶ôªº®ÉÔ·|¤£·|¥b¦~«á»«¹£¤Sn·PÁ¥ɤs«°¤¤¦b¬P¬Pªº°ò¥»±³v¨B©ú®Ô¼ÖÆ[ªº®ÉÔÁÙºB´n´£¨ÑÄw½X©O¡H »«¹£Ó¤HÆ[ÂI¡A¤Á¤Å§@¬°¾Þ§@°Ñ¦Ò ¤@ªM58¨Ó»»·Q©ú¦~ªº¬ü¦n®É¥ú¡ã |
|
|
·|û¡G¤jGE10145523 µoªí®É¶¡:2017/10/29 ¤U¤È 12:13:37²Ä 1616 ½g¦^À³
|
§Ú¦Û¤v¤]¥´¿ù ¬OIFN¤~¹ï |
|
|
·|û¡G¤jGE10145523 µoªí®É¶¡:2017/10/29 ¤U¤È 12:06:47²Ä 1615 ½g¦^À³
|
¬Ý¨Ó¥m¾´¯uªº¤£ª¾¹DINF £\ £] £^ªº®t§O ¦pªG¥m¾´n°Ý°ÝÃDÁÙ¬O¥ý¥h«×¤j¤G¥Í¤Æ¦n¤F |
|
|
·|û¡G¥m¾´10141821 µoªí®É¶¡:2017/10/29 ¤W¤È 11:29:16²Ä 1614 ½g¦^À³
|
## µoªí®É¶¡:2017/10/18 ¤W¤È 07:30:38 ¥D¦® ¥»¤½¥q©ó¥@¬ÉªÍÀù¤j·|(WCLC)¥H¤fÀY³ø§i¤è¦¡µoªí ADI-PEG 20»PPD-1/PD-L1§K¬ÌÀøªk¦X¨Ö¨Ï¥Î¤§¬ã¨sµ²ªG ............ II.ASSªí¹F²v§CªºªÍ¶¡¥ÖÀù²ÓM¡A¦b¥[¤JADI-PEG 20«á24~48¤p®É·|ÄÀ©ñ¤zÂZ¯À £\¤Î£]¡A³y¦¨PD-L1ªí¹F²v¤É°ª¡C©Ò¥H¡A¦bÁ{§É¤W°w¹ïPD-L1ªí¹F²v§Cªº¯f¤H¡A ¦bµ¹§K¬ÌÀøªkÃĪ«¤§«e1~2¤Ñ¥ý¨Ï¥ÎADI-PEG 20´N¥i¯à´£¤ÉÀø®Ä¡C ............ ## ¥_·¥¬P»{¬°¤zÂZ¯À£\¤Î£]¡A³y¦¨PD-L1ªí¹F²v¤É°ª¡C¦Óù¤ó¤]»{¬°¡A¡u¤j·§¥i¯à¤]³\¬O¡A®£©È¥¼¥²¤£ºÉµM¡v¬O¤zÂZ¯À£\¤Î£]³y¦¨ªº¡A¬°¨¾¸U¤@¡A©Ò¥Hù¤ó¤w¸g¶}©lÁp¦X¤zÂZ¯ÀI«¬¤F¡A¦Ó¥Bù¤ó¥i¥H±±¨î¡u¤zÂZ¯Àªº¶q¡v¡A¥H¹F¨ì¡uPD-L1ªí¹F¡vªº³Ì¨Î®ÄªG, ¡AADI¨S¿ìªk±±¨î¤zÂZ¯Àªº¶q¡A¡u½Ð°Ý¥_·¥¬PÀu¶Õ¦bþ¡v¡H ¡u£^¡v¥Î¥ß¥i¥Õ¶î±¼´N¦n¤F¡A«¢¡A¨S¦^µª§Úªº°ÝÃD¡A¬D¤@Ó§Ú¤£·Qq¥¿ªº¤p¿ù¡AÁÙ°µ¤F¤@ºRAP¡Aªº½T®¼Ãz¯ºªº¡A¯u¬O±Ð±Â?ÁÙ¬O¤p§¾«Ä? |
|
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2017/10/29 ¤W¤È 07:49:21²Ä 1613 ½g¦^À³
|
¬P¤Í¸sªºKevin¦³¤À¨É¤@½g«Ü¦nªº½×¤å,±q²ÓM®è©M°Êª«¹êÅç§âASS1,p53©MAKt¤§¶¡ªºÃö«YÄÄzªº«Ü²M·¡! Argininosuccinate synthase 1 is an intrinsic Akt repressor transactivated by p53 Sci. Adv. 2017;3: e1603204 ¥Ñ¤é¥»ªF¤jªº¾ÇªÌÌ°µªº¬ã¨s,§¹¥þ¨S¦³¥_·¥¬Pªº¸êª÷ÃÙ§U¦b¤º-----©Ò¥H¬O«D±`«ÈÆ[ªº¬ã¨s!!! ´Á¥Z¬OScience advances¡÷¥Ñ¬ü°ê¬ì¾Ç«P¶i·|(AAAS)¦b2015/02¥Xª©ªºopen access,¥Ø«eÁöµMÁÙ¨S¦³ impact factor,¦ý¬O±q2015,2016¨â¦~ªºµo¤å¼Æ©M³Q¤Þ¥Î¼Æ¨Ó¬Ý,¤£¿éNature communication!!! °ò¥»¤W ´N¬OScience¨t¦Cn©MNature¨t¦C¹ï·Fªº¤l¥Z´N¹ï¤F¡I---¤w¦¨¬°«Ü¦h°ò¦Âå¾Çªº³Õ¯Z³Ì´Á±æ§ë¤¤ªº´Á¥Z¤§¤@!!! ²³æ°O´N¬Op53,ASS1¬O¦n¤H,AKt¬OÃa³J!!!p53¬O¥Ø«e³Q¬ã¨s³Ì³z¹ýªº§íÀù°ò¦]!!!Akt«h¬OPÀù°ò¦]¤§¤@!!! Â^¨ú¤@¬qWiki¹ïp53ªº¸ÑÄÀ: -·íDNA¨ü·l®É¡Ap53³J¥Õ¯à¬¡¤ÆDNA×´_³J¥Õ (DNA repair proteins)¡C -p53³J¥Õ¯à§í¨î²ÓM¥Íªø¶g´Á°±¯d©óG1/Sªº¸`«ßÂI¤W¡A¥H¹F¦¨DNA·lÃa¿ëÃÑ¡C (Y¯à±N²ÓM©ó¦¹¸`«ßÂI¤W°±¯d°÷¤[¡ADNA×Å@³J¥Õ±N¦³§ó¥R¸Îªº®É¶¡×´_DNA·lÃa³¡¦ì¡A¨ÃÄ~Äò²ÓMªº ¥Íªø¶g´Á¡C) -Y²ÓMªºDNA¨ü·l¤w¤£¯à×´_¡Ap53³J¥Õ¯à°_©l²ÓMä¤`µ{§Ç¡AÁקK¾Ö¦³¤£¥¿±`¿ò¶Ç¸ê°Tªº²ÓMÄ~Äò ¤Àµõ¥Íªø¡C ·í¨Åé¾D¨ügenotoxic stress(·|¯}Ãa²ÓM¤º¿ò¶Çª«½è§¹¾ã©Êªº¬r¯À(¦p¤»»ù»Ì¡Bf¡B´åÂ÷¿ç®gµ¥)®É, p53·|±Ò°Ê¤@¨t¦Cªº target gene (ASS1, EPPK1, EPS8L2, APOBEC3C, FDXR, MDM2, and RRM2B)¨Ó«OÅ@²ÓMªº°·±d. ³o¤@¨t¦C³Qp53±Ò°Êªº¾÷Âत,ASS1¥i¯à´N¬O¨ä¤¤ª½±µ³Q±Ò°Êªº¾÷Âध¤@.¬°ÃÒ¹êASS1¬O¤£¬Op53ªºª½±µ ¤U´å,§@ªÌ̥ΤF«Ü¦h¹êÅç«Çªº¤èªk(¥Î¤HÃþ¤j¸zª½¸zÀùªº²ÓM®è,±µ¨üdoxorubicin¤ÆÀøÃĪ«,¥ÎPCR, Western blot)¨ÓÃÒ¹ê!!!----¡´ASS1·|ª½±µ³Qp53¬¡¤Æ!!!ASS1¬Op53ªºª½±µ¤U´å!!! ASS1 was confirmed to be a direct downstream target of p53!!! ¥Îp53+/+ and p53-/-ªºcell line±µ¨üdoxorubicin®Éµo²{,ASS1ªº¬¡©Ê¦bp53+/+²Õ¤W¤É!!! ¡´¦³p53ªºASS1¤~·|³Q¬¡¤Æ,¬Û¤Ï,«h¤£·|! ¬°¤F±Æ°£¬O¦]¬°¨ä¥Lp53»¤¾Éªº¥NÁ¾÷Âà¤zÂZ,§@ªÌ̥ΤF¤@¨Ç¤èªk(CRISPR)§âcell lineªºASS1©â±¼, µo²{¡÷ASS1-/-ªºcell line, ASS1´N¤£·|³Q¬¡¤Æ!!! ¡´©Ò¥Hµ²½×´N¬O,p53·|ª½±µ¬¡¤ÆASS1, ASS1¬Op53ªºª½±µ¤U´å!!! ³oÓµ²½×¦bÅý¦Ñ¹«±µ¨ü¥þ¨¿ç®g¨ë¿E(total body irradiation,TBI)¤]±o¨ìÃÒ¹ê!!! genotoxic stress¡÷·|«P¨Ï²ÓMAKt phosphorylation AKtÁC»Ä¤Æ·|¬¡¤ÆAKt¹L«×ªí²{,³y¦¨²ÓMÀù¤Æ!!! Akt, also known as protein kinase B, plays key roles in cell proliferation, survival and metabolism. Akt hyperactivation contributes to many pathophysiological conditions , including human cancers and is closely associated with poor prognosis and chemo- or radiotherapeutic resistance. Phosphorylation of Akt activates Akt. ASS1¥i§í¨îAKt phosphorylation!!! ©Ò¥Hµ²½×²³æªº»¡´N¬O p53ª½±µ¬¡¤ÆASS1¨Ó§í¨îAKtÁC»Ä¤Æ,¹F¨ì§íÀùªº®ÄªG!!! ¦pªGASS1ªºªí¹F³Q¤zÂZ,«h²ÓM·|®e©ö¾D¨ügenotoxic stress¦Ó¦º¤`!!!---³o´N¬O¬°¤°»ò¦bASS1¯Ê¥Fªº Àù²ÓM,¥un¦A§â¥~¨ÓªºArg.°¸Ñ,´N§ó®e©öÅýÀù²ÓM³Q¤ÆÀø,©ñÀøµ¥·F±¼ªºì¦]!!! |
|
|
·|û¡G³Á§JªL10142093 µoªí®É¶¡:2017/10/29 ¤W¤È 02:11:46²Ä 1612 ½g¦^À³
|
¤p§Ìªº¹Ú¹Ò¡A¥¼¨Óµ´¤j³¡¤ÀÀù¯gªº£¸½uÀøªk¡A³£¥²¶·¥ý¬I¤©ADI-PEG20¡AµM«á¦A°µì¥»ªº£¸½uªvÀø¡A¦Ó¥B쥻£¸½uªvÀøªº¾¯¶q¥i¥H´î¤Ö¡AÅý¬r©Ê°§C¹ï¤HÅ骺·l®`¡C ©Ò¿×Áp¦X¥ÎÃÄ¡A¤]¦³¬I¥´ªº¥ý«á¶¶§Ç¡A¥²¶·¥ý¬I¥´ADI-PEG20¡A¦A¬I¤©¼Ð·Çªº£¸½uªvÀø¡A¦¹®É£¸½uªvÀøªº¾¯¶qÀ³¥i°§C¡C ¥Ñ©óµ´¤j³¡¤Àªº£¸½uªvÀø§¡¾A¥Î¡A¦]¦¹n¥[³t®i¶}©Ò¦³ªºÁ{§É°ß¦³¨ÖÁÊ£¸³~¡A¤]¤~¥i§ÖÂI¤W¥«±Ïµ´¤j³¡¤ÀÀù¯gªº¯f¤H¡C ©Ò¥H¥_·¥¬P¡A½Ð¥[ªo¡I ¹Ú¹Ò¤£¥i°µ¬°§ë¸ê¨Ì¾Ú¡I |
|
|
·|û¡G12310000032 µoªí®É¶¡:2017/10/28 ¤U¤È 08:28:09²Ä 1611 ½g¦^À³
|
¦Ñ´¤j«e½ú±z¦n±ß¦w¡A¦U¦ì¬P¤Í̤j®a±ß¦w¡A «e½ú¯u¬O¦h¤~¦hÃÀ¡ARAP¯uªººqµü¶W¶K¤Áªº¡A°Û§@ѨΡA¶WÆgÆgÆg!!!!! ¯¬¤j®a¶g¥½´r§Ö~ |
|
|
·|û¡GDavid Xu10143450 µoªí®É¶¡:2017/10/28 ¤U¤È 01:00:58²Ä 1610 ½g¦^À³
|
¦Ñ·¨¤j¤j¤Î¬P¤ÍÌ ¥ð°²´r§Ö ¾´¤j¦n¤[¤£¨£¤F¡C·Pı¦nµL²áµL½ì¡C ¦Ñ·¨¤j¤£¥u¬OÓÂå¾Ç±M®a¨Ö¥BÁÙ¬O¤@¦ì±M·~ªº§@µü§@¦±®a¡C |
|
|
·|û¡GLeo10142037 µoªí®É¶¡:2017/10/28 ¤W¤È 11:39:15²Ä 1609 ½g¦^À³
|
½Ð±Ð¦Ñ´¤j ADI-PEG 20 ¬O¹ï©Ò¦³ªº¹êÅé¸~½F³£¦³®Ä¶Ü ¦³¥]²[¸£½F¶Ü ÁÙ¦³¨º¨Ç¹êÅé¸~½F¶Ü ·PÁ |
|
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2017/10/28 ¤W¤È 11:36:08²Ä 1608 ½g¦^À³
|
¥H¤U§Ṳ́j®a¤@°_¨ÓRAP¤@¤U,21¥@¬ö¦@¦Pªº»y¨¥,Music.... ¥m¥m,¾´¾´,¥m¾´---¤£ª¾¸£³¡¨º¸Ì---³Q ¦º ·í! alpha, beta, gamma---¶Ì¶Ì¤À¤£²M·¡ yo yo yo, everybody¤@°_¨Ó alpha, beta, gamma---¶Ì¶Ì¤À¤£²M·¡ ¸£³U,¤f³U,¥¬³U---¥m¾´³q³q³£¨S±a ª¾ÃÑ,¨£ÃÑ,±`ÃÑ---¥m¾´³q³q³£¤£»{ÃÑ ¦Û´Ý,¹p´Ý,¤Ñ´Ý---¥m¾´¨C¤Ñ³£¦b´Ý yo yo yo, everybody¤@°_¨Ó.....YA!!! «¢«¢¯¬¤j®a¶g¥½¹J§Ö!!!§â³oº§Y¿³ºq¦±Copy°_¨Ó³á~~~¥H«á¥i¥H©ñµ¹¾´¾´Å¥!!! |
|
|
·|û¡G12310000032 µoªí®É¶¡:2017/10/28 ¤W¤È 11:31:18²Ä 1607 ½g¦^À³
|
¦Ñ´¤j«e½ú±z¦n¦¦w¡A¦U¦ì¬P¤Í̤j®a¦¦w¡A ·P¿E«e½úªººë±m±M·~¤À¨É¡AÅý¤p§Ì©ú¥Õù¤óÃļt«æªºì¦]¡A·P®¦!!!!! ¤p§Ì¦Û¾Ö¦³¥_·¥¬P¥H¨Ó¡A¿ï¾Ü¤@ª½³£¬O²Ä¤T¶µ¡A¤j³g¤£³g¡A±±¨î¦Û¤vªº¤ß¡AÀR¤ßµ¥«Ý¤j¨Æ¥ó(°ê»ÚÃļt¤Ñ»ù¨ÖÁÊ)¨ì¨Ó¡A¤p§Ì±q¤£³Q³o´X¤Q¶ôªº¶^´T©Ò¼vÅT¡A¤p§Ì´Á«Ý¥_·¥¬P¥¼¨Óµo¥úµo¼ö¡C ¥H¤W¬°¤p§Ì¦Û¤vªº¬Ýªk¡A¤Á¤Å·í°µ§ë¸ê¨Ì¾Ú ¥_·¥¬P¥[ªo!!!!! |
|
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2017/10/28 ¤W¤È 11:24:01²Ä 1606 ½g¦^À³
|
¾´¾´,§A¬°¤°»òÁ`¬O·R¥á¤H²{²´©O? §A·dªºÀ´¤°»ò¬OInterferon-alpha, beta, gamma¶Ü? Roche Tecentriq¨t¦C148ÓÁÙ¦b¶i¦æªºclinical trials,¾´¾´¥i¥H§i¶D§Ų́º¸Ì¦³Ápinterferon-gamma ªº¬ã¨s¶Ü? »aÃǤj»¡ªº¬O³o¤@½g!!! A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors This global, multicenter, open-label study will evaluate the safety and tolerability of atezolizumab in combination with other immune-modulating therapies in the treatment of selected advanced or metastatic malignancies. The atezolizumab plus ipilimumab arm (Arm A) will focus primarily on participants with advanced or metastatic non-small cell lung cancer (NSCLC). The atezolizumab plus interferon alfa-2b arm (Arm B), plus pegylated interferon alfa-2a (PEG−interferon alfa-2a, Arm C), and atezolizumab plus PEG-interferon Alfa-2a plus bevacizumab (Arm D) will enroll participants with advanced or metastatic renal cell carcinoma (RCC), metastatic NSCLC and melanoma. The atezolizumab plus obinutuzumab) (Arm E) will enroll participants with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Atezolizumab will be administered as intravenous (IV) infusion every 3 weeks (q3w). Official Title: A Phase Ib Study of The Safety And Pharmacology of Atezolizumab (Anti−Pd-L1 Antibody) Administered With Ipilimumab, Interferon-Alpha, or Other Immune-Modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors Estimated Enrollment: 200 Actual Study Start Date: August 18, 2014 Estimated Study Completion Date: February 28, 2019 Estimated Primary Completion Date: February 28, 2019 (Final data collection date for primary outcome measure) ¾´¾´¾´ª¾¹DPegasys (interferon alfa-2a)ªº°Æ§@¥Î¦³¦h¤j¶Ü???¤µ¤ÑRoche¬Ý¨ìªº¬OADI°£¤F°¸ÑArg. ³ºµMÁÙ§K¶O©^°einterferon-alfa, betaªº¥\¯à!!! ±i¤j§Aªº½N½N²´¬Ý²M·¡,¯u¬O¨q¤~¹J¨ì§L!!! ¤£µMµ¹¾´¾´¾´¤@Ó¾÷·|¦n¤F,§A¥un¯à§i¶D¦Ñ´¥Ø«e¤w°Ý¥@ªºIFN-gammaªºÃĦ³¨º¨Ç?¤À§O¬O¥Î¨ÓªvÀø¤° »ò¯e¯fªº,¦Ñ´´Nì½Ì¾´¾´¾´ªº¸£´Ý¯Ê,¦p¦ó??? |
|
|
·|û¡G¸Û«H¦ó®¬10139574 µoªí®É¶¡:2017/10/28 ¤W¤È 09:33:30²Ä 1605 ½g¦^À³
|
´Nºâ¨S¦³¥[¹A¬¶¥X²{¡A¤£¬OÁÙ¦³¤T§â¤}¶Ü¡H §A¦³§Ú¹w´ú·Ç¶Ü¡H |
|
|
·|û¡G¥m¾´10141821 µoªí®É¶¡:2017/10/28 ¤W¤È 09:09:04²Ä 1604 ½g¦^À³
|
ù¤óª½±µÁp¦Xinterferon-£^¡A¦ó»ÝÁp¦XADI-peg 20¡A¦ó¥²¨ÖÁÊ¥_·¥¬P¡A©Ò¥H¥uµ¹ÃÄ¡A¨Sµ¹¿ú¡A ù¤ó¦Û®aªºÃÄ¥»¿ú«K©y¡AÃØÃĤp·N«ä¡A¥_·¥¬P¦Û±Ç¸y¥]ªá¤j¿ú°µ¹êÅç¡A³Ì«á¤H®a¥i¯à¤£»â±¡¡A ¦Ó¥Bù¤ó¤w¸g¦b°µÁpinterferon-£^¡A½Ð°Ý¥_·¥¬PÀu¶Õ¦bþ¡H |
|
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2017/10/27 ¤U¤È 10:43:24²Ä 1603 ½g¦^À³
|
»aÃǤj,¨ºÁÙ¬OClinical trial§r!!!©|µLData,©Î¬O¬Ý¬Ý¥H¤Uªº¦p¦ó??? ¦Ñ´¦¦b¬P¤Í¸s²Õ´N¤À¨É¹L,§ë¸ê¥_·¥¬Pªº¤T¤jµ¦²¤: 1. ¦pªG©È·ÀI¤Ó¤j,¤j¥i¤Fµ²(Àò§Qor»{½ß)±q¦¹»P¥xÆW¥Í§Þ¤½¥q³Q¨Ö¾ú¥v»¡¤£¨£ 2. ¦pªG¤w¸gÀò§Q¤£¿ù,¤j¥i¹s¦¨¥»¸ò¨ì©³,¤]¤£¥¢^¶¯¥»¦â 3. ¦pªG·Qn¤j³g¤£³g,´N§Ñ±¼ªi°ÊªºªÑ»ù,ª½±µµ¥¨ì¤j¨Æ¥óµo¥Í,Åý°]´I«¤À°t ¤£ºÞ¿ï¾Ü¨º¤@ºØ,³£¬O¦Û¤vªº¿ï¾Ü,n«i©ó©Ó¾á!!! ³Ìªñ¥J²Ó¦a°á¤F«Ü¦hTecentriqªº¬ã¨s,ªGµM·Å¬Gª¾·s,µo²{¤F«Ü¦h¦³½ìªº¦a¤è: 1. ¦bTecentriq vs.docetaxel¤G½uªvÀøNSCLCªºphase 2 study (POPLAR)¤¤,Roche°µ¤F«Ü¦h©MOpdivo, Keytruda³o¨â®aanti-PD1¤£¤@¼Ëªº¨Æ±¡!!! ¡´°£¤F¬Ýtumor cellªºPD-L1 expression(TC0,TC1,TC2,TC3), Á٬ݤFtumor-infiltrating immune cells ªºPD-L1 expression(IC0,IC1,IC2,IC3)-----©Ò¥H,¥H«áªºIHCÀËÅçÀ³¸Ó¨â¼Ë³£ÀË,¥i¥H©Ô°ª¾A¥Î±Ú¸s! ¡´RocheÁ٨ƥýÀË´ú¤FT-effector-INF-gamma associated gene expression,µo²{¥u¦³¦btumor-infiltrating immune cells¤W¤~¦³¬Ý¨ìT-effector-INF-gamma associatedªºPD-L1 expression,¥B high expression (>=50%) T-effector-INF-gamma (HR 0¡P43; 95% CI 0¡P24¡V0¡P77) vs. low expression (<=50%) T-effector-INF-gamma (HR 1¡P1; 95% CI 0¡P68¡V1¡P76) ¥H¤W´N»¡©ú¤F,Type 2 INF (INF-gamma)»¤¾ÉPD-L1 expressionªº¥\¯à! ¦ÓType 1 INF (alpha, beta)¤]¦³¦P¼Ëªº®ÄªG!!! ©Ò¥H±q³o¸Ì¥i¥Hª¾¹D ¡´Roche¤£¬Oéw¤H,§ó¤£¬OÃĤӦh,¬Ý¤¤ªº´N¬OADI-PEG»¤¾ÉPD-L1 expressionªº¥\¯à!!! 2.ADI+Pem+Cis+Tecentriq¡ARoche¬°¤°»òn³o»ò«æ?½Ð¬ÝKeytruda¦b·F¤°»ò Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study RocheªºTecentriq¤]¤£¬O¬Ùªoªº¿O,Áp3ÃĤ]¤w¶i¤JPhase 3!!! A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132) NCT02657434 Estimated Enrollment: 568 Actual Study Start Date: April 30, 2016 Estimated Study Completion Date: November 30, 2019 Estimated Primary Completion Date: November 30, 2019 (Final data collection date for primary outcome measure) A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110] Estimated Enrollment: 555 Actual Study Start Date: July 20, 2015 Estimated Study Completion Date: April 23, 2020 Estimated Primary Completion Date: January 17, 2019 (Final data collection date for primary outcome measure) 3.§AÌ·|«Ü¾á¤ßADI+Pem+Cis+Tecentriq°Æ§@¥Î¶Ü¡H---¥i¥H°Ñ¦ÒTecentriq (¤]¥sMPDL3280A)¦bASCOªºµoªí Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Tecentriq + carboplatin + paclitaxel= (Arm C, n=8) Tecentriq + carboplatin + pemetrexed= (Arm D, n=14) Tecentriq + carboplatin + nab-paclitaxel= (Arm E, n=15) G3-4 ¯Åªº¨ì§@¥Î anemia (Arms D & E, 7%), neutropenia (Arm C, 13%; Arm D, 7%) thrombocytopenia (Arms D & E, 7%) No pneumonitis was seen. »¡¨ì³o¸ÌÁ٬ݤ£À´´N°O¦í¡÷¬P¬P®³¨ìªº¬ORocheªºÃÄ!!!·à¤l®³¨ìªº¬OMerck & BMSªº¿ú!!! ¤]¤£¥Î¤Ó¦b·N¤jªÑªF¥É¤s«°¤¤ªº¥X³f,¥L¤]¥u¬O¦b°§C¦¨¥»¦Ó¤w,²¦³º¬O¥Í§Þ¥~¦æ¤H,åx¤F¤Q´X¦~¨ì²{¦b ¥´ºâ¥X±¼15%¥ª¥kªº«ùªÑ(¨ì¤µ¤Ñ®t¤£¦h11%),¤]¨S¥´ºâ¬å¦b70¥H¤U(§_«hµ¥©ó¬O¦Û±þ),¤w¸gÃø¯à¥i¶Q¤F, ªp¥B¥L¦pªG¤£¥X,°]´I¤S«ç¯à«¤À°t? ¥H¤W°£¤F¾Ç³N³£¬O¦Ñ´ªº¥L¤ß³q^^,¤£¥i°µ¬°§ë¸ê°Ñ¦Ò!!! |
|
|
·|û¡G¦Ñª¯10145373 µoªí®É¶¡:2017/10/27 ¤U¤È 04:40:22²Ä 1602 ½g¦^À³
|
¸Û«H¤j123¤j ÁÂÁ§AÌ ¨ä¹ê§Ú·|¤Öµo¨¥,²`©È¦Û¤v»¡¤F¤°»ò¸Ü³y¦¨§O¤Hªº³Â·Ð §Ú·|ÀRÀR¬Ý§A̤À¨É©M°Q½×ªº «Ü¦h¬P¤Í«Ü¥Î¤ß¦bÃö¤ß©M¤ä«ù,¨¯W§A̤F «D¬P¤Íªº,¤]«ÜÁÂÁ§AÌÅý¨ä¥¦¤Hª¾¹D¥t¤@ºØÁnµ |
|
|
·|û¡G12310000032 µoªí®É¶¡:2017/10/27 ¤U¤È 01:29:29²Ä 1601 ½g¦^À³
|
¦Ñ´¤j«e½ú±z¦n¤È¦w¡A¦U¦ì¬P¤Í̤j®a¤È¦w¡A ·P®¦«e½ú¡A«D±`´Á«Ý«e½úªº±M·~¤À¨É¡C¤]·PÁ»aÃǤjªº±M·~¤À¨É¡A·PÁ¤@¤ô´H¤jªºÄw½X¤ÀªR¡A¤]«Ü»{¦P¬P²y¤jªº°µ¤Hªº°ò¥»(Æg+1)¡A¹ï©óªÑ»ùµu¼Èªi°Ê¡A¤p§Ì¥±`¤ßµø¤§¡A¤p§Ì¨ÌÂÂ¥¿±`¥Í¬¡¡A¤£·|¹ï¤ß±¡³y¦¨¼vÅT¡A¤Ï˶}¤ß¥i¥H¦A§C±µ(±O½Þ)¡A·PÁ¤U¨®ªº¤H¡A·PÁÂ! Ps. ¦Ñª¯¤j¥[ªo¡A¦Ñ¤Ñ·Ý·|²²ÅU§µ¶¶¬°®a¤H¥I¥Xªº«Ä¤l¡C ¬P¤ÍÌÅý§Ṳ́@°_¬°¥_·¥¬P¥[ªo§a~ ¥_·¥¬P¥[ªo!!!!! |
|
|
·|û¡G@¦ÌµX10144792 µoªí®É¶¡:2017/10/27 ¤W¤È 08:40:56²Ä 1600 ½g¦^À³
|
¤@¤ô´H¤j! ·PÁ±z¯S§O¬°§ÚÄÀºÃ~¤åµ§¤W¬Ý¨Ó±z´N¬OÓ Åª®Ñ¤H¡A¤£¹³§Ú¤@°Æ¤j¶ý¦üªº½aºò±i~ ÁÙ¬O¬èë¥Í§ÞªÑ¦¤é²æL´«ªÑ¡AÂà°©Åܤj¤H°Ú!! Thanks a million¡G) |
|
|
·|û¡G¸Û«H¦ó®¬10139574 µoªí®É¶¡:2017/10/27 ¤W¤È 07:07:29²Ä 1599 ½g¦^À³
|
¦Ñ´¤j¤Î¦U¦ì¬P¤Í¦w¦w «D±`·P®¦»aÃǤjªº¤À¨É¡A±`ÂI¥X§Ú̬ݤ£¨ìªº¦a¤è ¦Ñª¯¤j¡A°í«H¨Ã°í«ù¡A¬P¬P¤£·|Åý±z¥¢±æªº |
|
|
·|û¡G»aÃÇ10141976 µoªí®É¶¡:2017/10/27 ¤W¤È 05:39:32²Ä 1598 ½g¦^À³
|
¦Ñ´¤j±z¦n¡A¦U¦ìª©¤Í¦n: ¥»·Qn¼ç¤ô¥h¤F¡A¦ý¬Ý¨ì´²°]µ£¤l¤@ª½§âÄ_ª«¥á¥X¨Ó¡A§V¤OÅý¤j®a¦³°Ñ»P°]´I«¤À°tªº¾÷·|¡A¤Þ°_¤j®aij½×¯É¯É¡A©ó¬O´N·Q»¡¡A¤£¦p¦A½Ð¤j®a¦A¬Ý¬Ý¦³½ìªºªF¦è§a! A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors (Offical Title: A Phase Ib Study of The Safety And Pharmacology of Atezolizumab (Anti−Pd-L1 Antibody) Administered With Ipilimumab, Interferon-Alpha, or Other Immune-Modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors) clinicaltrials.gov/ct2/show/NCT02174172 (§Æ±æ¦Ñ´¤j¦pªG¦³®É¶¡¬°¤j®a¸Ñ»¡¤@¤U³oÓ¸ÕÅç) ³oÓ¸ÕÅ礤¡A¤zÂZ¯À¬O¥ÎRoche¥L̦ۮaªºPegasys¡A¦³¬ã¨s¹LÃĵØP1101ªº³£ª¾¹D¡APegasysªº°Æ§@¥Î¤j¡A®ÄªG¦ü¥G¤£°÷¦n¡A¬Æ¦ÜÁÙ¦³ÁÁ¨¥»¡n°±²£¡C¦pªG¬ðµM«_¥X¤F¤@Ó¥sADI-PEG20ªºªF¦è¡A³ºµM·|Åý¸~½F²ÓMÄÀ©ñ¤zÂZ¯À¡AÁÙ¬O¤HÅ餺²£¥Íªº(ÃĵتºP1101¦A¯Â¤]¤£·|¤ñ³oӯ§a!)¡A°Æ§@¥Î¤p¡ARoche/Merck·|¤£·|·Qn©O? ¤£ª¾¹D¥_·¥¬P¦³¨S¦³´ú¶q¹L¡A¤HÅ饴¤FADI-PEG20«á¡AÅ餺ªº¤zÂZ¯À¿@«×¥i¥H¨ì¹F¦h¤Ö?(J«ä¶Ã·Q¤¤¡K¡K) ªÑ»ù¶}©lº¦¤§«á¡A§Ú¦A¥h¼ç¤ô¦n¤F¡C |
|
|
·|û¡G¦Ñª¯10145373 µoªí®É¶¡:2017/10/26 ¤U¤È 11:43:35²Ä 1597 ½g¦^À³
|
¬P²y¤jÁÂÁ§A |
|
|
·|û¡G¤@¤ô´H10144832 µoªí®É¶¡:2017/10/26 ¤U¤È 11:19:52²Ä 1596 ½g¦^À³
|
¬P²y±U°_¤j¤j±ß¦w¡B¦U¦ì¬P¤Í¤j¤j̱ߦw¡G ÃÙ¦P±z©Òz°µ¤H°ò¥»ªº¹D²z¡I ÀRԲĤT¦¸¨p¶Ò§¹¦¨¡I ÀR«ÝÁpK¼Æ¾Úªº¤½§G¡I ºK¿ý¾ã²z¸ê®Æ¦p¤U¨Ñ°Ñ¡G ¡¶¤é´Á¡¹¦¨¥æªÑ¼Æ¡»¥þÅé¨é°Ó¨C¤é®w¦s¼W´îªÑ¼Æ¡´¥þÅé¨é°Ó¨C¤é®w¦sÁ`ªÑ¼Æ ------------------------------------------------------------------ ¡¶2017/10/26¡¹1,440,701¡»376,715¡´41,740,272 ¡]¬ÛÃö¼Æ¾Ú»¡©ú½Ð°Ñ¦Ò²Ä486½g¦^À³¡A ¥H¤W¼Æ¾Ú¦p¦³¿ù»~¤§³B¡A ½Ð¦U¦ì¬P¤Í¤j¤j¦h¦h¥]²[¨Ã¤£§[´f¤©½ç±Ð¡C¡^ |
|
|
·|û¡GºÃ´bªÌ10140504 µoªí®É¶¡:2017/10/26 ¤U¤È 10:21:28²Ä 1595 ½g¦^À³
|
¤jªÑªF¤@ª½½æ ¦³¨S¦³¥i¯à¬O¸ò¤W¦¸¤@¼Ë ½æ¦ÑªÑ ·Ç³Æ¶R·sªÑ¡]¨p¶Ò¡^¡H ps.§Ú¬OÄw½X±ªºªù¥~º~ |
|
|
·|û¡G¬P²y±U°_10145048 µoªí®É¶¡:2017/10/26 ¤U¤È 09:03:19²Ä 1594 ½g¦^À³
|
¦Ñ´¤j±ß¦w¡A¦U¦ì¬P¤Í±ß¦w¡A ¦Ñª¯¥S¡A«Ü¶}¤ß±z¥i¥H¶}¶}ª±¯º¡A¤H¥Ín°l¨Dªº¨Æ¡Bª««Ü¦h¡Aª÷¿ú¦A¦h¤]¬O¥Î°÷¥Îªº¦Ó¤w¡A ¦A«ç»ò¦h¡A¦Ñ¤F³£n¤ÀÂIµ¹Âå¥Íªá¡A¤H¨«¤F³£±a¤£¨«¤@¤À¤@²@¡A¨S¦³¥²n¬°¤F¶^¤£¶^¥Í®ðªº¡C ³o¸Ì¬O¬P¤Í̪º¦a¤è¡A§Ú¤£·|§n¬[ªº¡A§Ú¤]¨S«ü¥ô¦ó¤H¡A¥u¬O¶K¥X¤@½g¶Ë¤ßªº¤å¡A ¦ó¨Ó®âÅB¡A¦ó¥²¹ï¸¹¡ã·Q·P®¦´N¦n¦n·P®¦¸ÓÁÂÁªº¤H¡C ¤pªº«ù¦³¥_·¥¬P¤@¦~¥b¥H¤W¡A¶^¤]¨S½æ¡Aº¦¤]¨S½æ¡A¦]¬°«ùªÑ¤Ö¡A¤]¨S¦³¤Ó¦h¼vÅT¡A ´N¬O¤£³ßÅw¤ß¸Ì¨S¦³µ½¨}ªº¤H¦Ó¤w¡ã ´¶³q¤H¬Ý¨ì¸ô¤H¶^Ë¡A³£·|·QÀ°¦£§ß¤@¤U¡A©Î¬Ý¬Ý¬O§_¨ü¶Ë¡A ¦Ó¤£¬O¨ú¯º»¡¹ï¤è¨«¸ô¤£¬Ý¸ôºLˬ¡¸Ó¡ã ³o´N¬O«Ü°ò¥»¡A«Ü²³æªº¹D²z¦Ó¤w¡C ¹ï©ó³ßÅw§á¦±ªº¤H¡B¨Æ¡A¤j®a´N·í¥ð¶¢®T¼Ö¤]¤£¿ù°Ú¡ã ¤S¥´ÂZ¤j®a¤F¡A«¢«¢«¢¡ã¦U¦ì±ß¦w |
|
|
·|û¡GÄƦV¥_¤è10144825 µoªí®É¶¡:2017/10/26 ¤U¤È 07:58:43²Ä 1593 ½g¦^À³
|
2016/02/15~2017/10/25 ¥D¤O¶i¥X ¶R¶W¨é°Ó ¶R¶i ½æ¥X ¶R¶W §¡»ù ·s¥ú 3307 2202 1106 56.10 ¦X®w 1220 280 941 59.88 ¤¸¤j-©²«° 1488 626 862 53.37 °ê²¼-¤¤¥¿ 1231 405 826 73.51 ³Í°ò-¥«©² 759 204 555 49.09 ¸s¯qª÷¹©-¼æ¤l 698 182 516 55.05 ´I¨¹-¤¯·R 1403 888 514 63.88 ¸s¯qª÷¹©-«ÌªF 551 81 470 56.67 ¥x·s 722 277 445 61.57 ´I¨¹-¤¤Ãc 724 325 399 49.97 ¦X®w-¦Û±j 547 184 362 57.87 ²Î¤@-Â×ì 520 180 340 66.62 ½æ¶W¨é°Ó ¶R¶i ½æ¥X ½æ¶W §¡»ù ¤j©M°ê®õ 0 7718 -7718 51.20 ¥É¤s-«°¤¤ 158 4287 -4129 59.37 ¤¤°ê«H°U 553 4395 -3843 77.78 ¤¸¤j-´°«n 152 3286 -3133 44.76 ¥üÂ× 7 2569 -2562 64.57 ¤¸¤j-ªO¾ô 58 2360 -2302 65.00 ³Í°ò-¤¤¤s 141 2217 -2076 61.95 ´I¨¹-¤j¦w 59 1930 -1871 71.90 ¥ÃÂת÷ 236 1891 -1655 62.55 ¤¸¤j-·s¦Ë 1355 2731 -1376 72.43 ¤é²±-´_¿³ 118 1078 -960 67.87 ¤¸¤j¸g¬ö 166 1107 -941 39.93 ²³æ©úÁA´N¤£¸ÑÄÀ¤F¡I |
|
|
·|û¡G¦Ñª¯10145373 µoªí®É¶¡:2017/10/26 ¤U¤È 07:39:14²Ä 1592 ½g¦^À³
|
¼Ú¤j¡A¬P²y¤j ¨S¨Æ¡A¤j®a³£¥u¬Oµoªí¦Û¤vªº¬Ýªk §Ú®a¥u¦³§Ú¿W¤l¡A®a¦³¦Ñ¥À¡An¦Û¤v¤Fµ²¤]¤£·|¬O²{¦b¡H §Ú¶}ª±¯ºªº ¤j®a§O§n¬[¡A°Q½×°Q½×´N¦n ¸ò¬Q¤Ñ¤@¼Ë´Á«Ý©ú¤Ñ·|§ó¦n ¦A¹L¤@¤Ñ¤S¬O©P¥½¤F |
|
|
·|û¡G¼Ú¬¥©_10144203 µoªí®É¶¡:2017/10/26 ¤U¤È 06:06:01²Ä 1591 ½g¦^À³
|
§Ú¤£ª¾¹D§â§Úªº¤å¸ò¦Ñª¯¤j³sµ²ªº¥Î·N¬O....? ³o¸Ì¤w¸g¤£¤Ö¤H²ßºD¶Ã®âÅB§O¤H¤F ªÑ»ù¤@ª½¶^ ¤£¬O½Öªº¿ù ½Ð¤Å®³µL¶dªº¤H¨Ó¥X®ð ·P®¦ |
|
|
·|û¡G¤@¤ô´H10144832 µoªí®É¶¡:2017/10/26 ¤U¤È 03:19:23²Ä 1590 ½g¦^À³
|
@¦ÌµX¤j¤j¤È¦w¡B¦U¦ì¬P¤Í¤j¤j̤Ȧw¡G ·PÁ±zªºÃöª`¡I ¡´¡u¥þÅé¨é°Ó¨C¤é®w¦sÁ`ªÑ¼Æ¡v¡H ¸Õ²µª¦p¤U¡G °²³]®É¥úËÂà¡A ¤µ¤é¬O105¦~2¤ë15¤é¥_·¥¬Pµn¿ý¿³Âd¶i¦æ¶R½æ¥æ©ö¡A «h ¥Ò§ë¸ê¤H¦b¢Ï¨é°Ó¶}¥ßÃÒ¨é±b¤á¶R¶i¥_·¥¬P1,000ªÑ¡F ¤A§ë¸ê¤H¦b¢Ï¨é°Ó¶}¥ßÃÒ¨é±b¤á¶R¶i¥_·¥¬P2,000ªÑ¡F ¤þ§ë¸ê¤H¦bB¨é°Ó¶}¥ßÃÒ¨é±b¤á¶R¶i¥_·¥¬P1,000ªÑ¡F ¤B§ë¸ê¤H¦bC¨é°Ó¶}¥ßÃÒ¨é±b¤á¶R¶i¥_·¥¬P1,000ªÑ¡F ¥³§ë¸ê¤H¦bD¨é°Ó¶}¥ßÃÒ¨é±b¤á¶R¶i¥_·¥¬P1,000ªÑ¡F ---------------------------------------------------------------------------------- ¢Ï¨é°Ó·í¤é®w¦s¥_·¥¬PªÑ¼Æp3,000ªÑ¡F B¨é°Ó·í¤é®w¦s¥_·¥¬PªÑ¼Æp1,000ªÑ¡F C¨é°Ó·í¤é®w¦s¥_·¥¬PªÑ¼Æp1,000ªÑ¡F D¨é°Ó·í¤é®w¦s¥_·¥¬PªÑ¼Æp1,000ªÑ¡F ----------------------------------------------------------------------------------- ¡u¥þÅé¨é°Ó¡]¢Ï¡B¢Ð¡B¢Ñ¡B¢Ò¡^¡y·í¤é¡z®w¦sÁ`ªÑ¼Æ¡v¬°¢µ,000ªÑ¡F =================================================== ¦Ü©ó¦¸¤é105¦~2¤ë16¤é¤§¡u¥þÅé¨é°Ó¡y¨C¤é¡z®w¦sÁ`ªÑ¼Æ¡v¡H ¬°ÁקK¥e¾Ú½g´T¡A ·q½Ð±z °Ñ¦Ò²Ä486½g¦^À³¤§¸Ô²Ó»¡©ú¡C ¡´¬°¤°»òªÑ»ù¤@ª½©¹¤U¨«§r?? ¤£ª¾¦³þ¤@¦ì¤j¤j¥i¥H¦CÁ|ÃÒ©ú¦³þ¤@®a¤½¥q¦b¥«³õ¥æ©öªºªÑ»ù¡u¥uº¦¤£¶^¡v¡H ¤pªº¤~²¨¾Ç²L¡A¥u¯àɥΩ]¶¡¸¦æ¤j¤j©Ò¨¥¡G ¡u·sÃĪѰ߰ò¥»±¬O°Ý¡A¡y¥Ø«e¬Ý¨Ó°ò¥»±¶V¨Ó¶V¦n¡z¡AªÑ»ù©|¥¼¤ÏÀ³¤£¥Nªí±N¨Ó¤£¤ÏÀ³¡A ©³³¡¬OµÑ·Ò¤H¤ßªº®ÉÔ¡A¤£@¤[Ôªº¤H°h³õ¤]µL§«¡A¶R½æªÑ²¼¬O¦Û¥Ñ¡A ¤ÀªR§PÂ_n²z©Ê¡B«ÈÆ[¡B¡¨²`¤J¡¨¡I ¡¨²`¤J¡¨ §AÀ´¶Ü¡H¡v ȱo¬Ù«äªº¬O¡A·í¬Y¦ì§ë¸ê¤H¤â¤¤´¤¦³²{ª÷¡A¨S¦³«ùªÑ¡A¥L¤S¬O¦p¦ó¬Ý«Ý¥_·¥¬PªÑ»ù¤@ª½©¹¤U¨«³o¥ó¨Æ©O¡H Go Go Polaris¡I¡I¡I |
|
|
·|û¡G@¦ÌµX10144792 µoªí®É¶¡:2017/10/26 ¤U¤È 01:59:30²Ä 1589 ½g¦^À³
|
²³¤j¤È¦w! ¦A½Ð±Ð¤@Ó¦n¯ºªº°ÝÃD! ¤@¤ô´H¤j¨C¤Ñ´£¨Ñªº¡u¥þÅé¨é°Ó¨C¤é®w¦sÁ`ªÑ¼Æ¡v ¬O¥Nªí¤°»ò·N«ä©O? §Ú¦Û¤vªº¨£¸Ñ¬O¦nªº¡A¨º¬°¤°»òªÑ»ù¤@ª½©¹¤U¨«§r?? ÁÙ¬O§Ú³oÁû²Â¸£³U¤]¸ò½Þ¶¤¤Í¤@¼Ë¿NÃa¤F@@ |
|
|
·|û¡G¬P²y±U°_10145048 µoªí®É¶¡:2017/10/26 ¤U¤È 01:30:56²Ä 1588 ½g¦^À³
|
¦Ñ´¤j¤È¦w¡A¦U¦ì¬P¤Í¤È¦w ¦³¤H¤@ª½n§O¤H«O«¡A¤S«O«¡A¤S«O«¡ã ¬On«´X¦¸¡ã »¡³Q¤@°ï¤Hðã½|¡A³oÓ»¡ªk¤]¥¼§K¤Ó¨H«¤F¡A¬Ý¬Ý¤U¦Cµo¨¥¡A ¬O§_¦³¤ß¤Hn³y¦¨§O¤H®£·W¡AÁÙ¬O§Æ±æÅý§O¤Hı±o¬¡¤£¤U¥h¤F¡H ·|û¡G¦Ñª¯10145373 µoªí®É¶¡:2017/10/14 ¤W¤È 07:18:49²Ä 1360 ½g¦^À³µ¹¼Ú*©_¤j ¤Ï¥¿§Ú³£¦í®M©Ð¤F ¤Ï¥¿§Úªº¤H¥Í¤w¸g¨S¦³¤°»òȱo´Á«Ýªº ¬P¬P§Ú¤@±i³£¤£·|½æ ¦Ñª¯¥S¡A¯uªº«Ü©êºp¡A¤£¬O¤@ª½ncue±z¡A¥u¬O§Æ±æ±N¨Ó¤j®a¤@°_À|¨ì²¢¬üªºªG¹ê¡A ¹Lµ{©Î³\´e¤F¨Ç¡A¦ý¤@°_¥[ªo§a¡C »¡§O¤H°Iªº¤H¤j®a³£¬Ý¨ì¤F¡ã |
|
|
·|û¡G©]¶¡¸¦æ10144996 µoªí®É¶¡:2017/10/26 ¤W¤È 10:52:30²Ä 1587 ½g¦^À³
|
¼Ú¬¥©_¡A¥u¯à»¡§A¥u¹ï¤F¤@¥b¡A¦Ó¥B¬O·L¤£¨¬¹Dªº¤@¥b¡I ¥_·¥¬P¤W¿³Âd¥H¨Ó ²Ä¤@¤j¤j½æ¶W¤j©M°ê®õ ½æ¥X±i¼Æ¤j¬ù7718±i §¡»ù51.2 ¤¸¤j¼[«n+¤¸¤j¸g¬ö ¦Xp¤j¬ù½æ¥X4000±i§¡»ù¦b39.93¡ã44.76 ³o¨â®a¬O¨è·NÀ£½L½æ¥X©Ò¥H¯S§OÂI¥X¨Ó¡I ·íµM¨ä¥L½æ¶W¦b1000±i¥H¤WÁÙ¦³7®a¡A½æ¥XÁ`¦³¥L̦ۤvªº²z¥Ñ»P¬Ýªk¡A ¹ï©Î¿ù¬Ý¥Î¦óºØ¨¤«×«ä¦Ò¡I °I¤H¬O½Ö¡H½æ¦b30¡B40¥H¤Uªº¤H§a¡I²{¤µªÑ»ù§A»{¬°·|¦^Àɨìþ¸Ì¡H Y§Ú»¡½Ö¬O²Ä¤@¤j°I¤H¡G¤j©M°ê®õ¸ò¤¸¤j¥S§Ì¡A¥L̤@½æ§¹ªÑ»ù«K¶}©lº¦¡I ¤j¤á¥¼¥²«ä¦Ò³£¬O¹ïªº¡I¥~¸ê¸ò§ë«Hªº¾Þ§@¤W¦¸¤£¬O¸ò§A»¡¹L¤F¶Ü¡I¥L̤£°÷¤j¶Ü¡H¤]·|¥Ç¿ù§a¡I ·sÃĪѰ߰ò¥»±¬O°Ý¡A¥Ø«e¬Ý¨Ó°ò¥»±¶V¨Ó¶V¦n¡AªÑ»ù©|¥¼¤ÏÀ³¤£¥Nªí±N¨Ó¤£¤ÏÀ³¡A ©³³¡¬OµÑ·Ò¤H¤ßªº®ÉÔ¡A¤£@¤[Ôªº¤H°h³õ¤]µL§«¡A¶R½æªÑ²¼¬O¦Û¥Ñ¡A ¤ÀªR§PÂ_n²z©Ê¡B«ÈÆ[¡B¡¨²`¤J¡¨¡I ¡¨²`¤J¡¨ §AÀ´¶Ü¡H |
|
|
·|û¡G¤ý£«¬Â10136621 µoªí®É¶¡:2017/10/26 ¤W¤È 10:48:19²Ä 1586 ½g¦^À³
|
¥x¿n¹q¦³±i©¾¿Ñ¤~¦³¤µ¤Ñ¡A¥_·¥¬P¦³§d§B¤å¤j®aÁ٩Ȥ°»ò¡H |
|
|
·|û¡G½ä®{10141199 µoªí®É¶¡:2017/10/26 ¤W¤È 10:15:57²Ä 1585 ½g¦^À³
|
¦Û¥j^¶¯½×¹ï¿ù Ĺªº¤H´N¬O^¶¯¡A¿éªº¤H´N¬Oª¯ºµ ¦b³oÓªÀ¹ÎùØ¡A¤@¡B¤GӬݪŪº¤Hªº¨¥½×¹ï¤j½Lªº¼vÅT¬O¦³ªº ¦bªÑ¥«³o»ò¤jªº½ä½LùØ¡A¤â¤W®³¦nµPªº¤H¬O¤£·|»´©ö«G¥X¨Óªº ®³¤F¦Pªá¶¶¡A¤£¤@¦¸ö«¢¤F¤£¬O¤Ó¥i±¤¤F¶Ü¡AÃø¹DÁÙnµ¹§A¤U¤@¦¸ªº¾÷·|°Ú µ¥§AÄw½X³£±þ¥X¨Óªº®ÉÔ¡A´N¬O«G©³µPªº®ÉÔ¤F @¤ß¡BÂÔ·V¡A¤£n·í³Ì«á¤@°¦¦Ñ¹« |
|
|
·|û¡GPETER10142151 µoªí®É¶¡:2017/10/26 ¤W¤È 09:56:29²Ä 1584 ½g¦^À³
|
¡m¸Ö¸g¡Pªõ·¡P¬f¦à¡n¡G¡u§Ú¤ßê¥Û¡A¤£¥iÂà¤]¡C¡v¥un·N§Ó°í©w,¤S¦ó¥²¥h²z·|¨º¨Ç¥Ø¥úµu²L¥B¥u·|©Ô½Þ«Ëªº¬Y¨Ç¤H |
|
|
·|û¡G¸Û«H¦ó®¬10139574 µoªí®É¶¡:2017/10/26 ¤W¤È 09:53:52²Ä 1583 ½g¦^À³
|
ªÑ²¼¥«³õ¬OÓ¦ÒÅç¤H¤ßªº¦a¤è ·í§A@¤£¦í¤F¡A½æ¤F §Q¦h©¹©¹´N§Ö¨Ó¤F ¶§Ãö¤TÅ|¡AÄU§g¶¼ªM¡A¦è¥X¶§ÃöµL¬G¤H |
|
|
·|û¡G½ä®{10141199 µoªí®É¶¡:2017/10/26 ¤W¤È 09:49:36²Ä 1582 ½g¦^À³
|
¨S¦³¿n·¥ªº¶R½L¶i¨Ó¡A¦A¦nªºªÑ²¼¤]¤£·|º¦ ©Ç½Ö³£¤£¹ï¡A¥u¯à@¤ßµ¥«Ý ¦pªG¯uªº¬O¦nªºªÑ²¼¡A®É¶¡·|ÁÙ¤½¹Dªº 70¯à¤£¯à¦uªº¦íÁÙ¤£ª¾¹D(¬Ý°_¨Ó¦³ÂI§xÃø) ©Ò¥H³oÓ®ÉÔ¤£¥h¬Ý½L¡A¬O³Ì¦nªº¿ï¾Ü ¤£¤ß¯B®ð¾¸´N¤£·|°µ¥X¿ù»~ªº¨M©w |
|
|
·|û¡GDavid Xu10143450 µoªí®É¶¡:2017/10/26 ¤W¤È 09:16:43²Ä 1581 ½g¦^À³
|
¯Q¾~©_¡]¹Lµó¦Ñ¹«¡^ §A¤@ª½¨Ó°Û°Iªºì¦]¡G¬O§A·Q³y¦¨¤j¶^µM«á¶i³õ¾ß«K©y³f ¦Ñô§Ú¥u¯àÄU§A¡G§g¤l·R°] ¨ú¤§¦³¹D¡C¦h¦æ¤£¸q¥²¦ÛÀÅ¡C ¦@«j¤§ |
|
|
·|û¡G»«¹£ô10144807 µoªí®É¶¡:2017/10/26 ¤W¤È 12:02:41²Ä 1580 ½g¦^À³
|
¬P¬P¬°¤°»ò·|¶^¡A¹D²z«Ü²³æ¡A¥un¦³¯Q¾|¤ì»ô³o¦ì°I°ÁÙ¦b¡A¬P¬P¼È®É¬O¤W¤£¥hªº ¦ý¬O¥un¬P¬P¶}©l°_º¦¡A¸ú¦b¤j¸sªº¯Q¾|¤ì»ô¥ý¥Í´N·|¤S¾¶Án¤F «Ü°ª¿³§AÁÙ¦b¡A¨S¦³®ø¥¢¡A¤£µM«ç»ò¦³¤s½Þ¥i¥H¥´°Ú §A¤@©wn¬¡ªº¦n¦nªº³á¡A¯Q¾|¤ì»ô¥ý¥Í¡A¤£µM§Ú«Ü¾á¤ß©ú¦~Ä«ªG¤é³ø¬Ý¤£¨ì§Aªº¹Dºp¤åC |
|
|
·|û¡G¼Ú¬¥©_10144203 µoªí®É¶¡:2017/10/25 ¤U¤È 11:47:01²Ä 1579 ½g¦^À³
|
¦U¦ì±ß¦w ¦n¤[¤£¨£ ³s¶^´X¤Ñ §Ú¤S¥X²{¤F §Ú·Qªí¹Fªº¬O ¤@¶}©l§Ú¤@ª½Á¿¤j¤á¥X³fªº°ÝÃD §Ú¹ê¨Æ¨D¬O «o·S¨Ó¤@°ï¤Hªºðã½| ²{¦bº¥º¥¤j¦h¼Æ¤H³£Ä@·N©Ó»{³oÓ¨Æ¹ê ¨S¿ù ¦pªG¥_·¥¬P³o¨Ç§Q¦h¬O¦b§Oªº¥Í§ÞªÑ ¦´Nº¦Â½¤Ñ ¤ñ¦p4174 ´X°¦¦Ñ¹«³£¯àº¦Óªñ20% ¦pªG¬Où¤ó¸ò¥L¦X§@ ¨ºÁÙ±o¤F? ¦ý¥_·¥¬P´N¬O¥_·¥¬P Äw½X´N¬O¦p¦¹ÁV¿| ¦pªG¤@¨Ç¦ÑªÑ¤Í ¬Ý¹L´ä¼@¤j®É¥N´Nª¾¹D ¬°¦ó³Ì«á¤è®i³ÕnÅý´X¦ì¤j¥ø·~®a¸ò¦Û¤v¯¸¤@°_ ¦ÓnÅýÀs¦¨¨¹¸ò©PÀ٥ͳo¨âÓ¶]¸ô¨ì¥xÆWªº¥h©ñªÅ´ä«ü ³o¨âÓ¥i¬O¥Lªº®¦¤H ¹D¸Ì«Ü²³æ ¤£¸ò°I°¯¸¤@°_ ¥_·¥¬P¤]¬O¤@¼Ë ¤@°ï°I¤H«ù¦³ ¦A«ç»ò¦³§Q¦h³£¨S¥Î «O« |
|
|
·|û¡G»«¹£ô10144807 µoªí®É¶¡:2017/10/25 ¤U¤È 11:42:33²Ä 1578 ½g¦^À³
|
¦Ñ´¤j¥¦w ¤µ¤Ñªº¤s½Þ«Ü·|¶]¡A¤S¶]¥X¨Ó100°¦¡A¤p§Ì§Ú¥[´î§ì´X°¦¦^¨Ó¡A¤]¦³·Q¹L¤£n¦A¥Î¦P¤@Ó½Þ°é©ñ¾i½Þ¡A§K±o¤@¨Ç©Ç«È¤SÁ¿¤@¨Ç¦³ªº¨Sªº¡A§Ú·|¨C¤Ñ§ìÓ´X°¦¡A¨ì®É§Ú̦b¤@°_¯N¨Ó°t58 ¦Ñª¯¤j §A¦n ©ñ¤ß¡A¦Ñ¬P¤Í¤@ª½³£¦b¡A»«¹£¤p§Ì§Ú¬O¬P¬P°¾°õ¨g¡A³Ì¦hªº®ÉÔ§ë¸ê¬P¬P±bÁ«1300¤j¬v ¦³®ÉÔ¼µ¹L¤F¡A¤@¤Á³£·|¶¶¶¶§Q§Q¤F¡An°O¦í¡A»«¹£§Ú¤]¬O¥Í·N¤H¡A¬Ý¨ì¥Ø«eªº¬P¬P¤w¸g¦³¶K¤Wù¤ó¼ÐÅÒ¤FÁÙ³oºØ»ù¦ì ¤@©w¬O·|¥[´î¶Rªº¡AC/PȤӰª¤F ·íµM¡A¦Û¤vªºªÑ²¼¦Û¤vt³d¡A¨CÓ¤H¦Ò¶qªºÂI¤]¤£¦P¡A¤Á¤Å§@¬°§ë¸ê°Ñ¦Ò ¨Ó¥hºÎ©ú¤ÑÄ~Äò§ì¤s½Þ |
|
|
·|û¡G¦Ñª¯10145373 µoªí®É¶¡:2017/10/25 ¤U¤È 11:26:22²Ä 1577 ½g¦^À³
|
¤p¶§¤j¤j,¶Â¿ÂÃƤj §A̱ߦw~ ¤£¦n·N«ä¤S¬Ý¨ì¦Û¤v³Qcue¨ì,¥XÓÁn ¤U¤È¶}§¹·|¤v¸g¬O¥|ÂI§Ö¤ÂI¤F,´N¬Ý¤F¤U¦¬½L ¶â.¤£ª¾¹D¬°¦ó,´NµL·P.¦ý¤]¨S¦³¨ì³B¤§®õµM©M¦Ñ¯«¦b¦b... ³o¸Ì·Q»¡ªº¬O,¥»¤H§ë¸ê¥_·¥¬P¬O¦ÛÄ@ªº,¨S¦³¥ô¦ó¤H¥²»Ýnt³d ´N¦Û¤v¹ï¦Û¤vt³d. µL½×§Ú¥h©Î¯d,¥u·Q¯¬ºÖ¦U¦ì¤j¤j¥¦w§Ö¼Ö¶¶¤ß ¤j®a±ß¦w,´Á«Ý©ú¤Ñ·|§ó¦n |
|
|
·|û¡G¤@¤ô´H10144832 µoªí®É¶¡:2017/10/25 ¤U¤È 11:24:59²Ä 1576 ½g¦^À³
|
¬P²y±U°_¤j¤j±ß¦w¡B¦U¦ì¬P¤Í¤j¤j̱ߦw¡G 쥻·Q¡u©ñ°²¡v´X¤Ñ¡A¨S·Q¨ì³º³Q²´¦yªº±zµo²{¡A¨þ¨þ¡I Go Go Polaris¡I¡I¡I ºK¿ý¾ã²z¸ê®Æ¦p¤U¨Ñ°Ñ¡G ¡¶¤é´Á¡¹¦¨¥æªÑ¼Æ¡»¥þÅé¨é°Ó¨C¤é®w¦s¼W´îªÑ¼Æ¡´¥þÅé¨é°Ó¨C¤é®w¦sÁ`ªÑ¼Æ ------------------------------------------------------------------ ¡¶2017/10/25¡¹1,122,041¡»156,676¡´41,363,557 ¡]¬ÛÃö¼Æ¾Ú»¡©ú½Ð°Ñ¦Ò²Ä486½g¦^À³¡A ¥H¤W¼Æ¾Ú¦p¦³¿ù»~¤§³B¡A ½Ð¦U¦ì¬P¤Í¤j¤j¦h¦h¥]²[¨Ã¤£§[´f¤©½ç±Ð¡C¡^ |
|
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2017/10/25 ¤U¤È 11:18:22²Ä 1575 ½g¦^À³
|
¤µ¤Ñ¦³°áTecentriqªº¨t¦C½×¤å,µo²{¦³«Ü¦h«Ü¦³·N«äªº¦a¤è,«Ý¹LÂo«á¦A¤À¨É. ¤j·§ª¾¹DRoche¬°¤°»ò·|³o»ò¦³¿³½ì,¤S³o»ò«æ¤F! µª®×ÁÙ¬OADIªºINF-alpha, beta! ¾ã²z¤@¤U¦A²Ó»¡!±ß¤F,¥ýµt!Ä~Äò±O½Þ!!! |
|
|
·|û¡G¶Â¿ÂÃÆ10145058 µoªí®É¶¡:2017/10/25 ¤U¤È 06:55:32²Ä 1574 ½g¦^À³
|
¤p¶§ ©Ò¥H§A¼Ð°O¦Ñª¯¤j ¦³¤°»ò©~¤ß¡H §A«ç»òª¾¹D¨ì¦Ñª¯¤j¤£¬O³B¤§®õµM¡H |
|
|
·|û¡G¤p¶§10139627 µoªí®É¶¡:2017/10/25 ¤U¤È 06:24:02²Ä 1573 ½g¦^À³
|
PETER¤j §A¦Ñ¯«¦b¦b~¨º¥s¦Ñª¯¤j±¡¦ó¥H³ô°Ú¡H |
|
|
·|û¡G¥Í§Þ00710142005 µoªí®É¶¡:2017/10/25 ¤U¤È 06:21:55²Ä 1572 ½g¦^À³
|
¦U¦ì¦Ñ¤j¡I ¤°»ò³£¨SÅÜ¡A·|Åܪº¬O¦Û¤wªº¤ß.......¡I ¤p§Ì¤@¼Ë¦b²î¤W¡AÄ_ÂôN¦b¤£»·³B....¥_¤èªº¬P¬P¡C |
|
|
·|û¡GPETER10142151 µoªí®É¶¡:2017/10/25 ¤U¤È 03:55:14²Ä 1571 ½g¦^À³
|
¦Ñ¯«¦b¦b |
|
|
·|û¡G¬P²y±U°_10145048 µoªí®É¶¡:2017/10/25 ¤U¤È 03:49:44²Ä 1570 ½g¦^À³
|
°Å¤M¤â¡B°Å¤M¤â¡B°Å¤M¤â¡I ³Q¦Ñ´¤j¤jÂI¦W¤F¡A§Ú·|§V¤O¦h¦YÂIªº¡ãÁÂÁ±z ÁÂÁ¤@¤jªºÄw½X¡AÅý±z¸É¤W¨º»ò¦h¤éªº¸ê®Æ¯u¬O¤£¦n·N«ä¤F¡C ¦n¶}¤ß³\¤j¡A»«¹£¤j¡A»aÃǤj¡AºÖ¥Ð¤j¡A123¤j¡AºÃ´b¤j³£¨Ó¬Ý¬P¬P¡C |
|
|
·|û¡G¸Û«H¦ó®¬10139574 µoªí®É¶¡:2017/10/25 ¤U¤È 03:38:16²Ä 1569 ½g¦^À³
|
¨ä¹ê¤£¥Î¤Ó¾á¤ß ù¤óªº¥[¤J¡A¦pªG¬O§Oªº¤½¥q°_½XnÅýªÑ»ù³Ð·s°ª¡I ¦åÀùÁp¦X¥ÎÃÄ¡A®ÄªGÀ~À~¥s¡A¦pªG´«°µ§Oªº¤½¥q¡A ü§r¡A§Ú¤£·|»¡¡A£¸Ó°Êª«¥ÎÃĵoªí¡A´N´Nº¦¦¨³o¼Ë¡A Â÷¤W¥«ÁÙn3¦~¥H¤W¡A§Ú¯uªº¤£·|»¡ ¯u¬O¤Ó§C½Õ¤F |
|
|
·|û¡GDavid Xu10143450 µoªí®É¶¡:2017/10/25 ¤U¤È 03:14:30²Ä 1568 ½g¦^À³
|
@¤ßµ¥ |
|
|
·|û¡G¬P²y±U°_10145048 µoªí®É¶¡:2017/10/25 ¤U¤È 02:51:02²Ä 1567 ½g¦^À³
|
ºCºC¨Ó¡ã ¤£µM°µÃ窺¤j½Þ¤½«ç»ò¨Óªº¡A ®É¶¡°ÝÃD°Ú¡ã¶Ì¶Ìºw |
|
|
·|û¡G@¦ÌµX10144792 µoªí®É¶¡:2017/10/25 ¤U¤È 02:17:02²Ä 1566 ½g¦^À³
|
«u!¤S¨Ó¤F~ ³o¼Ë¥s§Ú̳o¨Ç¤p½Þn«ç¿ì?! ¤@ª½¸}³Â¤£¨«¡A§Ú³£ÅܽޤF¡G( ²³¤jªº¤MÁÙ¨S¿i§Q¶Ü? «z«z¥s¬O§Úªº¯S½è~C C |
|
|
|